Conditions: Cystic Fibrosis
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 10
Healthy volunteers: no

Brief summary:
This study evaluates two doses of RPL554 and placebo in adult patients with cystic fibrosis. All patients receive all three treatments in a randomised sequence.

Detailed description:

Arms:
arm 1: Single dose of inhaled 6 mg RPL554 arm 2: Single dose of inhaled 1.5 mg RPL554 arm 3: Inhaled placebo dose

Interventions: intervention 1: RPL554 intervention 2: Placebo
Intervention descriptions: intervention 1: RPL554 suspension administered using a nebuliser intervention 2: Placebo solution administered using a nebuliser

Protocol document:
Prot_002.pdf: 
		

		
		
		 	
	
	!




			

#$%#&'(()*+#,-./(&'-*-.012'12(,-*$2#3'1.
3.,4+.22'-*4%+''5#63+.&&.7'+&40-64.#&&'&&4%'
$%#+/#3.8(,'4(3&.9+$2::;#-/(,(&4'+'-4.#-024
$#4(',4&5(4%36&4(39(1+.&(&

<	 =>>=?>
@ABCDEF
G<>
IJ@F
KJDL@A?>G
MIB@
I
EN@BJCOIJCDEIP
	 
@QCKCEIPADQRKJF

RQAIRSL@A
?>=>> ?=



	



















 !"# $
%&
#$#
 '#
()*+,-./0-123




5216
7)82+,
9:1-1
;-<8=>1?0-.1)3


@0AB2.8/+
@+)-2+
612
C+8.?0:
D+,+02?E



50FG12-E
H1,F.-0:

@0AB2.8/+I
@JKL
LDM
N).-+8
O.)/81A
PNOQ

RSS
PTQUKKL
VWXXTU

()*+,-./0-123



Y2
(2+)+
H+.AB+?Z
;-<8=>1?0-.1)3


()0A+8
[ABH



D1B+2-\O1?E\7::++
K]



XKULU
[0<-.)/



[+2A0)=



RS]
X]
X]L^W]KX

;F1),123



_+21)0
5E02A0
F:?



L
C12+
>1)81)
D.*+2,.8+
>1)81)I
;MU
KDM
NO
RSS
PTQKTL
KXL
SKTT

;F1),12`,
C+8.?0:
C1).-123


Y2
O+))+-E
a+GA0)



RU
]US
VWV
^TTV



Z+)b)+GA0)c*+21)0FE02A0b?1A
M\A0.:0882+,,
612
2+F12-.)/
;7M,3
D5>^^S\;7M\;N;7Dc*+21)0FE02A0b?1A
@1)-20?-D+,+02?E
d2/0).,0-.1)3
C+8.?.)+,
M*0:<0-.1)
N).-
>-8



eE+
>0)/:+=
J<.:8.)/



;1<-EA112
D108
C0)?E+,-+2I
CKL
]fg

NO



RSS
PTQUWU
]SW
ST^T
>1?0:>0B120-12.+,3


@:.).?0:
50-E1:1/=
>0B120-12=
P;06+-=7)0:=,.,Q


50FG12-E
H1,F.-0:

@0AB2.8/+I
@JKL
LDM
NO

;=):0B
C_g
>0B12
Ch)?E+)
g+)-2<A
[BD
J0=+2,-20i+
^L
XTLL^
C<).?E

[+2A0)=
















 !"# $
%&
()*+,(+-).+/).01
 

2,)/)
(+-
34536
789):+.;<.
=>+,0?9?


@+:-.9AB<
C>9D<.?9/0
E<F/
G<A9*9><
H).-)/I*<>/.<?J


GK@
(+-).+/).0
)H
G),<*L,+.
89),)B0



2.+>*9?
@.9*;
=D<>L<



@+:-.9AB<
89):<A9*+,
@+:FL?



@+:-.9AB<M
@8N
OPQ
CR
@<>/.+,(+-).+/).01



(S@
(/A
7TI+.:+*);9></9*
=>+,0?9?
 
U<V:+.;</
K)+A
H).-)/I*<>/.<?J


2).AI+:

@+:-.9AB<?I9.<M
@8W
XYY
CR
Z[[
7OJ
3\5]
WNO
XOO














 !"# $
%&'
!"#$ 
$("!("#)
) "
#*"
"
 +)

") 
,-./.0.1345.67879
:501;78.5
<-8/=-8>
?.-
@<AB



CD=
1.E=-
18F8/
.?
D=>-/
->/=
87
0D>5G=H
?-.FIJ/.
JK
L=>/7
6=-
F85;/=M

CD=
;66=-
18F8/
.?
,N
85/=-O>1
87
-=H;0=H
?-.F
PPK
F7=0
/.
PKKF7=0M
,-./.0.1345.67879
5=E
@Q01;78.5
<-8/=-8>B
,>/8=5/
/-=>/=H
E8/D
8O>0>?/.-
.-
8O>0>?/.-R
1;F>0>?/.-
E811
L=
=Q01;H=H
?-.F
7/;H4
6>-/8086>/8.5M
3=0/8.5IMS9
:501;78.5
<-8/=-8>
TU
V@<AWB

CD=
1.E=-
18F8/
.?
D=>-/
->/=
87
0D>5G=H
?-.F
IJ
/.
JKL=>/76=-
F85;/=M

CD=
;66=-
18F8/
.?
,N
85/=-O>1
/.
L=
-=H;0=H
?-.F
PPK
F7=0
/.
PKK
F7=0M
3=0/8.5IMP9
5=E
@Q01;78.5
<-8/=-8>B
,>/8=5/7
/-=>/=H
E8/D
8O>0>?/.-
.-
8O>0>?/.-R1;F>0>?/.-
E811L==Q01;H=H
?-.F
7/;H4
6>-/8086>/8.5M

















 !"# $
%&
'(' '
#&')*+,

-
/0123
4415
61789:;2385
89<=>3
=>;785
?>1@3=9
@97A69>>385
A0633
B1C
@69229D36
2A<8C
A9
122322
A03
?016:1@9E;73A;@2
9F
G/HIIJ
18:;7;2A3638
A9
18<>A
?1A;37A2
B;A0
KC2A;@
L;=692;2M
),
G/HIIJOPQPORPQI
")*#
),
 RPQIOPPJRSTOTS

,
441
',
U36971
/016:1
?>@

 V%,

/69F
-78632
L>9A9
W6
46373
X3;:=3@E
')*+,

K1:=6;8Y3
K37A63
F96
H<7Y
47F3@A;97
/1?B96A0
X92?;A1>
K1:=6;8Y35
KZRT
TG[
\7;A38
];7Y89:
^\]_
471:38
`:=X
G9=36AO]9@0O->>33
Ra
bRQTQ
`1<A;7Y
`36:17C
*')*+
*,
c17<16C
RPQd
A9
W3@3:=36
RPQd
eV,
+
eV
f9
;7D32A;Y1A3
?016:1@9E;73A;@2
9F
2;7Y>3
73=<>;238
89232
9F
G/HIIJ
;7
?1A;37A2
B;A0
KC2A;@
L;=692;2
^KL_
'*+
eV
g
 f9
;7D32A;Y1A3
A03
=697@098;>1A96
3FF3@A
97
?31E
F96@38
3i?;638
D9><:3
;7
Q
23@978
^L[UQ_
1FA36
2;7Y>3
73=<>;238
89232
9F
G/HIIJ
12
@9:?1638
A9
?>1@3=9
g
 f9
;7D32A;Y1A3
A03
=697@098;>1A96
3FF3@A
97
1631
<7836
A03
@<6D3
^-\K_
L[UQ
9D36
J5
S
178
b
09<62
9F
2;7Y>3
73=<>;238
89232
9F
G/HIIJ5
12
@9:?1638
A9
?>1@3=9
g
 f9
122322
A03
A9>361=;>;AC
178
21F3AC
9F
2;7Y>3
73=<>;238
89232
9F
G/HIIJ
;7
?1A;37A2
B;A0
KL
"j+
eV
g
 f9
3i1:;73
A03
17A;O;7F>1::1A96C
3FF3@A2
9F
2;7Y>3
73=<>;238
89232
9F
G/HIIJ
;7
?1A;37A2
B;A0
KL
')*+!%
*
k*%+,
f0;2
;2
1
/0123
4415
61789:;2385
89<=>3
=>;785
?>1@3=9
@97A69>>385
@9:?>3A3
=>9@E
A0633
B1C
@69229D36
2A<8C
A9
;7D32A;Y1A3
A03
?016:1@9E;73A;@2
9F
73=<>;238
G/HIIJ
^QMI
:Y
178
S
:Y_
;7
18<>A
?1A;37A2
B;A0
KLM
4A
;2
?>17738
A9
3769>
2<FF;@;37A
?1A;37A2
A9
372<63
A01A
QP
@9:?>3A3
1>>
A0633
A631A:37A
?36;982
1A
AB9
@37A632M
f03
2A<8C
@9:?6;232
F;D3
D;2;A2l
2@6337;7Y
^U;2;A
Q_5
A0633
A631A:37A
D;2;A2
^U;2;A
R
A9
U;2;A
J_
178
17
378
9F
2A<8C
D;2;A
^U;2;A
I_M
/1A;37A2
B;>>
=3
2@633738
F96
3>;Y;=;>;AC
^U;2;A
Q_5
;7@><8;7Y
1
63D362;=;>;AC
A32A
B;A0
21>=<A1:9>5
=3AB337
T
178
QJ
81C2
?6;96
A9
A03
F;62A
8923
9F
2A<8C
A631A:37AM

[>;Y;=>3
?1A;37A2
B;>>
A037
1AA378
F96
A0633
23?161A3
Q
81C
A631A:37A
D;2;A2
^U;2;A2
R
A9
U;2;A
J_
31@0
23?161A38
=C
1A
>312A
1
T
81C
B1209<A
?36;98M
/1A;37A2
B;>>
=3
61789:;238
?63O8923
1A
U;2;A
RM
/1A;37A2
B;>>
63@3;D3
1
2;7Y>3
73=<>;238
8923
9F
QMI
:Y
G/HIIJ
96
S
:Y
G/HIIJ
96
?>1@3=9
1A
31@0
D;2;AM
f03
?63O8923
L[UQ
1A
U;2;A
T
178
U;2;A
J
:<2A
=3
B;A0;7
mRPn
9F
A03
?63O8923
L[UQ
1A
U;2;A
R
;7
96836
A9
372<63
@972;2A37A
=123>;73
L[UQ
F96
31@0
2A<8C
A631A:37AM
-A
31@0
D;2;A5
?1A;37A2
B;>>
=3
632;837A
1A
A03
2A<8C
@37A63
F69:
A03
:967;7Y
<7A;>
1A
>312A
b
09<62
1FA36
892;7YM
/1A;37A2
B;>>
=3
8;2@016Y38
1FA36
b
09<625
=<A
63A<67
A03
F9>>9B;7Y
:967;7Y
F96
F;71>
122322:37A2
RJ
09<62
1FA36
892;7YM
f03
F9>>9B;7Y
B;>>
=3
?36F96:38
1A
31@0
A631A:37A
D;2;Al
g
 o312<63:37A2
9F
><7Y
F<7@A;97
^L[UQ
178
F96@38
D;A1>
@1?1@;AC
pLUKq_
?63O8923
178
<?
A9
RJ
09<62
?92AO8923
g
 Z>998
21:?>;7Y
?63O8923
178
<?
A9
RJ
09<62
?92AO8923
F96
?016:1@9E;73A;@
171>C2;2














 !"# $
%&'
(
 *+,-,.
01.+2345
+6789:07
149
1-
;
149
<=
>:,60
+:0-89:07
?:6
6>7:2:5@
149
.710,67.74-
:?
34?21..1-:6@
.7931-:60
A34-7627,B34
;
CDE8;FG
-,.:,6
47H6:030
?1H-:6
12+>1
CIJK8LFG
.@72:+76:M39107
CNOPFQ

(
 RM>1279
S671->
+T
.710,67.74-
+6789:07
149
1-
;
149
<=
>:,60
+:0-89:07
A1-
UV
H74-67
:42@Q
(
 U6347
+675414H@
-70-
+6789:07
A?7.127
+1-374-0
:42@Q
(
 W3-12
03540
149
X<82719
727H-6:H1693:561.
ARYZQ0
+6789:07
149
,+
-:
;
>:,60
+:0-89:07
[4
749
:?
0-,9@
\303-
AW303-
]Q
^322
S7
+76?:6.79
_
-:
X`
91@0
1?-76
->7
210-
9:07
:?
0-,9@
-671-.74-a
[9\7607
7\74-0
^322
S7
67H:6979
->6:,5>:,-
->7
0-,9@
149
21S:61-:6@
01?7-@
-70-0G
1
+>@03H12
7M1.341-3:4
149
,6347
+675414H@
-70-0
A?7.127
+1-374-0
:42@Q
^322
S7
+76?:6.79
1-
0H6774345
AW303-
XQ
149
1-
->7
749
:?
0-,9@
\303-
AW303-
]Qa

b'

cd
X`
+1-374-0
.,0-
H:.+27-7
122
->677
-671-.74-
\303-0
AW303-
<
-:
W303-
=Q
,+
-:
->7
<=
>:,6
100700.74-0
34
->7
0-,9@a
[4@
+1-374-0
^>:
9:
4:-
H:.+27-7
^322
S7
67+21H79a

e
'
"%fd
ghijklmnh
pqmrsqmt
Xa
 *354
14
34?:6.79
H:4074-
9:H,.74-
3493H1-345
->7@
,49760-149
->7
+,6+:07
:?
149
+6:H79,670
67u,3679
?:6
->7
0-,9@
149
167
^322345
-:
+16-3H3+1-7
34
->7
0-,9@a
<a
 N127
vw
yz{|}z
|~z
X;
@7160
:29G
1-
->7
-3.7
:?
34?:6.79
H:4074-a
K7.1270
:?
H>329S716345
+:-74-312
.,0-
>1\7
S774
,0345
1
H:4030-74-
149
67231S27
?:6.
:?
H:4-61H7+-3:4
?6:.
->7
210-
.74070
S7?:67
->7
?360-
0-,9@
-671-.74-
19.3430-61-3:4G
149
.,0-
H:..3-
-:
H:4-34,7
-:
9:
0:
9,6345
->7
0-,9@
149
?:6
_
.:4->0
1?-76
->7
210-
9:07
:?
0-,9@
-671-.74-a
_a
 T1\7
1
X<82719
RYZ
67H:69345
1-
0H6774345
AW303-
XQ
149
W303-
<
+6789:07
0>:^345
->7
?:22:^345
(
T716-
61-7
S7-^774
]`
149
X``
S71-0
+76
.34,-7
(
I
34-76\12
H:667H-79
?:6
>716-
61-7
,0345
K639763H310
?:6.,21
AIHKQ
34-76\12
`
.07H

(

zw|}

{z
(
O
zw|}
``
.07H
(
J:
H2343H122@
03543?3H14-
1S4:6.123-@
34H2,9345
.:6+>:2:5@
A7a5a
27?-
S,4927
S614H>
S2:HBG
1-63:\74-63H,216
4:912
9@0?,4H-3:4G
*I
075.74-
1S4:6.123-370Q
=a
 Y1+1S27
:?
H:.+2@345
^3->
122
0-,9@
670-63H-3:40
149
+6:H79,670
34H2,9345
1S323-@
-:
,07
->7
0-,9@
47S,23076
H:667H-2@a

]a
 :9@
.100
3497M
S7-^774
X;
149
_`
B5.<
A34H2,03\7Q
^3->
1
.343.,.
^735>-
:?
=`
B5a

a
 O1-374-0
^3->
1
5747-3H
93154:030
:?
YKa
a
 *+36:.7-6@
97.:40-61-345
14
KRWX
vy
`
|

vy
wzz
4:6.12a

;a
 Y1+1S27
:?
^3->961^345
?6:.
2:45
1H-345
S6:4H>:9321-:60
?:6
=;
>:,60
+63:6
-:
0-,9@
\303-0G
149
0>:6-
1H-345
S6:4H>:9321-:60
?:6
;
>:,60
+63:6
-:
0-,9@
\303-0a
a
 Y2343H122@
0-1S27
YK
34
->7
<
^77B0
+63:6
-:
6149:.301-3:4
AW303-
<Qa
ijklmnh
pqmrsqmt

Xa
T30-:6@
:?
H366>:-3H
23\76
9307107
:6
+:6-12
>@+76-7403:4a
<a
YK
7M1H76S1-3:4
67u,36345
>:0+3-12301-3:4
34
->7
.:4->
+63:6
-:
0H6774345
AW303-
XQ
:6
+63:6
-:
6149:.301-3:4
AW303-
<Qa
_a
U07
:?
:612
:6
34-61\74:,0
14-3S3:-3H0
A34
1993-3:412
-:
,0,12
.134-7414H7
->761+@Q
34
->7
<
^77B0
+63:6
-:
0H6774345
AW303-
XQ
:6
6149:.301-3:4
AW303-
<Qa
=a
P->76
4:48YK86721-79
670+361-:6@
930:69760
O1-374-0
^3->
1
H,6674-
93154:030
:?
1H-3\7
-,S76H,2:030G
2,45
H14H76G
016H:39:030G
0277+
1+4:71G
B4:^4
12+>18X
14-3-6@+034
97?3H374H@
:6
:->76
1H-3\7
+,2.:416@
93071070a
]a
O67\3:,0
2,45
6707H-3:4
:6
2,45
-6140+214-a














 !"# $
%&
'(
*+,-./0
.23
./
/45,.6
-.
748+494
5
:5-+46-
;5,3
</=>
./
58?.;.8
57=,4
@+-;+6
-;4
:5,-
A
045/,(
B(
C4?4+94<
56
4D:4/+E46-58
</=>
@+-;+6
A
E.6-;,
./
2+94
;582F8+94,3
@;+?;494/
+,
8.6>4/(

G(
H5-+46-,
@+-;
5
;+,-./0
.2
?;/.6+?
=6?.6-/.884<
<+,45,43
=684,,
IJ
/485-4<3
+6?8=<+6>3
7=-
6.-
8+E+-4<
-.3
?5/<+.95,?=85/
K+6?8=<+6>
5//;0-;E+5,L3
46<.?/+643
5?-+94
;0:4/-;0/.+<+,E3
64=/.8.>+?583
;4:5-+?3
>5,-/.+6-4,-+6583
/46583
;54E5-.8.>+?583
=/.8.>+?583
+EE=6.8.>+?58
./
.:;-;58E+?
<+,45,4,
-;5-
-;4
M694,-+>5-./
748+494,
5/4
?8+6+?5880
,+>6+2+?56-(
N(
O.?=E46-4<
?5/<+.95,?=85/
<+,45,4P
56>+653
/4?46-
./
,=,:4?-4<
E0.?5/<+58
+625/?-+.63
?.6>4,-+94
;45/-
25+8=/43
5
;+,-./0
.2
=6,-57843
./
=6?.6-/.884<
;0:4/-46,+.63
./
;5,
7446
<+5>6.,4<
@+-;
;0:4/-46,+.6
+6
85,-
A
E.6-;,(
QR(
*5,
;5<
E5S./
,=/>4/03
K/4T=+/+6>
>464/58
5654,-;4,+5L
+6
-;4
'
@44U,
:/+./
-.
,?/446+6>
KV+,+-
QL3
./
@+88
6.-
;594
2=880
/4?.94/4<
2/.E
,=/>4/03
./
:85664<
,=/>4/0
-;/.=>;
-;4
46<
.2
-;4
,-=<0(
QQ(
M624?-+.6
@+-;
6.6-=74/?=8.=,
E0?.75?-4/+53
E4-;+?+88+6F/4,+,-56-
W-5:;08.?.??=,
5=/4=,
KXCWYL
./
Z=/U;.8<4/+5
,:4?+4,(
Q[(
\,4
.2
+EE=64F,=::/4,,+.6]
8.6>
-4/E
=,4
.2
:/4<6+,.8.64
^QR
E>_<50(
QA(
*+,-./0
.2
E58+>656?0
.2
560
./>56
,0,-4E
@+-;+6
`
045/,
@+-;
-;4
4D?4:-+.6
.2
8.?58+,4<
,U+6
?56?4/,
K75,58
./
,T=5E.=,
?488L(
Qa(
I8+6+?5880
,+>6+2+?56-
576./E58
958=4,
2./
,524-0
857./5-./0
-4,-,
K;54E5-.8.>03
7+.?;4E+,-/0
./
=/+6580,+,L
5-
,?/446+6>
KV+,+-
QL3
5,
<4-4/E+64<
70
-;4
M694,-+>5-./(
Q`(
Y
<+,?8.,4<
;+,-./0
./
.64
U6.@6
-.
-;4
M694,-+>5-./3
.2
,+>6+2+?56-
6.6F?.E:8+56?4
+6
:/49+.=,
+694,-+>5-+.658
,-=<+4,
./
@+-;
:/4,?/+74<
E4<+?5-+.6,(
Q'(
H5-+46-,
-/45-4<
@+-;
+95?52-./
./
+95?52-./_8=E5?52-./
@+88
74
4D?8=<4<(
QB(
C4T=+/4,
.D0>46
-;4/5:0
.6
5
/4>=85/
75,+,(
QG(
H/4>656?0
./
85?-5-+.6
K24E584
,=7S4?-,
.680L(
QN(
Y60
.-;4/
/45,.6
-;5-
-;4
M694,-+>5-./
?.6,+<4/,
E5U4,
-;4
:5-+46-
=6,=+-5784
-.
:5/-+?+:5-4(
bcde#f
H5-+46-,
@+88
/4?4+94
-;4
2.88.@+6>
-;/44
,+6>84
<.,4,
.2
,-=<0
-/45-E46-3
.64
5-
45?;
-/45-E46-
9+,+-
KV+,+-
[
-.
V+,+-
aL3
+6
5
/56<.E+,4<
,4T=46?4P
Q(`
E>
CHg``a3
'E>
CHg``a
./
:85?47.(
Y88
,-=<0
-/45-E46-,
@+88
74
5<E+6+,-4/4<
=,+6>
-;4
+6;584<
/.=-4
=,+6>
5
,-56<5/<
h4-
647=8+,4/
KHYCM
gI
W:/+6-
:8=,
5
HYCM
i=/7.Zjk
Wl
?.E:/4,,./
=6+-L(
i;4
CHg``a
2./E=85-+.6
+,
5
,-4/+84
,=,:46,+.6
,=::8+4<
5,
,-4/+84
,-.?U
,=,:46,+.6,
.2
E+?/.6+,4<
CHg``a
+6
:*
B
:;.,:;5-4
7=224/4<
,58+643
?.6-5+6+6>
,=/25?-56-,
-.
5+<
,=,:46,+.6(
i;4
:85?47.
+,
-;4
,5E4
5,
-;4
CHg``a
,=,:46,+.6
4D?4:-
-;5-
-;4
5?-+94
CHg``a
+6>/4<+46-
+,
.E+--4<3
+(4(
+-
?.6,+,-,
.2
:*
B
:;.,:;5-4
7=224/4<
,58+64
56<
,=/25?-56-,
.680(
M-
+,
-;=,
5
?845/
,.8=-+.6
/5-;4/
-;56
5
:584
0488.@
,=,:46,+.6]
-;4/4
+,
6.
U6.@6
+64/-
0488.@
,.8+<
-;5-
@.=8<
74
5??4:-5784
2./
+6;585-+.63
56<
-;4/42./4
5
9+,=5880
E5-?;+6>
:85?47.
;5,
6.-
7446
<4948.:4<(
!c&
#f
i;4
5::/.D+E5-4
:85664<
<=/5-+.6
2./
45?;
:5-+46-
@+88
74
=:
-.
`[
<50,P
A
-.
Qa
<50,
,?/446+6>3
=:
-.
[G
<50,
-/45-E46-
K-;/44
-/45-E46-
9+,+-,
45?;
=,=5880
,4:5/5-4<
70
A
-.
Qa
<50,L
56<
56
46<
.2
,-=<0
9+,+-
A
-.
QR
<50,
52-4/
-;4
85,-
-/45-E46-
9+,+-(

b
mdf
 i;+,
+,
5
,5E:84
,+n4
.2
?.6946+46?4(
o.
:.@4/+6>
?58?=85-+.6
@5,
:4/2./E4<(
pqrstruvwxyrtzu{|
i/45-E46-,
@+88
74
?.E:5/4<
=,+6>
56580,+,
.2
?.95/+56?4
5<S=,-+6>
2./
-/45-E46-3
:4/+.<3
:5-+46-
56<
75,48+64(
X=8-+:8+?5-+94
E.<48,
@+88
74
=,4<
2./
J~VQ
56<
5<<+-+94
E.<48,
2./
78..<
:/4,,=/43
:=8,4
/5-4
56<
~I
;45/-
/5-4(
Y?-+94
-/45-E46-,
@+88
2+/,-
74
?.E:5/4<
-.
:85?47.
=,+6>
5
?8.,4<
-4,-
:/.?4<=/4
K@+-;+6
,=7,-56?4L
,-5/-+6>
@+-;
-;4
;+>;4,-
<.,4(
qs
yrx{{|
Z+.E5/U4/
E45,=/4E46-,
56<
4D;584<
7/45-;
:*
@+88
74
56580,4<
70
W-=<46-,
i
-4,-(
j-;4/
<5-5
@+88
74
56580,4<
<4,?/+:-+9480(
Y<94/,4
4946-,
@+88
74
:/4,46-4<
70
,0,-4E
./>56
?85,,
56<
:/424//4<
-4/E
56<
,=EE5/+,4<
70
,-=<0
-/45-E46-
56<
2=/-;4/
70
+6-46,+-0
56<
/485-+.6,;+:-.,-=<0-/45-E46-(














 !"# $
%&
#$'"
#"#(
$!
 (#

#$'"(
$!
 )*"(

#&
,-./,.0
,23/45607
-437
8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
9
2/;7,52345.0
,23/45607
-437
88888888888888888888888888888888888888888888888888888888888888888888888888888888888
<
=./>2?7/524@25A
,5457B7/5
888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
<
=./54=5
@2,5
88888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
C
?7542@.>
4B7/?B7/5,
,2/=7
5D7
-07;2.6,
;70,2./88888888888888888888888888888888888888
E
,A/.-,2,
888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
F
54G@7.>
=./57/5,
4/?
@2,5
.>
54G@7,
4/?
>23607,
888888888888888888888888888888888888
HI
5JKLM
NO
=NPQMPQR
88888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
HI
@SRQNO
5JKLMR
JPT
>SUVWMR
8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
H<
@2,5.>4GG07;2452./,
4/?
?7>2/252./
.>
570B,
88888888888888888888888888888888888888888888
HC
H
2/50.?6=52./
8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
HE
H8H
 ?SRMJRM
JPT
,QVTX
5WMJQYMPQ
0MZSM[
888888888888888888888888888888888888888888888888888888888888888888
HE
H89
 ,VYYJWX
NO
0SR\R
JPT
GMPMOSQR
8888888888888888888888888888888888888888888888888888888888888888888888888888
H]
9
.G^7=52;7,88888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
H_
98H
 -WSYJWX
.K`MaQSZM
8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
H_
989
 ,MaNPTJWX
.K`MaQSZMR
88888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
H_
98<
 7bcLNWJQNWX
.K`MaQSZMR
88888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
H_
<
2/;7,523452./4@
-@4/
8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
9I
<8H
 .ZMWJLL
,QVTX
?MRSUP
JPT
-LJP
?MRaWScQSNP
888888888888888888888888888888888888888888888888888888888
9I
<89
 ?SRaVRRSNP
NO
,QVTX
?MRSUPd
SPaLVTSPU
QeM
=eNSaM
NO
=NPQWNL
3WNVcR
8888888888888888
9H
<8<
 -LJPPMT
?VWJQSNP
NO
QeM
,QVTX
888888888888888888888888888888888888888888888888888888888888888888888888888888
99
<8C
 ?MOSPSQSNP
NO
QeM
7PT
NO
QeM
,QVTX
888888888888888888888888888888888888888888888888888888888888888888888888
99
C
,7@7=52./
.>
,56?A
-.-6@452./
88888888888888888888888888888888888888888888888888888888888888888888
99
C8H
 2PaLVRSNP
=WSQMWSJ888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
99
C89
 7baLVRSNP
=WSQMWSJ
8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
9<
C8<
 0MYNZJL
NO
-JQSMPQR
OWNY
5eMWJcX
NW
4RRMRRYMPQ
88888888888888888888888888888888888888888888888
9<
C8<8H
 ,QVTX
5WMJQYMPQ
?SRaNPQSPVJQSNP
88888888888888888888888888888888888888888888888888888888888
9C
C8<89
 -JQSMPQ
fSQeTWJ[JL
888888888888888888888888888888888888888888888888888888888888888888888888888888888
9C
C8<8<
 ,QVTX
?SRaNPQSPVJQSNP
88888888888888888888888888888888888888888888888888888888888888888888888888888
9C
C8<8C
 0McLJaMYMPQ
-NLSaX
88888888888888888888888888888888888888888888888888888888888888888888888888888888
9g
g
,56?A
50745B7/5,
88888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888
9g
g8H
 ,QVTX
5WMJQYMPQR
4TYSPSRQMWMT8888888888888888888888888888888888888888888888888888888888888888888888888888
9g
g89
 2TMPQSQX
NO
,QVTX
5WMJQYMPQR888888888888888888888888888888888888888888888888888888888888888888888888888888888
9g
g8<
 -WMcJWJQSNP
JPT
@JKMLLSPU
8888888888888888888888888888888888888888888888888888888888888888888888888888888888888
9E
g8C
 ,MLMaQSNP
NO
?NRMRd
?NRSPU
,aeMTVLM
JPT
0NVQM
NO
4TYSPSRQWJQSNP888888888888888888888
9E
g8C8H
 ,MLMaQSNP
NO
?NRMR
SP
QeM
,QVTX
88888888888888888888888888888888888888888888888888888888888888
9E
g8C89
,MLMaQSNPJPT5SYSPUNO?NRMONWMJae-JQSMPQ888888888888888888888888888888888888889E
g8g ,QNWJUM8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888889F
g8E 4aaNVPQJKSLSQX88888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888889F














 !"# $
%&
'()
 +,-./0
/2
344567576
89-5,7-4
-/
:;,9-<,7-
=;/>?4
(((((((((((((((((((((((((((((((((((((((((((((
@A
'(A
 BC570576
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
@A
'(D
 8;5/;
970
E/7F/<5-97-
:.,;9?5,4
970
+,05F9-5/74
((((((((((((((((((((((((((((((((((((((((((((((
@D
'(D(G
 8;5/;
970
E/7F/<5-97-
:.,;9?5,4
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
@D
'(D(@
 8;5/;
970
E/7F/<5-97-
+,05F9-5/74
(((((((((((((((((((((((((((((((((((((((((((((((((((((((
@D
'(GH
I,4F>,
+,05F9-5/74
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
@D
'(GG
:;,9-<,7-
E/<?C597F,
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
@D
J
K:LMN
8IOEPMLIPK
3:
P3EQ
RSKS:
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TH
J(G
 KF;,,7576
UR545-
GV
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
T@
J(@
 R545-
@
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
T@
J(@(G
 8;,WM/4,
344,44<,7-4
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
T@
J(@(@
 K->0X
:;,9-<,7-
30<5754-;9-5/7
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TT
J(@(T
 8/4-WM/4,
344,44<,7-4
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TT
J(T
 R545-
T
-/
Y
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TT
J(T(G
 8;,WM/4,
344,44<,7-4
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TT
J(T(@
 K->0X
:;,9-<,7-
30<5754-;9-5/7
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TY
J(T(T
 8/4-WM/4,
344,44<,7-4
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TY
J(Y
 P70
/2
K->0X
UR545-
'V
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TY
)
K:LMN
+P:QOMOZO=N
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
T'
)(G
 M,</6;9?.5F4[
B94,C57,
E.9;9F-,;54-5F4
970
PC565\5C5-X
344,44<,7-4
(((((((((((((((((
T'
)(G(G
 M,</6;9?.5F
R9;59\C,4
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
T'
)(G(@
 +,05F9C]K>;65F9C
970
M54,94,
Q54-/;X
((((((((((((((((((((((((((((((((((((((((((((((((((((
T'
)(G(T
 I,^,;45\5C5-X
:,4-
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
T'
)(G(Y
 KF;,,7576
Z9\/;9-/;X
PC565\5C5-X
344,44<,7-4
(((((((((((((((((((((((((((((((((((((((
T'
)(G('
 8;5/;
970
E/7F/<5-97-
+,05F9-5/74
970
:.,;9?5,4
((((((((((((((((((((((((((((((((
T'
)(G(J
 PC565\5C5-X
E.,F_
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
T'
)(@
 8.9;<9F/0X79<5F
344,44<,7-4
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TJ
)(@(G
 8>C</79;X
`>7F-5/7
:,4-4
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TJ
)(@(@
 K?>-><
+,94>;,<,7-4
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TJ
)(@(T
 Pa.9C,0
\;,9-.
?Q
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TJ
)(T
 8.9;<9F/_57,-5F
344,44<,7-4
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TJ
)(Y
 K92,-X
344,44<,7-4
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
T)
)(Y(G
 30^,;4,
P^,7-4
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
T)
)(Y(@
 Z9\/;9-/;X
K92,-X
344,44<,7-4
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
T)
)(Y(T
 R5-9C
K5674
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
T)
)(Y(Y
 8.X45F9C
Pa9<579-5/7
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
T)
)(Y('
 G@WZ,90
PE=
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TA
)('
 BC//0
K9<?C576(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TA
)(J
 3??;/?;59-,7,44
/2
+,94>;,<,7-4
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
TA
A
Q3bMZSb=O`3MRPIKPPRPb:K3bM8IP=b3bESPK(((((((((((((((((((((((((((((((((((TA
A(G 30^,;4,P^,7-M,2575-5/74((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((TA














 !"# $
%&
'()
 +,-./0123
520
677,77123
608,/7,
98,2:7
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
;<
'()(=
 >,8,/1:?
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
;<
'()()
 @A/.21-1:?
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BC
'()(;
 @5D75E1:?
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BC
'()(B
 6-:1.2
520
FD:-.G,
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B=
'(;
 +,H./:123
I/.-,0D/,
J./
>697
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B=
'(B
 K5253,G,2:
.J
I/,3252-1,7
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B=
<
LM6NOPQ
6>>M+6R@9
6RS
LM6NOPQ
@FRP+FN
(((((((((((((((((((((((((((((((((((((((((((((
B)
<(=
 6D01:
520
O27H,-:1.2
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B)
<()
 K.21:./123
520
>.D/-,
S.-DG,2:
T,/1J1-5:1.2((((((((((((((((((((((((((((((((((((((((((((((((((((
B)
<(;
 S5:5
K5253,G,2:
520
@.0123
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B;
=C
>P6PO>PO@6N
K9PUFS>
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BB
=C(=
>:5:17:1-5E
520
625E?:1-5E
IE527
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BB
=C()
I.HDE5:1.27
:.
V,
625E?7,0
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BB
=C(;
>:D0?
920H.12:7
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BB
=C(;(=
I/1G5/?
920H.12:7
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BB
=C(;()
>,-.205/?
920H.12:7
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BB
=C(;(;
9WHE./5:./?
920H.12:7
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BX
=C(B
>:5:17:1-5E
K,:A.07
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BX
=C(B(=
I5:1,2:
S17H.71:1.2
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BX
=C(B()
I/.:.-.E
S,815:1.27
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BX
=C(B(;
S,G.3/5HA1-7
520
F:A,/
Y57,E12,
@A5/5-:,/17:1-7
(((((((((((((((((((((((((((((((((
BX
=C(B(B
9W:,2:
.J
9WH.7D/,
520
P/,5:G,2:
@.GHE152-,
(((((((((((((((((((((((((((((((((((((
BX
=C(B(X
IA5/G5-.0?25G1-7
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BX
=C(B(Z
IA5/G5-.[12,:1-7
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BZ
=C(B(\
>5J,:?
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
BZ
=C(B('
U520E123
.J
]1:A0/5^5E7
./
K177123
S5:5
(((((((((((((((((((((((((((((((((((((((((((((
BZ
=C(B(<
O2:,/1G
625E?7,7
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B\
=C(X
S,:,/G125:1.2
.J
>5GHE,
>1_,
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B\
==
9PUO@6N
@FR>OS9+6POFR>
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B\
==(=
`D10,E12,7
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B\
==()
9:A1-7
520
+,3DE5:./?
6HH/.85E
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B\
==(;
O2J./G,0
@.27,2:
I/.-,77
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B\
==(B
I5:1,2:
@.2J10,2:15E1:?
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B\
==(X
+,-./0
K512:,252-,a+,:,2:1.2
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B'
=)
bOR6R@9
6RS
OR>M+6R@9
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B'
=;
IMYNO@6POFR
IFNO@Q
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B'
=B
+9b9+9R@9>
(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
B<
=X
6II9RSO@9>
((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
X=
6HH,201W= 6--,H:5VE,K,:A.07.J@.2:/5-,H:1.2(((((((((((((((((((((((((((((((((((((((((((((((((((X=














 !"# $
%&'
'#
(
%)
*+,-./1
 34-56
*789
:;<.4
==================================================================================================
>?
@<A7/1
:8BC8D+4+8E
8F
G/A-7+D/5
HIJKKL
<E5
I7<M/A8
*8.B-7<4+8ED
===========================
>K
@<A7/>
3M;/5-7/
8F
NDD/DDB/E4D
+E
HIJKKLO?1?O>?1K
===================================================
P1















 !"# $
%&
 '#$(("
 $# '
$!
!"  # 

#")'
*+,-.*
*0123454
67
8691:5108;
*<=
*>;:5810
<?6:1858
=685;@3

*A,
*:;1
B0C;:
@?;
8B:9;
DEF
D6C3
>144
50C;G
DH
D;8@60
H58I50460
,>1G
E1G5>B>
8608;0@:1@560
,J
,34@58
J5K:6454
,JL
,6C;
67
J;C;:12
L;MB21@5604
,J<L
,34@58
J5K:6454
@:104>;>K:10;
860CB8@108;
:;MB21@6:
,F
,6075C;08;
50@;:912
,-NH
,?:6058
6K4@:B8@59;
OB2>601:3
C54;14;
,LJ
,14;
:;O6:@
76:>
P19
*9;:1M;
;77;8@
PD,
PG?12;C
K:;1@?
860C;41@;
P,Q
P2;8@:681:C56M:1>
PH<*
P@?32;0;C51>50;@;@:118;@58
185C
P>1G
E1G5>B>
;77;8@
PL=
PB:6O;10
L;4O5:1@6:3
=685;@3
P<JP
P@?32;0;
@;@:172B6:6;@?32;0;
JH*
J66C
10C
H:BM
*C>5054@:1@560
JP.R
J6:8;C
;GO5:1@6:3
962B>;
50
R
4;860C
J.,
J6:8;C
95@12
81O185@3
Q,N
Q66C
,2505812
N:18@58;
QEN
Q66C
E10B718@B:50M
N:18@58;
JP.R
J6:8;C
;GO5:;C
962B>;
50
R
4;860C
J.,
J6:8;C
95@12
81O185@3
F,S
F0@;:01@56012
,607;:;08;
60
S1:>60541@560
FTUV
F0@;:2;BI50
V
FAN*,
F0@;:01@56012
A0560
67
NB:;
10C
*OO25;C
,?;>54@:3
T*D*
T60M
18@50M
K;@1
WU1M6054@
T*E*
T60M
18@50M
>B481:5058
10@1M6054@
TN=
T5O6O6234188?1:5C;
E*H
EB2@5O2;148;0C50MC64;X4Y














 !"# $
%&
'()*+,
'()./01
*./2.34056
735
+(89102356
,/2.:.2.(;
'<=
'6(13>(53?.)0;(
'+@,
'(2A./.11.4B5(;.;2042
@20>A613/3//9;
095(9;
<CDE'CA
<53:3/02.:(
/34/(42502.34
37
F(2A0/A31.4(
/A135.)(
/09;.48
0
7011
.4
GHIJ
37
DEK
753F
L0;(1.4(
<*H
<A3;>A3).(;2(50;(
MN/G
MN
.42(5:01
/355(/2()
735
A(052
502(
9;.48
G5.)(5./.0O;
735F910
@,H
@(5.39;
0):(5;(
(:(42
@,*
@.481(
0;/(4).48
)3;(P;Q
@,@
@202.;2./01
04016;.;
;372R05(
@*
@204)05)
)(:.02.34
@=C
@6;2(F
35804
/10;;
@=<
@204)05)
3>(502.48
>53/()95(
@S@,+
@9;>(/2()T
94(?>(/2()
;(5.39;
0):(5;(
5(0/2.34
2
JUD
V017B1.7(
2
F0?
N.F(
23
F0?.F9F
/34/(42502.34
NWGBX
N9F395
4(/53;.;
70/235
01>A0
SY
S4.2()
Y.48)3F














 !"# $
%&'

 #!)# 

!
*
+,*-
#
./
01233457
897::
9;:<=>:<
?8;@>?A;:;A<
B<C?D7E?D<5
?8
7
B>7:
?AF?G?E;C
;H
EI;
?8;H;C98
JEKL<
M
7AB4N;HEF<
LF;8LF;B?<8E<C78<
J1OPN
H79?:K
;H
<AQK9<8R
1OPM
7AB
1OP4
7C<
SA;IA
E;
F7D<7C;:<
?A
9;B>:7E?AT
EF<
?AH:7997E;CK
7?CI7K
C<8L;A8<
?A
C<8L?C7E;CK
B?8<78<85
?A=:>B?AT
=FC;A?=;G8EC>=E?D<
L>:9;A7CK
B?8<78<
JUV1ON5
7::<CT?=
78EF97
7AB
7::<CT?=
CF?A?E?8R
WA
T<A<C7:51OPM
?AF?G?E;C8
7=E
78
GC;A=F;B?:7E;C8
JEFC;>TF
?AE<C7=E?;A
I?EF
89;;EF
9>8=:<
=<::8N5IF?:8E
1OP4
?AF?G?E;C8
F7D<
7AE?X?AH:7997E;CK
LC;L<CE?<8
7AB
EF<C<
?8
7:8;
<D?B<A=<
E;
8>TT<8EEF7E
=;9G?A<B
?AF?G?E?;A
;H
1OPM
7AB
1OP4
=7A
F7D<
7BB?E?D<
;C
8KA<CT?8E?=
7AE?X?AH:7997E;CK
7AB
GC;A=F;B?:7E;C
<HH<=E8
JC<D?<I<B
GK
YGG;EEXZ7AA<C
[
17T<5
\]^4NR
1F7C97=;:;T?=7:
<D?B<A=<
HC;9
A;AX=:?A?=7:
9;B<:8
?A
IF?=F
B>7:
1OPM_4
?AF?G?E;C8
F7D<
G<<A<`79?A<B5
8>TT<8E8
EF7E
012334
97K
F7D<
L;E<AE?7:
EF<C7L<>E?=
7=E?D?EK
?A
7::<CT?=
78EF975UV1O5
7::<CT?=
CF?A?E?8
7AB
UK8E?=
a?GC;8?8
JUaNR
O>7:
1OPM_1OP4
?AF?G?E;C8
J7B9?A?8E<C<B
GK
?AF7:7E?;AN
7AB
1OP4
?AF?G?E;C8
JIF<A
7B9?A?8E<C<B
;C7::KN
F7D<
<`F?G?E<B
GC;A=F;B?:7E;C
 7AB
 7AE?X?AH:7997E;CK
 7=E?;A8
 C<8L<=E?D<:K
 ?A
 =:?A?=7:
 8E>B?<8
JbS<A7<E7:5
^cc3d
eC;;E<AB;C8E
<E
7:5
\]]fNd
F;I<D<C5
;C7:
7B9?A?8EC7E?;A
;H
1OP4
?AF?G?E;C8F78
G<<A
788;=?7E<B
I?EF
>AH7D;>C7G:<
T78EC;?AE<8E?A7:
8?B<
<HH<=E8
8>=F
78
A7>8<75
<9<8?85B?7CCF;<75
7GB;9?A7:
L7?A5
:;88
;H
7LL<E?E<
7AB
I<?TFE
:;88R
WAB<<B5
EF<8<
I<C<
8;9<
;HEF<9;8E
=;99;A
8?B<
<HH<=E8
;H
EF<
1OP4
?AF?G?E;C85
C;H:>9?:78E
7AB
=?:;9?:78E
;G8<CD<B
?A=:?A?=7:
8E>B?<8
?AD;:D?AT
L7E?<AE8
I?EF
78EF97
;C
UV1O
Jg7CG?A8;A
<E
7:5
^ccfd
D7Ah=F7:SIKS
<E
7:5
\]]3d
U;9LE;A
<E
7:5
\]]^d
07G<
<E
7:5
\]]3d
0<AA7CB
<E
7:5
\]]id
U7:D<C:<K<E
7:5
\]]fd
e79G:<
<E
7:5
\]]Md
eC;;E<AB;C8E
<E
7:5
\]]fNR
WE
?8
L:7>8?G:<
EF7E
?A=C<78<B<HH?=7=K
I?EF
C<B>=<B
8?B<
<HH<=E8
97K
G<
7=F?<D7G:<
I?EF
7B9?A?8EC7E?;A
;H
7
B>7:
1OPM_4?AF?G?E;C
GK
EF<
?AF7:<B
C;>E<
=;9L7C<B
E;
;C7::K
7B9?A?8E<C<B
1OPM
;C
1OP4
?AF?G?E;C8R

a>CEF<C9;C<5
?A
?8;:7E<B
F>97A
GC;A=F?
LC<X=;AEC7=E<B
I?EF
7=<EK:=F;:?A<5
=;A=;9?E7AE
7B9?A?8EC7E?;A
;H
:;I
=;A=<AEC7E?;A8
;H
012334
7AB
87:G>E79;:5
;C
:;I
=;A=<AEC7E?;A8
;H
0123347AB
7AE?X9>8=7C?A?=
7AE7T;A?8E8
J7EC;L?A<
7AB
T:K=;LKCC;:7E<N5
?AB>=<B
7BB?E?D<
7AB
8KA<CT?8E?=
C<:7`7E?;A5
C<8L<=E?D<:KR
WA
7BB?E?;A5
EF<
=;A=;9?E7AE
7B9?A?8EC7E?;A
;H
:;I
=;A=<AEC7E?;A8
;H
012334
L:>8
T:K=;LKCC;:7E<
7:8;
LC;B>=<B
7
8?TA?H?=7AE
8KA<CT?8E?=
C<:7`7AE
<HH<=E;HGC;A=F?
LC<X=;AEC7=E<B
I?EF
F?8E79?A<
JU7:Q<EE7
<E
7:5
\]^MNR
012334
7AB
T:K=;LKCC;A?>9
7:8;
=7>8<B
7
8KA<CT?8E?=
?AE<C7=E?;A
?A
C<:7`?AT
G;EF
F>97A
9<B?>9
7AB
897::?8;:7E<B
GC;A=F?5
A;E
j>8E
?A
E<C98
;H
L<7S
C<:7`7E?;A
G>E
7:8;
I?EF
C<T7CB8
E;
7A
<`E<AB<BB>C7E?;A
;H
7=E?;A
JU7:Q<EE7
<E
7:5
\]^3NR
012334
F78
7:8;
G<<A
8F;IA
E;
?AE<C7=E
I?EFG<E7
\X7T;A?8E8
7AB
7AE?X9>8=7C?A?=
7AE7T;A?8E8
?A
D?D;R
hL<=?H?=7::K
EF<
=;9G?A7E?;A
;H
012334 7AB
7EC;L?A<
;C
012334
7AB
87:G>E79;:
=7>8<B
7
TC<7E<C
C<:7`7E?;A
;H
G;9G<8?AX?AB>=<B
=;AEC7=E?;A
?A
T>?A<7
L?T
7?CI7K8
EF7A
012334
7:;A<
Jk<?C
<E
7:5
\]^4N
1C<:?9?A7CK
B7E7
F78
B<9;A8EC7E<B
EF7E
012334
=7A
7=E?D7E<
EF<
UK8E?=
a?GC;8?8
EC7A89<9GC7A<
=;AB>=E7A=<
C<T>:7E;C
JUal0N5
EF<
G78?=
B<H<=E
?A
Ua5
7AB
7:8;
EF7E
?E
?8
7BB?E?D<I?EF
k7:KB<=;
J?D7=7HE;Cd
mnff]N
Ual0
L;E<AE?7E?;A
?A
a3]oB<:_0^^fgXUal0
F>97AGC;A=F?7:
<L?EF<:?7:
=<::8
Jl>CA<C
<E
7:5
\]^iNR
WE
?8
FKL;EF<8?8<B
EF7E
012334
8F;>:B
G<;H8?TA?H?=7AE
G<A<H?E
E;
Ua
L7E?<AE8
GK
D?CE><
;H
?E8
LC;D<A
GC;A=F;B?:7E;C
7AB
7AE?X?AH:7997E;CK
7=E?D?E?<8
?A
97A5
EF>8
C<B>=?AT
8K9LE;98
7AB
LC<D<AE?AT
:>AT
E?88><
B<8EC>=E?;AR

lF<87H<EK5GC;A=F;B?:7E;C5GC;A=F;LC;E<=E?D<7AB7AE?X?AH:7997E;CK7=E?D?E?<8;HEF<A;D<:
B>7:1OPM_4?AF?G?E;C5012334F78G<<A<D7:>7E<B7ABC<L;CE<B?AH;>C=;9L:<E<B8E>B?<8?A
F<7:EFK8>Gj<=E85L7E?<AE8I?EF9?:BX9;B<C7E<L<C8?8E<AE78EF977ABEF;8<I?EFUV1O














 !"# $
%&
'()*+,-./-
12
*34
56789:
;<1/1
/2=>-1/
*)1
>1/,)-?1>
-+
>12*-3
-+
2<1
@+A1/2-B*2.)C/
D).,<=)1:
(.)*332<1/1
,.EF3121>
,3-+-,*3
/2=>-1/4
GHIJJK
L*/
M.)E=3*21>
*/
*
+1?=3-/1>
/.3=2-.+
.M
GHIJJK-+
,-2)*21NF<./F<*21
?=MM1)1>
/*3-+1
*2
FO
8:5:
PQ/21E-,
1RF./=)1
M.33.L-+B
-+<*3*2-.+
=/-+B
2<-/
/.3=2-.+
M.)E=3*2-.+
L*/
3.L
*+>
/.E1L<*2
A*)-*?314
L-2<
E*R-E=E
,.+,1+2)*2-.+
'SE*R9
A*3=1/
)*+B-+B
M).E
*?.=2
6:T
+BNEI
M.33.L-+B
*>E-+-/2)*2-.+
*2
6:67UEBNVB
2.
*?.=2
K
+BNEI
*2
6:6W5EBNVB:
X)1*
=+>1)
2<1
,=)A1
'XYS9
6Z2
A*3=1/
)*+B1>
M).E*?.=2
7:J
+B:<NEI
2.
77
+B:<NEI
.A1)
2<1
/*E1
>./1
)*+B1:
[1*+
<*3MZ3-M1
'2
7N59

A*3=1/
)*+B1>M).E
*FF).R-E*213Q
8
2.
W
<.=)/:
GHIJJK>13-A1)1>
?Q
-+<*3*2-.+
*/
*
+1?=3-/1>
/.3=2-.+
L*/
L133
2.31)*21>:
X>A1)/1
1A1+2/
L1)1E-3>
*+>
B1+1)*33Q
.M
1\=*3
M)1\=1+,Q
?12L11+
F3*,1?.
*+>
*,2-A1
2)1*2E1+2
B).=F/:
GHIJJKF).>=,1>
*
)*F->
?).+,<.>-3*2-.+
-+
*/2<E*2-,
F*2-1+2/
L-2<
*
E*R-E*3
M.),1>
1RF-)1> A.3=E1
-+
.+1
/1,.+>
'(]^79
-+,)1*/1
.M
J56
EI
'TJ_
,.+M->1+,1
-+21)A*3
`S@ab856ZW56
EIc
Fd6:666794
L<-,<
L*/
*
7K_
-+,)1*/1
M).E
?*/13-+1
*+>
-+,)1*/1>
2<1
F).A.,*2-A1
,.+,1+2)*2-.+
.M
E12<*,<.3-+1
,<3.)->1
,*=/-+B
*
M*33
-+
(]^7
.M
56_
M).E
?*/13-+1'HS56[S<9
?Q
7:J
>.=?3-+B
>./1/
'TJ_
S@b
6:e8Z5:5Uc
Ff6:66K9:
g<1+
-+<*31>
.+,1
>*-3QM.)e
>*Q/4
GHIJJK
F).>=,1>
*
/-E-3*)
E*B+-2=>1
.M
?).+,<.>-3*2-.+
1*,<
2-E1:
GHIJJKL*/
*?/.)?1>
-+2.
2<1
?3..>
/2)1*E4
?=2
<*>
3-E-21>
/Q/21E-,
?-.*A*-3*?-3-2Q
)1*,<-+B*
B1.E12)-,
E1*+
SE*R
.M
GHIJJK
-+
?3..>
.M
7W6e
FBNEI
'h*Q
79
*+>
7T6K
FBNEI
'h*Qe94L-2<
)*F->
F3*/E*
,31*)*+,1
*+>
+.
>)=B
*,,=E=3*2-.+:
@+
SiHh
F*2-1+2/4
GHIJJK
F).>=,1>,3-+-,*33Q
E1*+-+BM=3
?).+,<.>-3*2-.+
L-2<
*
E1*+
E*R-E*3
(]^7
-+,)1*/1
.M
7W_:
@+<1*32<Q
/=?j1,2/4
GHIJJK
*3/.
F).>=,1>
*
/-B+-M-,*+2
-+<-?-2-.+
.M
2<1
3-F.F.3Q/*,,<*)->1
'IHP9Z-+>=,1>
)1,)=-2E1+2
.M
2<1
2.2*3
+=E?1)
.M
-+M3*EE*2.)Q
,133/
2.
2<1
*-)L*Q/
'Ff6:66594
*/
L133
*/
*+
-+<-?-2-.+
.M
2<1
*?/.3=21
+=E?1)/
.M
+1=2).F<-3/
'Ff6:66594
1./-+.F<-3/
'Ff6:66794
3QEF<.,Q21/
'Ff6:6679
*+>
E*,).F<*B1/
'Ff6:6K9
-+
/F=2=E:
GHIJJK<*/
+.L
?11+
)1ZM.)E=3*21>
-+
*
+1=2)*3
FO
F<./F<*21
?=MM1)1>
/=/F1+/-.+
M.)E=3*2-.+
M.)
+1?=3-/*2-.+:

;<1/=/F1+/-.+
M.)E=3*2-.+
<*/
?11+
21/21>
-+
2<)11
,.EF3121>
/2=>-1/
'Dj1)E1)
12
*34
567ec
P-+B<12*34
567ec
P-+B<
12
*34
567e9:
P2=>Q
GHIJJKZ66WZ567K
L*/
*
H<*/1
@
)*+>.E-/1>4
>.=?31?3-+>4
F3*,1?.
,.+2).331>
/2=>Q
-+
L<-,<
/-+B31
*/,1+>-+B
>./1/
'PXh9
-+
2<1
)*+B1
7:JEB2.5K
EB
L1)1
*>E-+-/21)1>
2.
8J
<1*32<Q
/=?j1,2/4
E=32-F31
*/,1+>-+B
>./1/
'[Xh9
-+2<1)*+B1
e
EB
2.
5K
EB
2L-,1
>*-3Q
M.)
=F
2.
J:J
>*Q/
L1)1
*>E-+-/21)1>
2.
57
<1*32<Q
/=?j1,2/*+>
[Xh
-+
2<1
)*+B1
7:J
EB
2.
75
EB
2L-,1
>*-3Q
M.)
J:J
>*Q/
L1)1
*>E-+-/21)1>
2.
58SiHhF*2-1+2/:

P2=>QGHIJJKZ66UZ567K
L*/
*
H<*/1
@@
>.=?31
?3-+>4
F3*,1?.
,.+2).331>
/1A1+
L*Q
,.EF3121?3.,V
,).//.A1)
/2=>Q:
;<-/
/2=>Q
1+).331>
5T
F*2-1+2/
L-2<
E-3>ZE.>1)*21
,<).+-,
*/2<E**+>
F*2-1+2/
)1,1-A1>
M.=)
/-+B31
>./1/
.M
GHIJJK
'6:K
EB4
7:J
EB4
e
EB
*+>
5K
EB94
2L.>./1/
.M
+1?=3-/1>
/*3?=2*E.3
'5:J
EB
*+>
W:J
EB9
*+>
F3*,1?.
-+
*
)*+>.E-/1>
/1\=1+,1:GHIJJK
F).>=,1>
*
>./1Z>1F1+>1+2
?).+,<.>-3*2-.+
L-2<
*
E*B+-2=>1
2<*2
L*/
,.EF*)*?31
2.
*
E*R-E*3
>./1
.M
/*3?=2*E.34
?=2
L-2<
M1L1)
.M
2<1
L133
>1/,)-?1>
/*3?=2*E.3
/->11MM1,2/
'1:B:
<QF.V*3*1E-*4
2*,<Q,*)>-*4
2)1E.)
*+>
F*3F-2*2-.+/9:
P2=>QGHIJJKZ66TZ567J
L*/
*
H<*/1
@@
)*+>.E-/1>4
>.=?31
?3-+>4
>.=?31
>=EEQ4
F3*,1?.
,.+2).331>4
/-R
L*Q
,.EF3121
?3.,V
,).//.A1)
/2=>Q
-+
E.>1)*21
2.
/1A1)1
SiHh
F*2-1+2/:
;<-//2=>Q
1+).331>
8e
/=?j1,2/
L<.
)1,1-A1>
/*3?=2*E.3
'566
kB94
-F)*2).F-=E
'K6
kB9
.)
F3*,1?.=/-+B
*
F)1//=)-/1>
E121)1>
>./1
-+<*31)
M.33.L1>
-EE1>-*213Q
?Q
+1?=3-/1>
GHIJJK
'eEB9.)
F3*,1?.:
GHIJJK
*3.+1
L*/
*/
1MM1,2-A1
*/
/*3?=2*E.3
.)
-F)*2).F-=E
*/
*
?).+,<.>-3*2.)4*+>-EF.)2*+23QF).>=,1>/-B+-M-,*+2*>>-2-A1?).+,<.>-3*2-.+'F1*V*+>
*A1)*B1.A1)U<.=)/9L<1+>./1>L-2<1-2<1)/*3?=2*E.3.)-F)*2).F-=E'Fd6:6679:GHIJJK
*3/.)1/=321>-+*+*>>-2-A1*+>/-B+-M-,*+2)1>=,2-.+-+3=+BA.3=E1/*+>*-)L*Q)1/-/2*+,1:














 !"# $
%&'
()*++,./0
.122
34215/316
78
/22
39511
03:6710;
<9151
.151
84
01574:0
/6=1501
1=1830
45
/6=15011=1830
4>
?48?158;
<91@9/5A/?4B78137?0
4>
()*++,C
>4224.78D
078D21
81E:27016
789/216
64010
4>
3970
0:0@180748
>45A:2/3748C
.151
?9/5/?3157016
EF
/@@54G7A/312F
6401
@54@453748/2
0F031A7?
1G@40:5178
/22
39511
03:6710;
H/2:10
4>
IA/G
.151
D1815/22F
/33/7816
/54:86
J
34
J;+
94:50
/>31564078DC
0:DD10378D
/
031/6F
/86
04A1.9/3
@54248D16
/E045@3748
4>
391
()*++,
6401
>54A 3912:8D0
7834
391
0F031A7?
?75?:2/3748K
@2/0A/
?48?1835/37480
61?27816
024.2F
.739
/
A1/8315A78/2
9/2>L27>1
78
391
5/8D1
M
34
JN
94:50;
)1/B
@2/0A/
?48?1835/37480
4E3/7816
.739
3910:0@180748
>45A:2/3748
.151
481
39756
34
481
O:/5315
4>
39401
0118
.739
391
042:3748
>45A:2/3748;
P8
03:6F
()*++,LQQRLSQJ,C
391
3.7?1
6/72F
64078D
51D7A18
/64@316
>45
391
TUV@9/01
216
34
04A1
/??:A:2/3748
/86
031/6F
03/31
1G@40:51
/@@1/516
34
E1
/?971=16
EF
V/FW4>3.7?1
6/72F
64078D
78
E439
91/239F
0:EX1?30
/86
IY)V
@/371830;
<91
4E015=/3748
39/3
0F031A7?1G@40:51
34
()*++,
./0
D1815/22F
24.15
78
IY)V
@/371830
./0
78
2781
.739
1G@1?3/37480;
P3
70
?480761516
39/3
3970C
/86
391
61D511
4>
78315L0:EX1?3
=/57/E7273F
78
@9/5A/?4B78137?
@/5/A13150
0118
78
/22
?494530
/51
A/782F
/
51>21?3748
4>
67>>1518?10
78
391
1G31834>2:8D
61@4073748
E13.118
03:6F
0:EX1?30;
<91
@9/5A/?4B78137?
6/3/
4E3/7816
78
391
3.4)9/01
PP
03:6710
.151
?480703183
.739
391
@54>7210
103/E270916
78
391
)9/01
P
03:6FK
/D/78
73
./04E015=16
39/3
A1/8
0F031A7?
1G@40:51
@/5/A13150
.151
24.15
78
A726
34
A4615/31
/039A/37?@/371830
/86
78
@/371830
.739
03/E21
IY)VC
39/8
78
91/239F
0:EX1?30;
Y=15/22C
391
03:6710@15>45A16
.739
789/216
81E:27016
0:0@180748
64010
4>
()*++,
9/=1
094.8
51@546:?7E21
@9/5A/?4B78137?
E19/=74:5
E13.118
03:6710
/86
/?5400
@/37183
?494530;
Z/0164839101
6/3/C
391
81.
0:0@180748
>45A:2/3748
011A0
34
E1
7[
.122
34215/316C
@4007E2F
6:13424.15
@1/B
@2/0A/
21=120
77[
/8
1>>1?37=1
E548?94672/345
78
IY)V
/86
/039A/
@/371830
/0.122/0
91/239F
0:EX1?30
/86
777[
9/=1
/
@54248D16
9/2>L27>1
?4A@/516
34
391
042:3748
>45A:2/3748C
/224.78D
>45
3.7?1
6/72F
64078D;

<91@:5@401
4>
3970
03:6F
70
34
78=1037D/31
7>
()*++,
9/0
07A72/5
@9/5A/?4B78137?0
78
I\
@/37183034
39/3
0118
78
91/239F
0:EX1?30
/86
@/371830
.739
/039A/
45
IY)V;
U
01?486/5F
4:3?4A170
34
244B
>45
@9/5A/?46F8/A7?
186@47830C
@5164A78/832F
\]HJC
34
61315A781
391
E548?94672/345
1>>1?3
4>
()*++,
78
03/E21
@/371830
.739
I\;


_`a
'
b
c
d'
V/3/>54A
848L?2787?/2
03:6710
0:DD103
/
@431837/2
>45
9F@43180748
/86
3/?9F?/567/;
e4.1=15C
()*++,9/0
E118
/6A787031516
34
/E4:3
S,f
0:EX1?30
78
?2787?/2
03:6710
34
6/31
/86
9/0
E118
.12234215/316
78
IY)V
@/371830C
91/239F
0:EX1?30C
/039A/37?0
/86
/2215D7?
5978737?0;
g4
01574:0/6=1501
1=1830
hiU]0[
6:578D
0?916:216
351/3A183
/86
>4224.L:@
9/=1
E118
51@45316
.739()*++,;

U6=15011=1830
39/3
9/=1
E118
51@45316
/3
21/03
3.7?1
78
0:EX1?30
.94
9/=1
51?17=16
078D21
45
A:237@2164010
4>
391
042:3748
>45A:2/3748
4>
()*++,
.151
D1815/2
A726
/86
78
610?18678D
456154>>51O:18?F
/51
91/6/?91C
8/0/2
?48D103748C
67jj78100C
04A84218?1C
5978455941/C
>/37D:1C2/5F8G
75573/3748C
=/04672/3748C
/039A/C
65F
3954/3C
510@75/345F
35/?3
78>1?3748C
/86
0811j78D;T/8F
4>
391
1=1830
/204
4??:5516
.739
/
07A72/5
>51O:18?F
.739
@2/?1E4;
<91
482F
439154E015=/3748
84316
./0
/
A46103
78?51/01
78
03/8678D
91/53
5/31
78
481
03:6F;

<910:0@180748
>45A:2/3748
4>
()*++,
70
@e
E/2/8?16C
/86
9/0
>/=4:5/E21
848L?2787?/2
34G7?424DF
/86
@9/5A/?4B78137?
6/3/;
<91
@9/5A/?4B78137?0
.739
391
0:0@180748
>45A:2/3748
7065/A/37?/22F67>>15183>54A 39/3.739391042:3748>45A:2/3748;<91/E045@374870A:?9
024.15C.739/<A/G
4>J34J;+94:50C/86391315A78/29/2>L27>1A:?9248D15hM34JN94:50[;
<91IA/G
7024.1539/8.739391042:3748>45A:2/3748C/2394:D9391343/21G@40:5170D51/315;














 !"# $
%&
'()*)(,-
.))/
/0
)123)/4)
05
-26/2524,/7
,31)*-)
)1)/7-
*)8,7)3
70
7()
4,*3201,-498,*
0*
6,-7*02/7)-72/,8
-:-7);-<
)=4)>7
,--042,7)3
?27(
,/
2/4*),-)
2/
(),*7
*,7)
,7
(26(
30-)-
@AB
;6
70BC;6DE
'()-)
-;,88
2/4*),-)-
2/
(),*7
*,7)
;,:
*)8,7)
70
7()
FGHI
2/(2.270*:
,472127:
05
7()40;>09/3E
J/
-2/68)
30-)
-7932)-
7()*)
,>>),*-
70
.)
,/
2/4*),-)
2/
7()
*,7)
05
(),3,4()<
?(24(2-;0-7
>*0/09/4)3
,7
30-)-
01)*
K
;6E
'()*)
?,-
/0
07()*
,>>,*)/7
30-)
*)8,7)3
,31)*-))1)/7-<
?27(
7()
)=4)>720/
05
>,8>27,720/-
2/
>,72)/7-
30-)3
,7
BC
;6E
L)-987-
5*0;
;9872>8)30-)
3,7,
2/
>,72)/7-
?27(
MNFG
-966)-7-
,
7*,/-2)/7
2/4*),-)
2/
32OO2/)--P
7()
;,Q0*27:05
?(24(
0449**)3
39*2/6
->2*0;)7*:
0*
30-2/6<
.97
07()*?2-)
7()
*,7)
05
,31)*-)
)1)/7-?)*)
-2;28,*
2/
LFRSSC
0*
>8,4).0
7*),7)3
>,72)/7-E
'()*)
?,-
,/
,>>,*)/7
2/4*),-)
2/
;283,31)*-)
)1)/7-
2/
(),87(:
-9.Q)47-
7*),7)3
?27(
(26(
30-)-
05
LFRSSC<
?(24(
;,:
.)
,--042,7)3
?27(
7()
(26()*
-)*9;
8)1)8-
2/
(),87(:
2/321239,8-
7(,/
2/
7(0-)
?27(
0.-7*94721)
89/632-),-)E
J;>*01);)/7-
2/
89/6
59/4720/
4,/
.)
)=>)47)3
2/
>,72)/7-
?(0
,*)
30-)3
?27(
LFRSSCE
T0?)1)*<-9.Q)47-
?288
/07
2/321239,88:
.)/)527
5*0;
>,*7242>,720/
2/
7(2-
-793:E

VW"# 
"X

Y
Z[
'02/1)-726,7)
>(,*;,40\2/)724-
05
-2/68)
/).982-)3
30-)-
05
LFRSSC
2/
>,72)/7-
?27(
M]E

X^Y
Z[
_
'02/1)-726,7)
7()
.*0/4(0328,70*
)55)47
0/
>),\
]HaA
,57)*
-2/68)
/).982-)3
30-)-
05
LFRSSC
,-
40;>,*)3
70
>8,4).0
_
'02/1)-726,7)
7()
.*0/4(0328,70*
)55)47
0/
bcM
]HaA
01)*
C<
K
,/3
d
(09*-
05
-2/68)
/).982-)3
30-)-
05
LFRSSC<
,-
40;>,*)3
70
>8,4).0
_
'0,--)--
7()
708)*,.2827:
,/3
-,5)7:
05
-2/68)
/).982-)3
30-)-
05
LFRSSC

2/
>,72)/7-
?27(
M]
e
"fY
Z[
_
'0)=,;2/)
7()
,/72g2/58,;;,70*:
)55)47-
05
-2/68)
/).982-)3
30-)-
05
LFRSSC
2/
>,72)/7-
?27(
M]















 !"# $
%&
'
 
")# *$# $
$
'
+
),-.
!%
-

!
/01212450426
7748
94:;<=126;8
;<>?@6
?@1:;8
A@4B6?<
B<:C9<@@6;8
;<>?@6
;>==D8
B<=A@6C6
?@<BEC0966
F4D
B9<22<G69
2C>;D
C<
1:G62C1H4C6
C06
A049=4B<E1:6C1B2
<I
:6?>@126;
J5KLLM
1:
4;>@CA4C16:C2
F1C0
NOP
7C
12
A@4::6;
C<
6:9<@
2>II1B16:C
A4C16:C2
C<
6:2>96
C04C
QR
B<=A@6C6
4@@
C0966C964C=6:C
A691<;2
4C
CF<
B6:C962P
/06
2C>;D
B<=A91262
C06
I1G6
G121C2
20<F:
1:
O1H>96
QS
2B966:1:HTU121C
QV8
C0966
C964C=6:C
G121C2
TU121C
W
C<
U121C
MV
4:;
4:
6:;
<I
2C>;D
G121C
TU121CLVP/06
A9<B6;>962
A69I<9=6;
4C
64B0
G121C
496
2>==49126;
1:
X6BC1<:
Y
4:;
C06
2C>;D
422622=6:C2
496
;62B91?6;
1:
X6BC1<:
ZP
%, ),-.
[

\
^_
`a
bcde

























\
^_
`a
bcde



















\
^_
`a
bcde




























\
^_
`f
bcde








g4h
j4D
?6
A69I<9=6;
42
4
21:H@6
G121C
<9
=<96
C04:
<:6
G121C
TI<9
6k4=A@6
1I
C06
A4C16:C
12
C4E1:H
=6;1B4C1<:2
C04C
96l>196
F420<>C
I<9
C06
96G6921?1@1CD
C62CV

g?h
54C16:C2
F1@@
?6
94:;<=126;
A96m;<26
4C
U121C
W
54C16:C2F1@@
?6
2B966:6;
I<9
6@1H1?1@1CD
TU121C
QV8
1:B@>;1:H
4
96G6921?1@1CD
C62C
F1C0
24@?>C4=<@
?6CF66:n
4:;
QM
;4D2
?6I<96
C06
I192C
;<26
<I
2C>;D
C964C=6:CP

o@1H1?@6A4C16:C2
F1@@
C06:
4CC6:;
I<9
C0966
26A494C6
Q
;4D
C964C=6:C
G121C2
TU121C2
W
C<
U121C
MV
64B026A494C6;
?D
4C
@642C
4
n
;4D
F420<>C
A691<;P
54C16:C2
F1@@
?6
94:;<=126;
A96m;<26
4C
U121CWP54C16:C2
F1@@
96B61G6
4
21:H@6
:6?>@126;
;<26
<I
QPL
=H
J5KLLM
<9
Y
=H
J5KLLM
<9
A@4B6?<4C
64B0
G121CP
pC
64B0
G121C8
A4C16:C2
F1@@
?6
9621;6:C
4C
C06
2C>;D
B6:C96
I9<=
C06
=<9:1:H>:C1@
4C
@642C
q
0<>92
4IC69
;<21:HP
54C16:C2
F1@@
?6
;12B049H6;
4IC69
q
0<>928
?>C
96C>9:C06I<@@<F1:H
=<9:1:H
I<9
I1:4@
422622=6:C2
WM
0<>92
4IC69
;<21:HP
/06I<@@<F1:H
F1@@
?6
A69I<9=6;
4C
64B0
C964C=6:C
G121CS
r
j642>96=6:C2
<I
@>:H
I>:BC1<:
TOoUQ
4:;
I<9B6;
G1C4@
B4A4B1CD
gOUNhV
A96m;<26
4:;
>AC<
WM
0<>92
A<2Cm;<26
r
s@<<;
24=A@1:H
A96m;<26
4:;
>A
C<
WM
0<>92
A<2Cm;<26
I<9
A049=4B<E1:6C1B
4:4@D212

r
XA>C>=
24=A@1:H
A96m;<26
4:;
4C
q
4:;
WM
0<>92
A<2Cm;<26
I<9
906<@<HD
4:;
=642>96=6:C<I1:I@4==4C<9D=6;14C<92T1:C69@6>E1:qg7Kmqh8C>=<>9:6B9<212I4BC<9
4@A04g/tOmuv4:;=D6@<A69<k1;426gj5whV
Jptxwj7Xp/7wtg?h
QR
A4C16:C2
A@4::6;


 ) #

"!

)#y!z

 ) #

 ) #

)"" *
{|

 ) #

)#
#


 ) #
'
!
#

 ) #

'!
#
}~



}~

}}}

%


%

















 !"# $
%&
'
)*+,-./
12.,3+
45
6.,782.6.93
42.:/;7.
,9/
,3
<
,9/
=>
+;827
4;73:/;7.
?,3
@A
B.932.
;9-CD
'
@2E9.
42.F9,9BC
3.73
42.:/;7.
?G.6,-.
4,3E.937
;9-CD
'
HE3,-
7EF97
,9/
I=:-.,/
.-.B32;B,2/E;F2,67
?)JKD
42.:/;7.
,9/
84
3;
<
+;827
4;73:/;7.
L9.9/;G
738/C
ME7E3
?HE7E3
ND
OE--
1.
4.2G;26./
P
3;
IQ
/,C7
,G3.2
3+.
-,73
/;7.
;G
738/C
32.,36.93R

L/M.27..M.937
OE--
1.
2.B;2/./
3+2;8F+;83
3+.
738/C
,9/
-,1;2,3;2C
7,G.3C
3.737S
,
4+C7EB,-
.*,6E9,3E;9
,9/
82E9.
42.F9,9BC
3.737
?G.6,-.
4,3E.937
;9-CD
OE--
1.
4.2G;26./
,3
7B2..9E9F
?HE7E3ID,9/
,3
3+.
.9/
;G
738/C
ME7E3
?HE7E3
NDR
T
!V
&
WVXY
!%Z
VX%


&

[V
L3;3,-;G,442;*E6,3.-C
IQ
J\
4,3E.937
,F./
]^_
C.,27
OE--
1.
2,9/;6E7./R
`+.
4824;7.
;G
3+.738/CE7
3;
E9M.73EF,3.
3+.
4+,26,B;aE9.3EB7
;G
bcdNN>
E9
4,3E.937
OE3+
J\R
e9
,//E3E;9S
3+.,B83.12;9B+;/E-,3;2
.GG.B3
;G
bcdNN>
OE--
1.
738/E./
E9
3+.7.
4,3E.937R


fE9F-.9.18-E7./
/;7.7
;G
bcdNN>
;2
4-,B.1;
OE--
1.
,/6E9E73.2./R
L--
4,3E.937
OE--
2.B.EM.
,--3+2..32.,36.937
E9
3+E7
738/C
E9
,
2,9/;6E7./S
B2;77;M.2
/.7EF9
3+.2.G;2.
.,B+
4,3E.93
OE--
,B3,7+E7;2
+.2
;O9
B;932;-
E9
3+.
738/CR
`+E7
/.7EF9
6,a.7
E3
4;77E1-.
3;
;13,E9
891E,7./
E9G.2.9B.7
,1;83
/EGG.2.9B.7
1.3O..9
32.,36.937S
1,7./
;9
E932,:4,3E.93
/EGG.2.9B.7R
`2.,36.937
OE--
1.
,/6E9E73.2./
/;81-.
1-E9/
OE3+
3+.
e9M.73EF,3;2
,9/
4,3E.93
89,O,2.
;G
3+.
32.,36.93E/.93E3C
3;
G823+.2
6E9E6E7.
,9C
4;3.93E,-
1E,7
E9
3+.
;M.2,--
,77.776.93
;G
32.,36.93.GG.B3
,9/
7,G.3CR

`+.O,7+;83
4.2E;/
1.3O..9
3+.
3+2..
32.,36.937
O,7
7.-.B3./
1,7./
84;9
3+.
,M,E-,1-.
7E9F-./;7.
4+,26,B;aE9.3EB7
;G
3+.
7874.97E;9
G;268-,3E;9
bcdNN>
E9
+.,-3+C
6,-.
781g.B37
?fLh 4,23
;G
f38/C
bcdNN>:QQi:=QI>DR
`+.
6.,9
?2,9F.D
+,-G:-EM.7
O.2.
<RP
?jRQ
3;
IQRND+;827
,3
3+.
IRN
6F
/;7.S
<RN
?iRj
3;
kR=ID
+;827
,3
3+.
PRQ
6F
/;7.S
IQRN
?kRI
3;
IIRiD+;827
,3
3+.
j
6F
/;7.S
kR>
?iR<
3;
IIR<D
+;827
,3
3+.
I=
6F
/;7.
,9/
IQR=
?<RI
3;
I=RND+;827
,3
3+.
=>
6F
/;7.R
\;--;OE9F
3+.
lLh
4,23
;G
3+.
7,6.
738/C
3;
+.,-3+C
781g.B37S
3+.6.,9?2,9F.D
+,-G:-EM.7
G;--;OE9F
3+.
GE9,-
/;7.
;9
h,C
j
O.2.
IPR=
?<RIi
3;
=jRPD
+;827
,33+.j6F
/;7.
,9/
I=R<
?kR<
3;
INR<D
+;827
,3
3+.
I=
6F
/;7.R
\EM.
+,-G:-EM.7
E7
B;97E/.2./
,73+.3E6.
G;2
.-E6E9,3E;9
;G
738/C
/28F
G2;6
3+.
1;/CR
e9
3+E7
738/CS
,
O,7+;83
4.2E;/
;G
P3; I> /,C7
O,7
/..6./
,/.m8,3.
3;
.9782.
3+.2.
O,7
9;
;M.2-,4
1.3O..9
3+.
4+,26,B;aE9.3EB
42;GE-.7
;G
B;97.B83EM.
32.,36.937R

bcdNN> 9.18-E7,3E;9S
4+,26,B;/C9,6EB7S
7,G.3C
,9/
3;-.2,1E-E3C
,77.776.937
OE--
1.
4.2G;26./
O+E-73
4,3E.937
,2.
2.7E/.93
,3
3+.
738/C
B.932.R
`+E7
E7
3;
.9782.
73,9/,2/E7./
B;9/E3E;97
G;2
/;7E9F
,9/
;3+.2
738/C
42;B./82.7R
`+.
42.:/;7.
\)HI
,3
HE7E3
P
,9/
HE7E3
>
68731.OE3+E9
n=Qo
;G
3+.
42.:/;7.
\)HI
,3
HE7E3
=
E9
;2/.2
3;
.9782.
B;97E73.93
1,7.-E9.
\)HIG;2.,B+
738/C
32.,36.93R
eG
3+.
\)HI
E7
F2.,3.2
3+,9
=Qo
/EGG.2.93S
3+.9
3+.
ME7E3
6,C
1.2.7B+./8-./
?OE3+E9
=
O..a7DR
c,3E.937
6873
1.
;GG
,93E1E;3EB7
G;2
,9
,B83.
E9G.B3E;9
G;2
,3
-.,73=O..a7
42E;2
3;
.,B+
ME7E3R
eG
4,3E.937
1.B;6.
8973,1-.
1.3O..9
ME7E37S
3+.E2
,33.9/E9F
4+C7EBE,97+;8-/
FEM.
3+.6
,442;42E,3.
3+.2,4C
,9/
2.7B+./8-.
3+.
ME7E3
G;2
=
O..a7
,G3.2
2.B;M.2C?-,73
/;7.
;G
,93E1E;3EBDR














 !"# $
%&
''
)
!*
&

+*),
-./1223456718/
291::/;
;<31864:
=43
/1>.
2186/:8
?699
@/
<2
84
AB
;1CDE
F
84
GH
;1CD
D>3//:6:IJ
<2
84
BK
;1CD
83/187/:8
L8.3//
83/187/:8
M6D68D
/1>.
D/21318/;
@C
F
84
GH
;1CDN
1:;
1:/:;4=D8<;C
M6D68
F
84
GO
;1CD
1=8/3
8./
91D8
83/187/:8
M6D68P

'
!&
&

")
&

+*),
-.//:;4=
8./
D8<;C
6D
;/=6:/;
1D
8./
;18/
4=
8./
91D8
/:;
4=
D8<;C
M6D68
4=
8./
91D8
2186/:8
6:
8./D8<;CP

+""# 

+#Q!R
Q$# 
-./242<91864:
84
@/
3/>3<68/;
6:84
8.6D
D8<;C
6D
D81@9/
2186/:8D
?68.
ST
1:;
?68.4<8
D6I:6=6>1:8
./138
43
96M/3
;6D/1D/P
U<@V/>8D
?68.
199
ST-W
7<81864:D
13/
/96I6@9/
=43
8./
D8<;CJ
1:;8./3/13/
:4
/5>9<;/;
ST
7/;6>1864:D
48./3
8.1:
@34:>.4;691843D
1:;
1:86@6486>D
1D
:48/;P

 *

GP
U6I:
1:
6:=437/;
>4:D/:8
;4><7/:8
6:;6>186:I
8./C
<:;/3D81:;
8./
2<324D/
4=
1:;
234>/;<3/D
3/Y<63/;
=43
8./
D8<;C
1:;
13/
?6996:I
84
21386>6218/
6:
8./
D8<;CP
BP
Z19/
43
=/719/
1I/;
[\]
C/13D
18
8./
867/
4=
6:=437/;
>4:D/:8P
T/719/D
4=
>.69;@/136:I
248/:8619
7<D8
.1M/
@//:
<D6:I
1
>4:D6D8/:8
1:;
3/961@9/
=437
4=
>4:831>/2864:
LD//
^22/:;65
GN
=347
8./
91D8
7/:D/D
@/=43/
8./
=63D8
D8<;C
83/187/:8
1;76:6D831864:J
1:;
7<D8
>47768
84
>4:86:</
84
;4
D4
;<36:I
8./
D8<;C
1:;
=43
F
74:8.D
1=8/3
8./
91D8
;4D/
4=
D8<;C
83/187/:8P
FP
_1M/
1
GB`9/1;
aSb
3/>43;6:I
18
D>3//:6:I
Lc6D68
GN
1:;
c6D68
B
23/`;4D/
D.4?6:I
8./
=4994?6:IE
d
_/138
318/
@/8?//:
AO
1:;
GOO
@/18D
2/3
76:<8/
d
e-
6:8/3M19
>433/>8/;
=43
./138
318/
<D6:I
T36;/36>61fD
=437<91
Le->TN
6:8/3M19
ghij
lmno

d
pqr
stunvwxy
g\zj
lmno
d
{q
stunvwxy
gzOO
7D/>
d
|4
>96:6>199C
D6I:6=6>1:8
1@:4371968C
6:>9<;6:I
7432.494IC
L/PIP
9/=8
@<:;9/
@31:>.
@94>}J
18364M/:836><913
:4;19
;CD=<:>864:J
U-
D/I7/:8
1@:43719686/DN
HP
S121@9/
4=
>4729C6:I
?68.
199
D8<;C
3/D836>864:D
1:;
234>/;<3/D
6:>9<;6:I
1@6968C
84
<D/
8./D8<;C
:/@<96D/3
>433/>89CP
AP
~4;C
71DD
6:;/5
L~ZN
@/8?//:
GK
1:;
FO
}I7B
L6:>9<D6M/N
?68.
1
76:67<7
?/6I.8
4=HO
}IP
P
186/:8D
?68.
1
I/:/86>
;61I:4D6D
4=
STP
P
U26347/83C
18
D>3//:6:I
;/74:D83186:I
1:
TacG
[hj
xt
g]j

vnsoun
tvlxyP
KP
S121@9/
4=
?68.;31?6:I
=347
94:I
1>86:I
@34:>.4;691843D
=43
HK
.4<3D
23643
84
D8<;C
M6D68DJ
1:;
D.438
1>86:I
@34:>.4;691843D
=43
K
.4<3D
23643
84
D8<;C
M6D68DP
P
S96:6>199C
D81@9/
ST
6:
8./
B
?//}D
23643
84
31:;476D1864:
Lc6D68
BNP














 !"# $
%&'

")*


+,
./01234
26
7/33821/7
9/:;3
</0;=0;
23
>231=9
84>;31;?0/2?,
@,
AB;C=7;3D=1/2?
3;EF/3/?G
820>/1=9/0=1/2?
/?
18;
H2?18
>3/23
12
073;;?/?G
IJ/0/1
+K
23
>3/23
12
3=?<2H/0=1/2?
IJ/0/1
@K,
L,
M0;26
23=9
23
/?13=:;?2F0
=?1/D/21/70
I/?
=<</1/2?=9
12
F0F=9
H=/?1;?=?7;
18;3=>4K
/?
18;
@N;;O0
>3/23
12
073;;?/?G
IJ/0/1
+K
23
3=?<2H/0=1/2?
IJ/0/1
@K,
P,
Q18;3
?2?RAB
3;9=1;<
3;0>/3=1234
</023<;30S
T=1/;?10
N/18
=
7F33;?1
</=G?20/0
26
=71/:;
1FD;37F920/0U
9F?G
7=?7;3U
0=372/<20/0U
09;;>
=>?2;=U
O?2N?
=9>8=R+
=?1/134>0/?
<;6/7/;?74
23
218;3
=71/:;
>F9H2?=34
</0;=0;0,
V,
T3;:/2F0
9F?G
3;0;71/2?
23
9F?G
13=?0>9=?1,
W,
./01234
26U
23
3;=02?
12
D;9/;:;
=
>=1/;?1
8=0U
<3FG
23
=972829
=DF0;
N/18/?
18;
>=01
L4;=30,
X,
Y;7;/:;<
=?
;C>;3/H;?1=9
<3FG
N/18/?
L
H2?180
23
6/:;
8=96R9/:;0U
N8/78;:;3
/0
92?G;3,

Z,
T=1/;?10
N/18
=
8/01234
26
7832?/7
F?72?13299;<
</0;=0;U
F?9;00
AB
3;9=1;<U
/?79F</?GU
DF1
?21 9/H/1;<
 12U
 7=3</2:=07F9=3
 I/?79F</?G
 =338418H/=0KU
 ;?<273/?;U
 =71/:;
84>;318432/</0HU
?;F3292G/7=9U
8;>=1/7U
G=0132/?1;01/?=9U
3;?=9U
8=;H=1292G/7=9U
F3292G/7=9U
/HHF?292G/7=9
23
2>818=9H/7
</0;=0;0
18=1
18;
[?:;01/G=123
D;9/;:;0
=3;
79/?/7=994
0/G?/6/7=?1,
\,
]27FH;?1;<
7=3</2:=07F9=3
</0;=0;S
=?G/?=U
3;7;?1
23
0F0>;71;<
H427=3</=9
/?6=371/2?U
72?G;01/:;
8;=31
6=/9F3;U
=
8/01234
26
F?01=D9;U
23
F?72?13299;<
84>;31;?0/2?U
23
8=0
D;;?
</=G?20;<
N/18
84>;31;?0/2?
/?
9=01
L
H2?180,
+^, .=08=<
H=_23
0F3G;34U
I3;EF/3/?G
G;?;3=9
=?=;018;0/=K
/?
18;
W
N;;O0
>3/23
12
073;;?/?G
IJ/0/1
+K
23
N/99
?21
8=:;
6F994
3;72:;3;<
632H
0F3G;34U
23
>9=??;<
0F3G;34
1832FG8
18;
;?<26
18;
01F<4,
++, [?6;71/2?
N/18
?2?1FD;37F92F0
H472D=71;3/=U
H;18/7/99/?R3;0/01=?1
`1=>84927277F0
=F3;F0
IaY`bKU
23
cF3O829<;3/=
0>;7/;0,
+@, M0;26
/HHF?;R0F>>3;00/2?d
92?G
1;3H
F0;
26
>3;<?/0292?;
e+^
HGf<=4,
+L, ./01234
26
H=9/G?=?74
26
=?4
23G=?
0401;H
N/18/?
V
4;=30
N/18
18;
;C7;>1/2?
26
927=9/0;<
0O/?
7=?7;30
ID=0=9
23
0EF=H2F0
7;99K,
+P, A9/?/7=994
0/G?/6/7=?1
=D?23H=9
:=9F;0
623
0=6;14
9=D23=1234
1;010
I8=;H=1292G4U
D/278;H/0134
23
F3/?=940/0K
=1
073;;?/?G
IJ/0/1
+KU
=0
<;1;3H/?;<
D4
18;
[?:;01/G=123,
+V, b</07920;<
8/01234
23
2?;
O?2N?
12
18;
[?:;01/G=123U
26
0/G?/6/7=?1
?2?R72H>9/=?7;
/?
>3;:/2F0
/?:;01/G=1/2?=9
01F</;0
23
N/18
>3;073/D;<
H;</7=1/2?0,
+W, T=1/;?10
13;=1;<
N/18
/:=7=6123
23
/:=7=6123f9FH=7=6123
N/99
D;
;C79F<;<,

+X, Y;EF/3;0
2C4G;?
18;3=>4
2?
=
3;GF9=3
D=0/0,
+Z, T3;G?=?74
23
9=71=1/2?
I6;H=9;
0FD_;710
2?94K,
+\, b?4
218;3
3;=02?
18=1
18;
[?:;01/G=123
72?0/<;30
H=O;0
18;
>=1/;?1
F?0F/1=D9;
12
>=31/7/>=1;,
&
g
'

'
#h

$
[?:;01/G=1230
8=:;
18;
=F1823/14
12
=0O
623
18;
N/18<3=N=9
26
=
>=1/;?1
=1
=?4
1/H;
623
H;</7=9
23?2?R72H>9/=?7;3;=02?0,`82F9<18;[?:;01/G=123<;7/<;/1/0?;7;00=3412N/18<3=N=?4
>=1/;?16230>;7/6/73;=02?0U18/0082F9<D;3;723<;</?N3/1/?G=?<</07F00;<N/1818;>=1/;?1
/?EF;01/2?,`F783;=02?0623N/18<3=N=9=3;;C>;71;<12D;H;</7=9233;9=1;<129=7O26
72R2>;3=1/2?D418;>=1/;?1,














 !"# $
%&
'(*+*,-./,
0-,123*04
(56650-/7
3*/258-4*,-5/9
.:.3;
*,,.8+,
415<62
=.
8*2.
,5
>5/,*>,
,1.
+*,-./,,52.,.38-/.
,1.
3.*45/
(53
0-,123*0*6
*/2
,5
>58+6.,.
,1.
3.>532-/7
5(
*/;
*:*-6*=6.
+1*38*>52;/*8->
2*,*
*/2
*66
*2:.34.
.:./,
2*,*?
'(
*
+*,-./,
*73..2
,5
./,.3
,1.
4,<2;
*/2
4-7/.2*>5/4./,
(538
=<,
0-,123.0
(358
,1.
4,<2;9
53
0*4
0-,123*0/
(358
,1.
4,<2;9
0-,15<,3.>.-:-/7
*/;
4,<2;
,3.*,8./,9
/5
(<3,1.3
(56650@<+
-4
/.>.44*3;?
A/25(4,<2;
:-4-,4
0-66
5>><3
B
,5
CD
2*;4
*(,.3
,1.
6*4,
254.
5(
4,<2;
,3.*,8./,?
E66
0-,123*0/
+*,-./,4
0-66
(56650
,1-4
35<,-/.
</6.44
-,
-4
>5/4-2.3.2
=;
,1.
'/:.4,-7*,53
,1*,
,1.;
3.F<-3.73.*,.3
8.2->*6
4<+.3:-4-5/
*/2G53
-/:.4,-7*,-5/4
*/2
-/
01->1
>*4.
*/
</4>1.2<6.2
:-4-,+3-53,5
*/2
-/
*22-,-5/
,5
,1.
4>1.2<6.2
(56650
<+
:-4-,
8*;
=.
+.3(538.2?
'(*+*,-./,
2.>-2.4
,5
0-,123*0
:56</,*3-6;9
53
-4
0-,123*0/
=;
,1.
'/:.4,-7*,53
3.4+5/4-=6.
*,
*/;,-8.9,1.
3.*45/4
(53
0-,123*0*6
*/2
3.4<6,4
5(
*66
3.6.:*/,
,.4,4
0-66
=.
3.>532.2
-/
,1.
>*4.3.+53,
(538
HIJKL?
M*,-./,4
015
0-,123*0
8*;
=.
3.+6*>.2?
N
PQRS
#
!Q
T,<2;,3.*,8./,
8<4,
=.
2-4>5/,-/<.2
(53
,1.
(56650-/7
3.*45/4U
V
X/*>>.+,*=6.
,5Y->-,;
3.6*,.2
,5
4,<2;
,3.*,8./,
V
'/,56.3*=6.
53
+.34-4,./,
*2:.34.
.:./,4
5(
*/;
4.:.3-,;
V
M3.7/*/>;
-/
(.8*6.
+*,-./,4
V
Z./.3*6
53
4+.>-(->
>1*/7.4
-/
,1.
+*,-./,[
4
>5/2-,-5/
3./2.3-/7
,1.
+*,-./,
</*>>.+,*=6.
(53(<3,1.3
,3.*,8./,
-/
,1.
\<278./,
5(
,1.
'/:.4,-7*,53
V
I6-/->*66;
4-7/-(->*/,
+3573.44-5/
5(
2-4.*4.
N

]R^
_1.+*,-./,
1*4
,1.
3-71,
,5
0-,123*0
*,
*/;
,-8.
*/2
(53
*/;
3.*45/9
0-,15<,
.Y+6*/*,-5/
*/2
0-,15<,\.5+*32-4-/7
*/;
4<=4.F<./,
,3.*,8./,
=;
,1.
>6-/->-*/9
-(
*++6->*=6.?
`50.:.39
*/;5/.0-,123*0-/7
415<62
=.
./>5<3*7.2
,5
5((.3
*/
.Y+6*/*,-5/
(53
,1.-3
0-,123*0*6
+*3,-><6*36;
-(
-,
3.6*,.4
53
-4
+.3>.-:.2
,5
3.6*,.
-/
*/;
0*;
,5
,1.
4,<2;
,3.*,8./,9
53
,5
,1.
>5/2<>,5(
,1.
4,<2;?
M*,-./,4
>*/
*645
=.
0-,123*0/
-/
>*4.
5(
+35,5>56
:-56*,-5/4
*/2
/5/@>58+6-*/>.?
',415<62=.
8*2.
>6.*3
,1*,
,1.
+*,-./,
-4
(3..
,5
0-,123*0
(358
,1.
4,<2;
*,
*/;
,-8.?

NN
PQRS
!Q
I5/2-,-5/4
,1*,
8*;
0*33*/,
,.38-/*,-5/
5(
,1.
4,<2;
-/>6<2.9
=<,
*3.
/5,
6-8-,.2
,5U
V
_1.2-4>5:.3;
5(
*/
</.Y+.>,.29
4.3-5<49
53
</*>>.+,*=6.
3-4a
,5
+*,-./,4
./3566.2
-/
,1.
4,<2;
V
_1.2.>-4-5/
5/
,1.
+*3,
5(
,1.
T+5/453
,5
4<4+./2
53
2-4>5/,-/<.
,.4,-/79
.:*6<*,-5/9
53
2.:.65+8./,
5(
JMbccd
V
T.3-5<4
(*-6<3.
5(
,1.
'/:.4,-7*,53
,5
>58+6;
0-,1
,1.
'/,.3/*,-5/*6
I5/(.3./>.
5/
`*385/-4*,-5/
H'I`L
Z<-2.6-/.4
5/
Z552
I6-/->*6
M3*>,->.
HZIML
53
65>*6
3.7<6*,-5/4
V
T<=8-44-5/5(a/50-/76;(*64.-/(538*,-5/(358,1.3.4.*3>1(*>-6-,;,5,1.T+5/4539
,1..,1->4>588-,,..53*/;/*,-5/*63.7<6*,53;5((->-*64
V
e*\5393.+.*,.2/5/@*21.3./>.,5,1.+35,5>56














 !"# $
%&
'()+,-./-0
12/3
4)
5.6-01)7
511)7583)9:
5.
3()
);).3
-6
8.:
18<-0
,0-3-=-9
;5-9835-.
-0
/)05-2/40)8=(
-6
>?@A
+327:3)015.835-.
8.7
6-99-BC2,
B599
4)
,)06-01)7
5.
=-1,958.=)
B53(
3()
=-.7535-./
/)3
6-03(5.D?E
>?@A
'()
7)=5/5-.
3-
75/=-.35.2)
3()
/327:
5/
83
3()
75/=0)35-.
-6
3()
+,-./-0F
3()D.;)/35G83-0F
3()
0)G2983-0:
823(-053:
-0
)3(5=/
=-11533))
8.7
/(-297
56
,-//549)
4)
38H).
4:123289
8G0))1).3A
I
0)=-07
-6
/2=(
8
75/=2//5-.
B599
4)
,0),80)7
8.7
/3-0)7
5.
3()
+327:
J59)A'()+,-./-0
B599
)./20)
3()
0)G2983-0:
823(-0535)/
8.7
)3(5=/
=-11533))/
80)
.-3565)7A
K

M
I3-389-6
NO
,835).3/
12/3
=-1,9)3)
899
3(0))
30)831).3
;5/53/
PQ5/53
R
3-
Q5/53
ST
2,
3-
3()
RS(-208//)//1).3/
5.
3()
/327:A
I.:
,835).3/
B(-
7-
.-3
=-1,9)3)
B599
4)
0),98=)7A
'(5/
/(-2974)75/=2//)7
B53(
3()
+,-./-0
-.
8
=8/)
4:
=8/)
48/5/A
U),98=)1).3
,835).3/
B599
4)
899-=83)73()
.)V3
08.7-15/835-.
.214)0
5.
3()
30)831).3
/)W2).=)A

X#Y!Z
#"$#["#X

X\]M
#
$]]
@835).3/B599
0)=)5;)
3()
6-99-B5.G
3(0))
/5.G9)
7-/)/
5.
8
08.7-15/)7
/)W2).=)
83
Q5/53
R
3-
Q5/53S^
NA
NA`1G
U@a``S
RA
b1G
U@a``S
cA
@98=)4-
I993(0))/327:
30)831).3/
B599
4)
8715.5/3)0)7
2/5.G
3()
5.(89)7
0-23)
B53(
.)4295/)7
U@a``S-0
,98=)4-
8715.5/3)0)7
2/5.G
8
/38.7807
d)3
.)4295/)0
P@IUD
a?
+,05.3
,92/
8
@IUD
'204-efg
+h
=-1,0)//-0
2.53T
8/
7)/=054)7
5.
+)=35-.
`ASARA


 ]M
&
X\]M
#
U@a``S8.7
,98=)4-
B599
4)
18.268=320)7
2/5.G
8/),35=
18.268=3205.G
3)=(.5W2)/
3-
>--7
i8.268=3205.G
@08=35=)
P>i@TA
'()
D.3)0.835-.89
j.5-.
-6
@20)
8.7
I,,95)7
?()15/30:
PDj@I?T
.81)
 6-0
 U@a``S
 702G
 /24/38.=)
 5/
 kFNOC751)3(-V:CRCPRFSFbC
3051)3(:9,().:9515.-TCcCPlC=80481-:9CRC815.-)3(:9TCcFSFbFmC3)308(:70-CRnC,:05157-obFNC
8p5/-W25.-95.CSC-.)A

'()U@a``S
6-0129835-.
5/
8
/3)059)
/2/,)./5-.
6-0
.)4295/835-.F
/2,,95)7
8/
/3)059)
/3-=H
/2/,)./5-./
-6
15=0-.5/)7
U@a``S
5.
,E
m
,(-/,(83)
4266)0)7
/895.)
B53(
/2068=38.3/
3-
857
/2/,)./5-.A
'()
,98=)4-
5/
3()
/81)
8/
3()
U@a``S
/2/,)./5-.
)V=),3
3(83
3()
8=35;)
U@a``S
5.G0)75).3
5/
-1533)7F
5A)A
53
=-./5/3/
-6
,E
m
,(-/,(83)
4266)0)7
/895.)
8.7
/2068=38.3/
-.9:A
D3
5/3(2/8=9)80
/-9235-.
083()0
3(8.
8
,89)
:)99-B
/2/,)./5-.q
3()0)
5/
.-
H.-B.
5.)03
:)99-B
/-9573(83B-297
4)
8==),3849)
6-0
5.(89835-.F
8.7
3()0)6-0)
8
;5/2899:
183=(5.G
,98=)4-
(8/
.-34)).7);)9-,)7A
U@a``S
8.7
,98=)4-
80)
,0)/).3)7
8/
8
.-15.89
RA`
1a
7-/)
5.
bU
rDs
814)0G98//
;589/
/)89)7
B53(
8.
)3(:9).)
3)308692-0-)3(:9).)
Pt'JtT
=-83)7
0244)0
/3-,,)0
8.73)80C695,
=8,A
'()=-1,-/535-.
-6
3()
.)4295/)7
U@a``S
8.7
,98=)4-
/3-=H
6-0129835-./
5/
/(-B.
5.
'849)
NA














 !"# $
%&'
#

'
()

)

(
*# #+"#
"#$# 
,%-.
/01223
56789:;7<=>?
@
5A
BCD8=E:?F
@GHF
IG3
0:CJ<:9EDK=
I@
5LM==;
I@?
@G2
N:9E7KD;
O:;:CDP9DK=
5NBD;
I@?
@G@2
O:;:<:>7P6
0Q:<BQDK=
R7QJ>9DK=
SG33
R7TN:>7P6
UJ>9:V=;
0Q:<BQDK=
W;QJ>9:P<
HGX@
N:>7P6
YQC:97>=
3GX@
ZDK=9
[\W
]

)
%
NK:8_VCD<<
`7DC<
:a
/01223
D;>
BCD8=E:
M7CC
E=
CDE=CC=>
7;
8:6BC7D;8=
M7KQ
bO0F
9=C=D<=>
EJDcPDC7a7=>
B=9<:;
D;>
KQ=;
<Q7BB=>
K:
KQ=
<KP>J
8=;K9=<G
/01223D;>
BCD8=E:
M7CC
E=
B9=BD9=>
D<
D
IG2
61
`:CP6=
a:9
;=EPC7<DK7:;
EJ
D;
P;EC7;>=>
7;>7`7>PDC
MQ:
M7CC
;:K
>7<8C:<=
KQ=
7>=;K7KJ
<KP>J
K9=DK6=;K
K:
KQ=
EC7;>=>
d;`=<K7VDK:9
D;>
<KP>J<KDaaG
LQ=
=;K79=
8:;K=;K<
:a
KQ=
C7cP7>
M7CC
E=
B:P9=>
a9:6
KQ=
`7DC
K:
KQ=
;=EPC7<=9
8PBG

*
'
!e
!%
*)(
)
(
'
$)


*
'
!


*()f
LQ=>:<=<
:a
gG2
6V
/01223
D;>
H
6V
/01223
M=9=
<=C=8K=>
ED<=>
:;
KQ=
9=<PCK<
a9:6
KQ9==
8:6BC=K=>
8C7;78DC
<KP>7=<G
h:KQ
:a
KQ=<=
>:<=<
M=9=
7;8CP>=>
7;
NKP>J
/01223T@@STI@g3
7;`=<K7VDK7;V
NWR
D;>
OWR
:a
/01223
7;
Q=DCKQJ
<PEi=8K<
D;>
OWR
7;
Yj0R
BDK7=;K<F
577?NKP>J/01223T@@XTI@g3
D;>
NKP>J
/01223T@@XTI@g3
7;
BDK7=;K<
M7KQ
D<KQ6DG
LQ=
H
6V
>:<=MD<DC<:
7;`=<K7VDK=>
7;
NKP>J
/01223T@@kTI@g2
7;
BDK7=;K<
M7KQ
Yj0RG
LQ=<=
>:<=<
M=9=M=CC
K:C=9DK=>
D;>
DC<:
8DP<=>
E9:;8Q:>7CDK7:;
7;
Q=DCKQJ
<PEi=8K<F
D<KQ6DK78
BDK7=;K<
D;>Yj0R
BDK7=;K<G


*
)
#%
'
!
'


WCCKQ9==K9=DK6=;K<
<Q:PC>
E=
V7`=;
DK
DBB9:l76DK=CJ
5mg
Q:P9?
KQ=
<D6=
K76=
:a
>DJ
DK
=D8Q
`7<7K5n7<7K
I
K:
n7<7K
3?G

LQ=a:CC:M7;V
9=<K978K7:;<
7;
9=CDK7:;
K:
<KP>J
`7<7K<
<Q:PC>
E=
D>Q=9=>
K:o
p
0DK7=;K<
<Q:PC>
9=a9D7;
MQ=9=
B:<<7EC=F
a9:6
lD;KQ7;=
58Q:8:CDK=F
8Daa=7;=
8:;KD7;7;V
>97;_<
D;>
a::>?F
a:9
DK
C=D<K
I3
Q:P9<
E=a:9=
D;>
>P97;V
DCC
`7<7K<G
R=8Daa=7;DK=>
E=`=9DV=<
D9=
B=967KK=>
p
0DK7=;K<
<Q:PC>
9=a9D7;
a9:6
DC8:Q:C
a:9
I3
Q:P9<
E=a:9=
D;>
>P97;V
DCC
`7<7K<
57;8CP>7;V
`7<7K<
a:9
<Da=KJ
CDE:9DK:9J
K=<K<?
D;>
P;K7C
DCC
B9:8=>P9=<
a:9
KQDK
<KP>J
`7<7K
D9=
8:6BC=K=>
p
0DK7=;K<
6P<K
aD<K
5MDK=9
B=967KK=>?
a9:6
I
Q:P9<
B9=T>:<=
P;K7C
I
Q:P9<
B:<KT>:<=
DK
DCC
K9=DK6=;K<`7<7K<5n7<7KIK:n7<7K3?GNKD;>D9>7<=>6=DC<M7CCE=<=9`=>>P97;VKQ=`7<7K
>DJ














 !"# $
%&
'
)*+,-.+/
/12345
6-76*,.
7628
/829,.:
2.
+1-
5*;
27
+1-
<,/,+=
*+
+1-
<-6;
4-*/+
*>/+*,.
7628
/829,.:
,.
+1-
?
1236/
@6,26
+2
52/,.:
*.5
A,+1,.
B
1236
27
*44
/@,628-+6;
*//-//8-.+/
'
)*+,-.+/
/12345
6-76*,.
7628
/+6-.323/
-C-6D,/-
726
E?
1236/
@6,26
+2
*44
/+35;
<,/,+/
*.5
/12345
3.5-6+*9-
.2
3.*DD3/+28-5
/+6-.323/
-C-6D,/-
7628
/D6--.,.:
FG,/,+
BH
3.+,4
+1-
-.527
/+35;
<,/,+
FG,/,+
IH
J)KIIL26
@4*D->2
A,44
>-
*58,.,/+-6-5
>;
,.1*4*+,2.
27
*.
*-62/24
:-.-6*+-5
>;
*
)MJN
KO
P@6,.+QR-+
.->34,/-6
*++*D1-5
+2
*
)MJN
S36>2TUVQ
PW
D28@6-//26X
Y1-6-<-6
@2//,>4-=
+1-/*8-D28@6-//26
3.,+
/12345
>-
3/-5
726
-*D1
52/-
A,+1,.
*
@*+,-.+X
M7,4+-6<*4<-
/-+
A,44
>-
*++*D1-5
+2
+1-
)MJN
KO
P@6,.+Q
R-+
.->34,/-6
*.5
*
/-@*6*+-
7,4+-6
@*5A,44>-
3/-5
726
-*D1
52/-
F/--
/-@*6*+-
)MJN
,./+63D+,2./
@62<,5-5
A,+1
+1-
7,4+-6
<*4<-
/-+HX
S1-52/,.:
D3@
2.
-*D1
.->34,/-6
A,44
>-
2>/D36-5
A,+1
+*@-
+2
<,/3*44;
>4,.5
+1-
/+35;
+6-*+8-.+X

)*+,-.+/83/+
A-*6
*
@62+-D+,<-
:2A.
536,.:
+1-
52/,.:
@62D-536-
+2
@6-<-.+
D2.+*8,.*+,2.
27+1-D*..34*
726
@1*68*D29,.-+,D
/*8@4-/X
S1--.5+,8-
27
.->34,/*+,2.
F/@3++-6,.:H
27
+1-
/+35;
+6-*+8-.+
A,44
>-
D2./,5-6-5
S,8-
Z
726
+1-@36@2/-/
27
/D1-534,.:
*44
@2/+[52/-
/+35;
@62D-536-/X
\->34,/*+,2.
+,8-
/12345
.2+
-CD--5BZ
8,.3+-/X
S1-72442A,.:
83/+
>-
6-D265-5
,.
+1-
OJ]^
'
O28@6-//26
3.,+
.38>-6
'
P+*6+
*.5
-.5
+,8-/
27
.->34,/*+,2.
F+,8-/
A,44
>-
623.5-5
52A.
+2
+1-
.-*6-/+
8,.3+-H
'
S1-<2438-
27
6-/,53*4
@6253D+
*+
+1-
-.5
27
.->34,/*+,2.


`%
J)KIIL*.5
@4*D->2
/12345
>-
/+26-5
>-42A
?IaO
*.5
/12345
.2+
>-
762b-.X
S1-
-C@,6;
5*+-
A,44>-,.5,D*+-5
2.
+1-
>2C
4*>-4X

S-8@-6*+36-
42:/
/12345
>-
8*,.+*,.-5
,.
*6-*/
A1-6-
/+35;
+6-*+8-.+
,/
/+26-5X
N7
+-8@-6*+36-
D2.5,+,2./
1*<-
>--.
/-6,23/4;
D28@628,/-5
26
*.;
/+35;
+6-*+8-.+
1*/
.2+
>--.
/+26-5*@@62@6,*+-4;=
+1,/
/12345
>-
52D38-.+-5=
*.5
+1-
/+35;
+6-*+8-.+
c3*6*.+,.-5
3.+,4
+1-
P@2./261*/
>--.
.2+,7,-5
*.5
D2.7,68-5
A1-+1-6
,+
8*;
>-
3/-5X

P+35;+6-*+8-.+/
A,44
>-
/+26-5
3.5-6
+1-
D2.+624
27
+1-
N.<-/+,:*+26
26
5-/,:.--
,.
*
/-D36-
7*D,4,+;*@@62@6,*+-
726
+1-
*5<,/-5
/+26*:-
D2.5,+,2./X
P+35;
+6-*+8-.+/
+1*+
*6-
+2
>-
6-+36.-526
5-/+62;-5
>;
+1-
N.<-/+,:*+26d/+*77
26
1*<-
-C@,6-5
83/+
>-
/+26-5
/-@*6*+-4;
7628
+1-3.3/-5
/+35;
+6-*+8-.+/X
e
$fg
S1-N.<-/+,:*+26
A,44
>-
6-/@2./,>4-
726
+1-
5,/@-./,.:=
,.<-.+26;
*.5
*DD23.+*>,4,+;
27
/+35;
+6-*+8-.+=
-C-6D,/,.:
*DD-@+-5
8-5,D*4
*.5
@1*68*D-3+,D*4
@6*D+,D-/
*.5
-./36,.:
+1*+
*.
*DD36*+-=+,8-4;
6-D265
27
+1-
5,/@2/,+,2.
,/
8*,.+*,.-5X
S1-
/+35;
+6-*+8-.+
/3@@4,-/
*.5
,.<-.+26;83/+>-*<*,4*>4-726,./@-D+,2.>;+1-5-/,:.*+-56-@6-/-.+*+,<-/27+1-P@2./26
3@2.6-c3-/+X














 !"# $
%&'
()*+-./.0)1
*2
13.
41567
1-.819.+1:
13.
;+<.410=81*-
*-
6.40=+..
>0??
0+4)./1
13.
/*+1.+14
8+6
-.15-+13./*9)?.1.6
8/@+*>?.6=.9.+1
*2
-./.0)1A
B*)0.4
*2
8??
41567
1-.819.+1
0+<.+1*-7
-./*-649541
C.
-.180+.6
2*-
8//*5+18C0?017
*2
41567
)-*65/14
8+6
45))?0.4A
D//*5+18C0?017
9541C.6*/59.+1.6
2-*9
13.
109.
*2
0+0108?
-./.0)1
81
13.
41567
/.+1-.
1*
13.0-
20+8?
-.9*<8?
2-*913./.+1-.
*-
6.41-5/10*+A

E-011.+-./*-64
9541
8?4*
C.
980+180+.6
1*
/*+20-9
13.
)5-)*4.
8+6
-.84*+
2*-
8+7
41567
1-.819.+1604)*48?:
.A=A
13.
89*5+1
/*+1890+81.6:
C-*@.+:
*-
?*41:
8+6
13.
+89.F40=+815-.
*2
13.).-4*++.?
-.4)*+40C?.
2*-
6.41-5/10*+A
G*
41567
981.-08?
H0+/?560+=
54.6
<08?4I
987
C.
6.41-*7.65+10?
20+8?
41567
1-.819.+1
8//*5+18C0?017
384
C..+
).-2*-9.6
8+6
>-011.+
8))-*<8?
384C..+-./.0<.6
2-*9
13.
J)*+4*-A
D113..+6
*2
13.
41567:
13.
5+54.6
41567
1-.819.+1
>0??
.013.-
C.
6.41-*7.6
?*/8??7
*-
-.15-+.61*
13.
J)*+4*-
2*-
6.41-5/10*+
821.-
8//*5+18C0?017
384
C..+
<.-020.6A

LM
'
$%%


#
NO
D??)810.+14
/*+4.+1.6
>0??
C.
8440=+.6
8
4/-..+0+=
+59C.-
540+=
13.
41567
/.+1-.P4
418+68-6
/*+<.+10*+A
Q810.+14>0??
-./.0<.
13-..
6022.-.+1
1-.819.+14
0+
13.
41567
H4..
J./10*+
RASI
81
T0401
U
1*
T0401V0+8
-8+6*904.6
4.W5.+/.A
X8+6*904810*+
+59C.-4
>0??
C.
8??*/81.6
540+=
8
13-..
+59C.-2*-981A

D 65997
-8+6*904810*+
4/3.65?.
>0??
C.
8))-*<.6
C7
13.
J)*+4*-
C.2*-.
13.
20+8?
-8+6*904810*+
4/3.65?.
04
)-*65/.6A
&
YM%
XQZRRV8+6
)?8/.C*
>0??
C.
8690+041.-.6
6*5C?.
C?0+6A
;1
384
+*1
C..+
)*440C?.
1*
/*9)?.1.?7
981/3
13.
)?8/.C*
1*
XQZRRV
84
13.
<0458?
8)).8-8+/.
04
6022.-.+1A
[3.
41567
).-4*++.?)-.)8-0+=
13.
XQZRRV
8+6
)?8/.C*:
)?8/0+=
13.9
0+1*
13.
+.C5?04.-
8+6
45).-<040+=
415671-.819.+1
8690+041-810*+
>0??
13.-.2*-.
+*1
C.
C?0+6.6
1*
1-.819.+1
06.+1017A
[3.
6*40+=
/5)*+.8/3
+.C5?04.-
>0??
C.
*C4/5-.6
>013
18).
1*
<0458??7
C?0+6
13.
41567
1-.819.+1A
[3.
J)*+4*-:;+<.410=81*-
H6.20+.6
84
Q-0+/0)8?
;+<.410=81*-
8+6
8??
41567
)3740/08+4I:
8??
)810.+14
8+6 8?? *13.-
-.4.8-/3
).-4*++.?
H.\/.)1
C0*8+8?710/8?
).-4*++.?
).-2*-90+=
13.
)38-98/*@0+.10/
844874I
>0??
13.-.2*-.
C.
C?0+6.6
1*
13.
1-.819.+1
8??*/810*+A

;+60<0658?
189).-
.<06.+1
/*6.
C-.8@
.+<.?*).4
>0??
C.
=.+.-81.6
2*-
.8/3
)810.+1
06.+10270+=
13.1-.819.+1
8??*/810*+A
D
4.1
*2
.+<.?*).4
>0??
C.
3.?6
C7
13.
J)*+4*-P4
].60/8?
]*+01*-
8+6.8/3;+<.410=81*-
2*-
54.
0+
13.
.<.+1
*2
13.
+..6
2*-
.9.-=.+/7
5+C?0+60+=A
;+
C*13
/84.4:13./*6.
C-.8@
.+<.?*).4
9541
C.
3.?6
0+
8
4./5-.
-.41-0/1.6^8//.44
?*/810*+
1381
04
8//.440C?.
UV
3*5-4
8
687A

[3.C?0+6
43*5?6
C.
C-*@.+
*+?7
02
4)./020/
.9.-=.+/7
1-.819.+1
>*5?6
C.
60/181.6
C7
@+*>0+=13.
1-.819.+1
418154
*2
13.
)810.+1A
;2
13.
C?0+6
+..64
1*
C.
C-*@.+:
13.
;+<.410=81*-
43*5?6*).+:
40=+
8+6
681.
13.
/*--./1
.+<.?*).:
02
)*440C?.
38<0+=
604/544.6
01
>013
13.
J)*+4*-P4
].60/8?
9*+01*-
0+
86<8+/.A
_13.->04.:
8??
C?0+60+=
>0??
C.
980+180+.6
5+10?
8??
W5.-0.4
8-.
-.4*?<.6
8+6
13.
6818C84.
04
?*/@.6A














 !"# $
%&


(

#
(
)(


(

#
*+,-+/01+23,14
5-+
67
/2819
,9
/01
:24/
;
<-9/04
29=
2::
>-9>-<,/29/
/01+23,14
5-+
67
?,::
@1
+1>-+=1=,9
/01
6A7B
?,/0
/01
<1=,>2/,-9B
+-C/1
-5
2=<,9,4/+2/,-9B
=-41
29=
4/2+/
29=
4/-3
=2/1D4E29=
/,<1D4E
>:12+:F
+1>-+=1=
/-
=->C<19/
2::
+1GC,+1=
?240-C/
31+,-=4
29=
>-<3:,29>1
?,/0/01,9>:C4,-9
29=
1H>:C4,-9
>+,/1+,2I
J9F
-+2:
<1=,>2/,-94
5-+
67
C41=
2/
4>+119,9K
40-C:=@1>-9/,9C1=
=C+,9K
/01
4/C=FB
3+151+2@:F
2/
2
4/2@:1
=-41B
24
=11<1=
233+-3+,2/1
@F
/01L9M14/,K2/-+I
*2/,19/4/28,9K
,902:1=
4/1+-,=4
<2F
>-9/,9C1
/01,+
<1=,>2/,-9
-9:F
,5
/01
=-41
,4
4/2@:1
5+-<
2/:124/5-C+
?1184
3+,-+
/-
4>+119,9K
29=
,4
1H31>/1=
/-
+1<2,9
4/2@:1I
N-9K2>/,9K
@+-9>0-=,:2/-+4
<C4/
@1
?,/001:=
5-+
2/
:124/
OP
0-C+4
3+,-+
/-
12>0
4/C=F
M,4,/I

Q0-+/2>/,9K
@+-9>0-=,:2/-+4
<C4/
@1
?,/001:=
5-+
2/
:124/
P
0-C+4
3+,-+
/-
12>0
4/C=F
M,4,/I
L5
/0,4?,/00-:=
,4
9-/
<1/B
/01
32/19/
40-C:=
@1
+14>01=C:1=
5-+
2
+1312/
M,4,/
?,/0,9
R
=2F4I

*2/,19/4<C4/
@1
-55
29/,@,-/,>4
5-+
29
,951>/,-C4
1H2>1+@2/,-9
5-+
2/
:124/
S
?1184
3+,-+
/-
12>0/+12/<19/
M,4,/
DT,4,/4
S
/-
T,4,/
OEI
L5
32/,19/4
@1>-<1
C94/2@:1
@1/?119
M,4,/4B
/01,+
2//19=,9K30F4,>,29
40-C:=
K,M1
/01<
233+-3+,2/1
/01+23F
29=
+14>01=C:1
/01
91H/
/+12/<19/
M,4,/5-+S?1184
25/1+
/01
:24/
=-41
-5
29/,@,-/,>4I
L9
/0,4
,94/29>1
/01
?240-C/
31+,-=
@1/?119
>-941>C/,M1
/+12/<19/4
,4
31+<,//1=
/-
@1
:-9K1+
/029
UO
=2F4I
*2/,19/4<2F
>-9/,9C1
-/01+
3+14>+,@1=
9-9V+143,+2/-+F
/01+23,14
=C+,9K
/01
4/C=F
/02/
/01
L9M14/,K2/-+
>-94,=1+4
/-
91,/01+
>-<3+-<,41
4C@W1>/
4251/F
9-+
2551>/
4/C=F
=2/2I
*C:<-92+F
+102@,:,/2/,-9
3+-K+2<4
40-C:=
9-/
@1
4/2+/1=
-+
>-<3:1/1=
=C+,9K
/0,4
31+,-=I
XHFK19
/01+23F-9
2
+1KC:2+
@24,4
,4
29
1H>:C4,-9
>+,/1+,-9
5-+
/0,4
4/C=FI


(

)(
X/01+3+,-+
3+14>+,3/,-9
-+
9-9V3+14>+,3/,-9
<1=,>2/,-94
D<1=,>2/,-9B
=-41B
+-C/1
-5
2=<,9,4/+2/,-9B
/+12/<19/
=C+2/,-9
29=
,9=,>2/,-9E
/2819
;
<-9/04
@15-+1
/01
5,+4/
4/C=F
/+12/<19/2=<,9,4/+2/,-9
<C4/
@1
+1>-+=1=
,9
/01
6A7
,9
-+=1+
/-
>-95,+<
>-<3:,29>1
?,/0
/01,9>:C4,-9
29=
1H>:C4,-9
>+,/1+,2I

J::>-9>-<,/29/
<1=,>2/,-94
<C4/
2:4-
@1
=->C<19/1=
,9
/01
6A7I
Y01
,<32>/
-5
29F
>-9>-<,/29/
<1=,>2/,-94
?,::
@1
1M2:C2/1=
=C+,9K
/01
3+1V=2/2@241
:->8
+1M,1?
29=
/01
=1>,4,-9/2819
?01/01+
/-
1H>:C=1
/01
32/,19/
5+-<
29F
292:F4,4
3-3C:2/,-94I

Z
)(
Q/29=2+=3+->1=C+14
5-+
1<1+K19>F
>2+1
40-C:=
@1
5-::-?1=
5-+
29F
,9=,M,=C2:
2=M1+41
1M19/B
?0191M1+>:,9,>2::F
911=1=
D=1>,4,-9
/-
@1
/2819
@F
/01
L9M14/,K2/-+EI
Q0-+/
2>/,9K
@+-9>0-=,:2/-+4
<2F
@1
C41=
24
+14>C1
<1=,>2/,-9I
L5
/0,4
,4
,92=1GC2/1
/-
>-9/+-:
/01,+
4F<3/-<4
/01F
40-C:=
>-9/2>/
/01
L9M14/,K2/-+I
A14>C1
<1=,>2/,-9
C41
=C+,9K
12>0
/+12/<19/
M,4,/<C4/
@1
4132+2/1:F
=->C<19/1=
,9
/01
6A7
D<1=,>2/,-9B
=-41B
+-C/1
-5
2=<,9,4/+2/,-9B
=2/129=/,<1
-5
12>0
2=<,9,4/+2/,-9EI
*+-/->-:
3+->1=C+14
<C4/
4/,::
>-9/,9C1
1M19
,5
+14>C1
<1=,>2/,-9
024
@119
/2819I

#

Q/C=F/+12/<19/2=<,9,4/+2/,-9?,::/2813:2>12//014/C=F>19/+129=?,::@12=<,9,4/1+1=@F
/01L9M14/,K2/-+-+=14,K92/1=29=/+2,91=4/C=F>19/+131+4-991:IY013+1>,41=2/129=/,<1














 !"# $
%&'
()+,-./.012+1.(/0
03+44
56
,(78-6/16,
./
136
9:;<
=36
018,>
?.44
56
-(/.1(26,
5>
+
-(/.1(2
+@@2(A6,5>
136
B@(/0(2<
C82./D
13606
A.0.10E
+44
@2(76,8260
?.44
56
-(/.1(26,
)(2
7(-@4.+/76
?.13
136
@2(1(7(4<
B(8276
,(78-6/10
?.44
56
26A.6?6,
+/,
7(-@+26,
?.13
136
,+1+6/12.60
./
136
9:;0
1(
6/0826
7(/0.016/7><


F
H#I!J
"!I"H
$#
"$K

 H #
=36018,>?.44
7(/0.01
()
).A6
A.0.10L
M
B7266/./D
OP.0.1
QR
?.44
1+S6
@4+76
./
136
@62.(,
561?66/
T
+/,
QU
,+>0
@2.(2
1(
136
).201
018,>
126+1-6/1
+,-./.012+1.(/<
=3.0
-+>
56
@62)(2-6,
+0
+
0./D46
A.0.1
(2
-(26
13+/
(/6A.0.1<
V4.D.546
085W6710
-+>
56
26X07266/6,
+1
136
,.07261.(/
()
136
Y/A601.D+1(2E
+/,
)(44(?./D
,.07800.(/
?.13
136
B@(/0(2E
.)
136
26+0(/
)(2
07266/
)+.4826
?+0
7(/0.,626,
16-@(2+2>
./
/+1826<
Z44
07266/./D
,+1+
-801
56
(51+./6,
?.13./
QU
,+>0
@2.(2
1(
+,-./.012+1.(/
()
018,>
126+1-6/1
M
=3266
126+1-6/1
A.0.10
OP.0.1
[
1(
P.0.1
UR
6+73
06@+2+16,
5>
T
1(
QU
,+>0
M
Z/6/,
()
018,>
A.0.1
OP.0.1
\R
561?66/
T
+/,
Q]
,+>0
+)162
136
4+01
018,>
126+1-6/1
+,-./.012+1.(/
:6@6+1E260736,846,
+/,
8/0736,846,
A.0.10
+/,
@2(76,8260
+26
@62-.116,
+1
136
,.07261.(/
()
136Y/A601.D+1(2<
=360736,846
()
+00600-6/10
+1
6+73
A.0.1
.0
03(?/
./
=+546
[
+/,
4.016,
./
B671.(/
^<Q
1(
B671.(/^<U<
=36
018,>
+00600-6/10
+26
,6072.56,
./
B671.(/
_<














 !"# $
%&'
#
()*
'
$


(

#
"(


+,




-
.
)
/
&
)/0
+,
#

!



&







1

2



+,



456789:;<75=:5>
?












@:97A8BCDE<=
?












F:;E<BGH=J8AE<BG
B5;
;E=:B=:
DE=>78K
?












L8E5:C8:A5B5<K
>:=>
M6:9BG:
CB>E:5>=
75GKN
?
?










?
45<GJ=E75O:P<GJ=E75
<8E>:8EB
?
?Q;R











S:TJGE=B>E75
>8BE5E5A

?Q;R











UB5;79E=B>E75

?Q;R











V>J;K>8:B>9:5>
E5DBGB>E75
MUWXYYZ
78
CGB<:T7N


?










U:[:8=ETEGE>K
>:=>
Q:R
?












VCE879:>8KM\]^_
B5;
\^`N

?Q6R

?
?
?
?
?
?
?
?
?

W8E78O<75<79E>B5>
9:;E<B>E75=O>D:8BCE:=

aD87JAD7J>
U:=<J:9:;E<B>E75



aD87JAD7J>
XBT78B>78K=B6:>K
>:=>=
?











?
^E>BG=EA5=MTG77;
C8:==J8:
B5;
CJG=:
8B>:N
?
?


?
?
?
?
?
?
?


WDK=E<BG:PB9E5B>E75
?











?
_bcG:B;]`d

?
?



?
?
?

?



]PDBG:;T8:B>D
Ce
QAR

?







?

?

VCJ>J9E56GB99B>78K
9:;EB>78=
M4Xcfg
aS\ch
FWiN

?







?

?

VCJ>J98D:7G7AK

?







?

?

WDB89B<7jE5:>E<
TG77;
=B9CG:

?

?
?
?
?
?
?
?

?

k;[:8=::[:5>
lJ:=>E75E5A

aD87JAD7J>
kTT8:[EB>E75=m
]`dn:G:<>87<B8;E7A8B9o
]7Vn:5;
76
=>J;Ko
\]^_n678<:;
:PCE8:;
[7GJ9:
E5
_
=:<75;o
\^`n678<:;
[E>BG
<BCB<E>Ko
DnD7J8o
4XcfnE5>:8G:JjE5cfo
9E5n9E5J>:o
FWin9K:G7C:87PE;B=:o
CF@4nC8:==J8E=:;
9:>:8:;
;7=:
E5DBG:8o
aS\cpq>J97J8
5:<87=E=
6B<>78
BGCDB
QBR
s
>7
_Z
;BK=
C8E78
>7
^E=E>
bt
V<8::5E5A
9BK
T:
C:86789:;
7[:8
978:
>DB5
_
;BK
QTR
]7V
uEGG
7<<J8
sc_v
;BK=
B6>:8
>D:
GB=>
;7=:
76
=>J;K
>8:B>9:5>
Q<R
d:89B5
<:5>8:
75GK
Q;R
^E=E>
b
75GK
Q:R
VCE879:>8K
M\]^_
B5;
\^`N
T:678:
B5;
sv
9E5J>:=
B5;
_
D7J8
B6>:8
CF@4
=BGTJ>B97G
B;9E5E=>8B>E75t
aD:
C8:cT875<D7;EGB>78
\]^_
wxyz
|}
~

fv
76
C8:;E<>:;
5789BG
678
E5<GJ=E75t

Q6R
 i5:
9:B=J8:9:5>
B>
c_Y
9E5J>:=

QAR
L
<:5>8:
75GK














 !"# $
%&'
(
*%
+

,
-./0012/245.617
8529120
:/;;
<1
5<0=/217
<>
0?1
@2A190/B=05.
=9
9C18/4/17
/2
D180/52
EEFG
C./5.05=2>
90H7>
.1;=017
C.5817H.19
<1/2B
C1.45.617F

I=0/1209:/;;
<1
98.11217
05
7101.6/21
1;/B/</;/0>
=B=/290
0?1
/28;H9/52
=27
1J8;H9/52
8./01./=
<10:112G
=27
EK
7=>9
<145.1
0?1
4/.90
7591
54
90H7>
0.1=06120F
L?1.1
=.1
25
4=90/2B
.1MH/.161209
45.
0?1
98.112/2B
A/9/0F
I=0/1209
6H90
:/0??5;7
NO
0?1.=C/19
C./5.
05
98.112/2B
=9
714/217/2
D180/52
PFQFEF
L?145;;5:/2B
=9919961209
:/;;
<1
C1.45.617R
S
U1A1.9/</;/0>
0190R
9C/.5610.>
<145.1
=27
GV
6/2H019
=27
E
?5H.
=401.
9=;<H0=65;
=76/2/90.=0/52
S
U185.7/2B
54
7165B.=C?/8
/245.6=0/52
S
U185.7/2B
54
617/8=;W9H.B/8=;
=27
7/91=91
?/905.>
S
U185.7/2B
54
C./5.
617/8=0/529
=27
0?1.=C/19
S
X/0=;
9/B29
Y<;557
C.199H.1
=27
CH;91
.=01Z
S
I?>9/8=;
1J=6/2=0/52
S
E[\;1=7
]N^
S
_;557
=27
H./21
9=6C;19
45.
;=<5.=05.>
9=410>
01909

S
`./21
C.1B2=28>
01909
Y416=;1
C=0/1209
52;>Z

S
aH190/52/2B
45.
=7A1.91
1A1209
@40?1C=0/120
61109
0?1
/28;H9/52
8./01./=
=27
2521
54
0?1
1J8;H9/52
8./01./=b
0?1>
:/;;
<1
/290.H801705
.10H.2
/2
G
05
EK
7=>9
45.
X/9/0
[F

(



I=0/12096H90
:/0??5;7
9?5.0
=27
;52B
=80/2B
<.528?57/;=05.9
C./5.
05
X/9/0
[
=9
714/217
/2
D180/52PFQFEF
I=0/1209
9?5H;7
4=90
4.56
[
?5H.9
C.1\7591
H20/;
[
?5H.9
C590\7591
Y1J81C0
45.
:=01.Z=27
50?1.
.190./80/529
714/217
/2
D180/52
PFKF[
9?5H;7
<1
=7?1.17
05F
I=0/1209:/;;
<1
1A=;H=017
05
=981.0=/2
/4
0?1
/28;H9/52
=27
1J8;H9/52
8./01./=
=.1
90/;;
610F

(
!
$
S
N524/.6
0?=0
.19C/.=05.>
617/8=0/529
:1.1
:/0??1;7
=9
.1MH/.17F
@4
250
.198?17H;1
0?1
A/9/0
45.
:/0?/2
0?1
.1MH/.17
:/275:
S
aH190/52/2B
45.
=7A1.91
1A1209

S
N52856/0=20
617/8=0/52
8?18c
S
`./21
C.1B2=28>
0190
Y416=;1
C=0/1209
52;>Z
S
d1<H;/91.
/2?=;=0/52
0.=/2/2B
S
E[\;1=7]N^
S
X/0=;9/B29Y<;557C.199H.1=27CH;91.=01Z














 !"# $
%&&'
(
*+,,-
/012+3
4,5
2605107,89:3;97/

(
<=60+3-
>530;6
2?
@AB
73:;53
,:+CD
(
E2F;F1
4,5
563,+,GC
0:-
9:4+0110;,5C
13-90;,5
130/F5313:;/
(
E295,13;5C
@,:3
130/F5313:;
0;
HIJ
19:F;3/D
<+9G9>+320;93:;/
K9++
;63:
>3
50:-,19/3-
0:-
53739L3
0
50:-,19/0;9,:
:F1>35M
N
PQRS
#
$R
T0;93:;/K9++
>3
-,/3-
39;635
UTVJJW
,5
2+073>,
F/9:G
0
:3>F+9/35
077,5-9:G
;,
50:-,19/0;9,:M

N&
!
$
(
IXH+30-
<YZ/
0;
I[
X[
W
0:-
\
6,F5/

(
]9;0+
/9G:/
0;
^_
19:F;3/
0:-
I[
X[
W[
`
0:-
\
6,F5/

(
*+,,-
/012+3/
4,5
2605107,89:3;97/
0;
IJ[
^_
19:F;3/
0:-
I[
X[
W[
`[
\
0:-
XW
6,F5/

(
E295,13;5C
0;
IJ
0:-
^_
19:F;3/
0:-
I[
X[
W[
`[
\
0:-
XW

6,F5/

(
aF3/;9,:9:G
4,5
0-L35/3
3L3:;/
(
<=60+3-
>530;6
2?
0;
\
0:-
XW
6,F5/
@AB
73:;53
,:+CD
(
E2F;F1
,>;09:3-
4,5
563,+,GC
0:-
9:4+0110;,5C
13-90;,5
130/F5313:;
0;
\0:-
XW
6,F5/

T0;93:;/7,12+3;9:G
;63
L9/9;
K9++
>3
9:/;5F7;3-
;,
53;F5:
9:
^
;,
IW
-0C/
4,5
]9/9;
^M


N&


&


T0;93:;/1F/;
K9;66,+-
/6,5;
0:-
+,:G
07;9:G
>5,:76,-9+0;,5/
259,5
3076
L9/9;
0/
-349:3-
9:
E37;9,:JMbMIM
T0;93:;/
/6,F+-
40/;
45,1
X
6,F5/
253H-,/3
F:;9+
X
6,F5/
2,/;H-,/3
@3=732;
4,5
K0;35D0:-
,;635
53/;597;9,:/
-349:3-
9:
E37;9,:
JMWMX
/6,F+-
>3
0-6353-
;,M
c63
4,++,K9:G
0//3//13:;/
K9++
>3
2354,513-d
N&
!
$
(
Y,:4951
;60;
53/2950;,5C
13-970;9,:/
K353
K9;663+-
0/
53eF953-M
f4
:,;
53/763-F+3
;63
L9/9;
4,5
K9;69:
;63
53eF953-
K9:-,K
(
aF3/;9,:9:G
4,5
0-L35/3
3L3:;/

(
Y,:7,19;0:;
13-970;9,:
76378
(
A59:3
253G:0:7C
;3/;
@4310+3
20;93:;/
,:+CD
(
IXH+30-
<YZ
(
]9;0+
/9G:/
@>+,,-
253//F53
0:-
2F+/3
50;3D
(
*+,,-/012+34,52605107,89:3;97/
(
<=60+3->530;62?@AB73:;53,:+CD
(
E2F;F14,5563,+,GC0:-9:4+0110;,5C13-90;,5130/F5313:;/














 !"# $
%&'
(
*+,-./01-2
451
678
/,9:10;<=
,9>?:@,9A
>.9B,-/51,.9
1C51
DEF7
,;
G,1C,9
HIJ
.B
1C51
51
F,;,1
H

K&
MNOP
#
$O
Q51,091;G,??
R0
@.;0@
0,1C0-
SQT88U
.-
+?5>0R.
:;,9A
5
90R:?,;0-
5>>.-@,9A
1.
-59@./,;51,.9V

K&&
!
$
(
7H6?05@
EWX;
51
7=
H=
U
59@
Y
C.:-;

(
F,15?
;,A9;
51
ZI
/,9:10;
59@
7=
H=
U=
[
59@
Y
C.:-;

(
\?..@
;5/+?0;
B.-
+C5-/5>.],901,>;
51
78=
ZI
/,9:10;
59@
7=
H=
U=
[=
Y=
7H
59@
HU
C.:-;

(
*+,-./01-2
51
78
59@
ZI
/,9:10;
59@
7=
H=
U=
[=
Y

59@
HU
C.:-;

(
^:0;1,.9,9A
B.-
5@_0-;0
0_091;
(
E`C5?0@
R-051C
+a
51
Y
59@
HU
C.:-;
4bc
>091-0
.9?2<
(
*+:1:/
.R15,90@
B.-
-C0.?.A2
59@
,9B?5//51.-2
/0@,51.-
/05;:-0/091
51
Y
59@
HUC.:-;

Q51,091;>./+?01,9A
F,;,1
Z
G,??
R0
,9;1-:>10@
1.
-01:-9
,9
Z
1.
7U
@52;
B.-
F,;,1
UV
Q51,091;
>./+?01,9A
F,;,1
U
G,??
R0
,9;1-:>10@
1.
-01:-9
,9
Z
1.
7I
@52;
B.-
F,;,1
8V
K
"O
'
MNOP
d

e
fC0B.??.G,9A
G,??
R0
+0-B.-/0@g
(
^:0;1,.9,9A
B.-
5@_0-;0
0_091;
(
W.9>./,1591
/0@,>51,.9
>C0>]
(
QC2;,>5?
0`5/,951,.9
(
\?..@
59@
:-,90
;5/+?0;
B.-
?5R.-51.-2
;5B012
10;1;
(
b-,90
+-0A959>2
10;1
4B0/5?0
+51,091;
.9?2<














 !"# $
%&'

)#*!+
,"#-!.+

!%/
0

1
"%2
$

3456784::6::;6<7:
=>4?@A47@A8
:45678
4::6::;6<7:B
CD74>
:DE<:B
FGH>64I
JKL
4<I
MN8:DO4>
6P4;D<47D@<Q
RD>>
?6
M6A5@A;6I
47
:OA66<D<E
=SD:D7
FQ
4:
I6:OAD?6I
D<
36O7D@<
TUVUG
7@
36O7D@<TUVUW
4:
M4A7
@5
7N6
6>DED?D>D78
4::6::;6<7U

!%


X6;@EA4MNDO
 C4AD4?>6:B
 D<O>YID<E
 I476
 @5
 ?DA7NB
 :6PB
 N6DEN7B
 R6DEN7B
 Z[\
=R6DEN7]^E_`N6DEN7
];_
GQB
A4O6
4<I
:;@^D<E
:747Y:
RD>>
?6
O@>>6O76I
47
:OA66<D<E
=SD:D7
FQU


,1a)b%
1
!
-2
cO7DC6;6IDO4>
O@<ID7D@<:
4<I
4>>
:YAE6AD6:
RD>>
?6
A6O@AI6I
47
:OA66<D<E
=SD:D7
FQU
XD:64:6
ND:7@A8BD<O>YID<E
I476
@5
ID4E<@:D:
@5
Kd
4<I
7N6
:M6OD5DO
Kd
;Y747D@<:
RD>>
4>:@
?6
A6O@AI6IU
&
e2
#
c A6C6A:D?D>D78
76:7
D<
A6:M@<:6
7@
:4>?Y74;@>
RD>>
?6
M6A5@A;6I
47
:OA66<D<E
=SD:D7
FQU
3MDA@;67A8
=dJSF
4<I
dSKQ
RD>>
?6
M6A5@A;6I
?65@A6
4<I
4576A
=47
fg
;D<Y76:
4<I
F
N@YAQ
7R@MY55:
@5
:4>?Y74;@>
4I;D<D:76A6I
Y:D<E
4
MA6::YAD:6I
;676A6I
I@:6
D<N4>6A
RD>>
?6
M6A5@A;6I
4<I
A6O@AI6IU
hN6
MA6H?A@ON@ID>47@A
dJSF
ijkl
no
pqrs
tuv
wxgy
@5
MA6IDO76I
<@A;4>5@A
D<O>Y:D@<U
hN6
A6C6A:D?D>D78
A6:M@<:6
D:
<@7
4<
6>DED?D>D78
;64:YA6U
c74>>7NA66
7D;6M@D<7:B
7NA66
76ON<DO4>>8
4OO6M74?>6
;64:YA6;6<7:
:N@Y>I
?6
;4I6
4<I
A6O@AI6ID<
7N6
KzdU
3MDA@;67A8
4::6::;6<7:
;48
?6
A6M6476I
YM
7@
6DEN7
7D;6:
7@
@?74D<
7NA66 4OO6M74?>6
A64ID<E:
4OO@AID<E
7@
c;6ADO4<
hN@A4ODO
3@OD678
ch3
EYDI6>D<6:
=[D>>6ABGggWQU
hN6
NDEN6:7
A64ID<E
5A@;
64ON
4::6::;6<7
RD>>
?6
Y:6I
5@A
O4>OY>47D@<
@5
MA6IDO76IC4>Y6:
4<I
D<OA64:6
5A@;
?4:6>D<6U
L{\
|Y4<}6AB
GgFG
RD>>
?6
Y:6I
4:
4
A656A6<O6
5@AMA6IDO76I
<@A;4>
C4>Y6:U


)%
2
"%2
$
{4?@A47@A8
:45678
4::6::;6<7:
RD>>
?6
M6A5@A;6I
4:
I6:OAD?6I
D<
36O7D@<
TUVUGU

~<:ON6IY>6I
4<I`@A
A6M647
76:7D<E
;48
?6
M6A5@A;6I
47
7N6
ID:OA67D@<
@5
7N6
\<C6:7DE47@AU


1

,1
1
#
AD@AA6:MDA47@A8
7N6A4MD6:
4<I
;6IDO47D@<:
74^6<
D<
7N6
>4:7
f
;@<7N:
RD>>
?6
A6O@AI6I
47
:OA66<D<E =SD:D7
FQ
4<I
O@<O@;D74<7
Y:6
IYAD<E
7N6
:7YI8
A6O@AI6I
4:
I6:OAD?6I
D<
36O7D@<WUUFU

7N6AMAD@A
;6IDO47D@<:
74^6<
D<
7N6
>4:7
f
;@<7N:
RD>>
?6
:6M4A476>8
A6O@AI6I
47
:OA66<D<E
=SD:D7FQ4<I
O@<O@;D74<7
Y:6
IYAD<E
7N6
:7YI8
A6O@AI6I
4:
I6:OAD?6I
D<
36O7D@<
WUUGU

"%2

47D6<7:RD>>?6O@<5DA;6I4:6>DED?>64OO@AID<E7@7N6D<O>Y:D@<4<I6PO>Y:D@<OAD76AD45A@;
4::6::;6<7:;4I647:OA66<D<E=SD:D7FQRD7N45D<4>ON6O^@54>>A6:Y>7:MA6HI@:647SD:D7GU














 !"# $
%&'(

*+
$

,+
,
#
-./0123405
78838823948
:;<=>
79?
;=@A
B/CC
D3
27?3
74
4E3
F1CC1B/9G
4/23.1/948
74
=/8/4
H
41=/8/4IJ
.03K?183
:74
K>L
2/9M438AN
>L
79?
OP
2/9M438
79?
>N
HN
IN
QN
R
79?
HI
E1M08
.184K?183 /9
7SS10?79S3
B/4E
TU-V<M01.379
W38./074105
-1S/345
:<W-A
GM/?3C/938
:X/CC30NHPPLAY
T4
7CC
4/23.1/948N
4E033
43SE9/S7CC5
7SS3.47DC3
2378M0323948
8E1MC?
D3
27?3
79?03S10?3?
/9
4E3
@W;Y
-./0123405
78838823948
275
D3
03.3743?
M.
41
3/GE4
4/238
41
1D47/9
4E0337SS3.47DC3
037?/9G8
7SS10?/9G
41
TU-
GM/?3C/938
:X/CC30N
HPPLAY
UE3
E/GE384
;<=>
79?
;=@037?/9G8
F012
37SE
7883882394
B/CC
D3
M83?
F10
797C58/8
3Z39
/F
4E3
;<=>
79?
;=@
Z7CM38S123
F012
4B1
?/FF30394
F10S3?
3[E7C74/198Y

\,,
],
-.M4M2872.C38
B/CC
D3
47^39
.03K?183
79?
74
R
79?
HI
E1M08
.184K?183
74
=/8/4
H
41
=/8/4
I
D58.1947931M8
3[.3S41074/19
1Z30
91
2103
4E79
L
2/9M438
79?
40798.1043?
19
/S3
F10
07./?
.01S388/9G
:S1CC3S4/19
41
84107G3
B/4E/9
OP
2/9M438AY
_E1C3
8.M4M2
B/CC
D3
/223?/743C5
F01`39 74
KHPa@
79?
4E39
40798F3003?
41
bcdef
hij
klijmno
pjqij
li
mrmstkqk
:u108C3534
7CN
HP>IAY
WE31C1G/S7C
797C58/8
B/CC
D3
.30F1023?
D3F103
79?
7F430
/9SMD74/19
74
Ovw@
F10
QP
2/9M438
:u108C3534
7CN
HP>IAY
x9FC72274105
23?/74108
:xyKRN
Uz;K{
79?
X|}A
B/CC
D3
2378M03?
7SS10?/9G41
4E3
.MDC/8E3?
234E1?1C1G5
:~1B935
34
7CN
HPPvAY

W38MC48B/CC
D3
.01Z/?3?
41
4E3
x9Z384/G7410
F10
39405
/941
4E3
@W;Y
&
"*



<[E7C3?D0374E
.u
:
S39403
19C5A
B/CC
D3
2378M03?
.03K?183
79?
74
R
79?
HI
E1M08
.184
?18374=/8/4
H
41
=/8/4
IY
<[E7C3?
D0374E
.u
2378M032394
B/CC
D3
.30F1023?
/9
7SS10?79S3
B/4E4E3234E1?
?38S0/D3?
D5
X7Sz33
34
7CN
HP>>Y
x9
D0/3FN
3[E7C3?
D0374E
S19?398743
:<@A
872.C38B/CC
D3
S1CC3S43?
?M0/9G
4/?7C
D0374E/9G
F10
>P
2/9M438N
B/4E1M4
9183
SC/.8N
M8/9G
4E3
WUMD3UX
:W38./074105
W38370SE
x9SN
@E70C14438Z/CC3N
=/0G/9/7AY
T
HPP
y
7C/M14
1F
<@
B/CCD3M83?
F10
4E3
.u
78875Y
X378M032394
1F
.u
B/CC
D3
.30F1023?
7F430
?3K73074/19
D5
DMDDC/9G70G19
4E01MGE
4E3
872.C3
74
H
yV2/9
BE/C3
219/410/9G
.u
M94/C
4E3
037?/9G
847D/C/83?N
M8M7CC5
7F430
R
2/9M438
1F
?3K73074/19
B/4E
70G19Y
&

$
|E7027S1^/934/S
797C58/8
B/CC
D3
.30F1023?
19
872.C38
47^39
F012
7CC
8MD3S48Y
I
2y
DC11?
872.C38B/CC
D3
S1CC3S43?
74
4E3
F1CC1B/9G
4/23.1/948
74
=/8/4
H
41
=/8/4
IJ
.03K?183N
>L
79?
OP2/9M438
79?
>N
HN
IN
QN
R
79?
HI
E1M08
.184K?183Y
-72.C38
B/CC
D3
S1CC3S43?
D5
Z393.M9S4M03
10
Z/7
/9?B3CC/9G
S799MC7
/9
4E3
F103702
/941
C/4E/M2
E3.70/9
4MD38
79?
B/CC
D3
/223?/743C5
SE/CC3?
:/S3
D74EAY
UE3
DC11?
B/CC
D3
S3940/FMG3?
B/4E/9
OP
2/9M438
1F
S1CC3S4/19Y
UE3.C7827
B/CC
D3
83.70743?
/9
7
03F0/G30743?
S3940/FMG3
:7D1M4
Iw@A
74
>>PPG
F10
>L
2/9M438
79?40798F3003?
/941
.1C5.01.5C393
4MD38Y
TF430
37SE
DC11?
S1CC3S4/19N
4E3
.C7827
B/CC
D3
?/8.3983?/941
4B1
7C/M148Y
TF430
7..01.0/743
C7D3CC/9GN
4E3
.C7827
872.C38
B/CC
D3
84103?
74N
10D3C1B KHPw@Y
UE3
.C7827
872.C38
B/CC
4E39
D3
40798.1043?
/9
?05
/S3
41
4E3
S39407C
C7D1074105BE3034E35B/CCD384103?7410D3C1B KHPw@M94/C4E35703797C583?M8/9G7
Z7C/?743?234E1?Y














 !"# $
%&'

)'*
$

$+,
",
-./012345
742
1.8019345
72:.1;.
.:.49;
3;
2.;/13<.2
34
2.973=
34
>./9304
?@

*
)'*
$
A==B.C7=.
8793.49;
D3==
E7:.
7
F134.
81.5474/G
9.;9
79
;/1..4345
HI3;39
JKL
81.M20;.
79
I3;39
N
90I3;39O742
79
9E.
.42
0B
;9F2G
:3;39
HI3;39
PK
7//012345
90
9E.
;9F2G
/.491.Q;
;9742712
08.179345810/.2F1.;
H>RS;K@
A==09E.1=7<017901G
;7B.9G
7;;.;;C.49;
D3==
<.
8.1B01C.2
79
.7/E
;9F2G
/.491.Q;
=0/7=
=7<017901G@
>7C8=.;
D3==
<.
E742=.2
742
747=G;.2
7//012345
90
9E.
;9F2G
/.491.
742
=0/7=
=7<017901G
;9742712
810/.2F1.;@
T040:.99.M>U
H>71;9.29K
9F<.;
D3==
<.
F;.2
90
/0==./9
;7B.9G
=7<017901G
<=002
;7C8=.;@
VD0
;7C8=.;D3==
<.
/0==./9.2
79
.7/E
93C.80349L
04.
;7C8=.
B01
E7.C790=05G
F;345
7
N@W
CX
.9EG=.4.237C34.9.9177/.93/
7/32
HYZVAK
DE0=.
<=002
/0==./9304
9F<.
742
04.
O@[
CX
;7C8=.
B01<30/E.C3;91G
F;345
7
;.1FC
9F<.@
A
C32;91.7C
F134.
;7C8=.
D3==
7=;0
<.
/0==./9.2
34
7
;9.13=./049734.1@

>7C8=.;D3==
<.
97\.4
79
;/1..4345
HI3;39
JK
742
.42
0B
;9F2G
:3;39
HI3;39
PK
742
747=G;.2
B01]
^7.C790=05G]
E7.C05=0<34L
E7.C790/139L
9097=
DE39.
/.==
/0F49L
=.F\0/G9.
23BB.1.4937=
/0F49
742
8=79.=.9
/0F49
_30/E.C3;91G]
/1.793434.L
9097=
<3=31F<34L
7=\7=34.
8E0;8E797;.L
7=7434.
9174;7C347;.L
57CC7M`VL
8097;;3FCL
;023FCL
F1.7
a1347=G;3;]

 =.F\0/G9.;L
<=002L
\.904.;L
<3=31F<34L
F10<3=3405.4L
8109.34
742
5=F/0;.
F;345
7
238;93/\@
b4
9E.
.:.49
0B
74
7<401C7=
238;93/\
F1347=G;3;
1.;F=9L
C3/10;/083/
F1347=G;3;
C7G
<.
/042F/9.2@

b472239304L
F4;/E.2F=.2
742c01
1.8.79
9.;9345
C7G
<.
8.1B01C.2
79
9E.
23;/1.9304
0B
9E.
b4:.;9357901@
X7<017901G
1.;F=9;
D3==
<.
810:32.2
90
9E.
b4:.;9357901
B01
.7/E
8793.49
742
.7/E
:3;39@VE.b4:.;9357901
;E0F=2
7;;354
DE.9E.1
.7/E
7<401C7=
1.;F=9
3;
409
/=343/7==G
;3543B3/749
017/=343/7==G
;3543B3/749@

&


)%
_=00281.;;F1.
742
8F=;.
179.
D3==
<.
C.7;F1.2
79
;/1..4345
HI3;39
JK
742
81.M20;.L
deC34F9.;
742
JL
NL
OL
W
742
?
E0F1;
80;9M20;.
79
I3;39
N
90
I3;39
O@

A9.7/E93C.80349L
;F834.
:397=
;354;
D3==
<.
7;;.;;.2
DE3=.
9E.
8793.49
E7;
<..4
79
1.;9
B01
79
=.7;9PC34F9.;@


*
"f
ABF==8EG;3/7=
.g7C3479304L
/0:.1345
C7h01
<02G
;G;9.C;
H7;;.;;C.49;
0B
9E.
40;.L
9E1079L
;\34L9EG1032
5=742L
4.F10=053/7=
;G;9.CL
1.;8317901G
;G;9.CL
/71230:7;/F=71
;G;9.CL
7<20C.4
i=3:.1742
;8=..4jL
=GC8E
402.;
742
.g91.C393.;K
D3==
<.
8.1B01C.2
79
;/1..4345
HI3;39
JK@
-.;F=9;D3==<.1./012.2349E.k-l7;401C7=L7<401C7=409/=343/7==G;3543B3/74901
7<401C7=/=343/7==G;3543B3/749@VE.8EG;3/7=.g7C3479304D3==<.1.8.79.2799E..420B;9F2G
:3;39HI3;39PKL74274G/E745.;04=G1./012.2@














 !"# $
%&'(

*
"+
,-./0124567
89//
:0
;1<0=
1;
7>?00=9=@
AB979;
,C
1=2
D?0.2E70
1=2
,F
-F
G
1=2
H
IEJ?7
DE7;.2E701;
B979;
-
;E
B979;
GK

L;01>I;9M0DE9=;F
,-./012
4567
7IEJ/2
:0
;1<0=
1N;0?
1;
/017;
O
M9=J;07
9=
;I0
7JD9=0
DE79;9E=KL=
456
D?9=;
EJ;
MJ7;
:0
;1<0=
1;
01>I
;9M0DE9=;
1=2
79@=02
1=2
21;02
:P
;I0
Q=R07;9@1;E?K
L=
ER0?1//
177077M0=;
A=E?M1/F
1:=E?M1/
=E;
>/9=9>1//P
79@=9N9>1=;
E?
1:=E?M1/
>/9=9>1//P79@=9N9>1=;C
1=2
>E=;9=JEJ7
R1?91:/07F
9=>/J29=@
STF
I01?;
?1;0
1=2
ST>U
AE?
VV
;E
20?9R0ST>UC
89//
:0
?0>E?202
9=
;I0
5VUK

W*
X%
TI0M1Y9MJM
RE/JM0
EN
:/EE2
;1<0=
N?EM
1=P
7J:Z0>;
2J?9=@
;I0
7;J2P
8I9>I
9=>/J207
/1:E?1;E?P
71N0;P
;07;7
1=2
DI1?M1>E<9=0;9>
71MD/07
89//
:0
JD
;E
1DD?EY9M1;0/P
-[[
M\F
1//E89=@NE?
1=P
?0D01;
71MD/9=@
?0]J9?02K
^
$
(
_`
TI0177077M0=;7
D/1==02
9=
;I97
7;J2P
1?0
?0>E@=9702
17
?0/91:/0F
1>>J?1;0
1=2
?0/0R1=;K
a/17M1>E=>0=;?1;9E=7
EN
Va\OOG
89//
:0
0R1/J1;02
J79=@
1
R1/921;02
1771P
1=2
]J1/9;P
>E=;?E/71MD/07
89//
:0
1=1/P702
;I?EJ@IEJ;
;I0
7;J2PK
TI0
>E=>0=;?1;9E=7
89//
:0
J702
;E
20;0?M9=089;I9=
?J=F
:0;800=
?J=
1=2
ER0?1//
D?0>979E=
1=2
1>>J?1>P
EN
;I0
M0;IE2K
TI0
D?E>02J?07F
9=>/J29=@
;I0
/9M9;7
EN
]J1=;9;1;9E=
1=2
?07J/;7
89//
:0
207>?9:02
9=
20;19/
9=
1
70D1?1;0:9E1=1/P;9>1/
D?E;E>E/
1=2
?0DE?;K
TI0
;9M9=@
EN
DI1?M1>E<9=0;9>
71MD/07
97
200M02
1DD?ED?91;0
;E
07;1:/97I
;I0
0YDE7J?0
EN
D1;90=;7
;E
79=@/0
2E707
EN
7;J2P
;?01;M0=;K
bD9?EM0;?P
97
1
7;1=21?2
/J=@
NJ=>;9E=
;07;
J702
;E
7>?00=
NE?F
1=2
ME=9;E?F
?07D9?1;E?P
2970170KbD9?EM0;?P
1=2
219/P
>1/9:?1;9E=7
89//
:0
D0?NE?M02
9=
1>>E?21=>0
89;I
LTbc4Vb
;17<NE?>0
7;1=21?2971;9E=
@J920/9=07
Ad9//0?
0;
1/F
-[[OC
J79=@
;I0
7;J2P
>0=;?0e7
7;1=21?2
7D9?EM0;?P
0]J9DM0=;
1=2
bfa7K
TI0M017J?0M0=;
EN
7DJ;JM
9=N/1MM1;E?P
M0291;E?7
1=2
0YI1/02
:?01;I
Dg
89//
:0
D0?NE?M02
9=
1>>E?21=>0
89;I
bfa7
9=
D/1>0
1;
L220=:?EE<07
1=2
a1D8E?;I
gE7D9;1/7
?07D0>;9R0/PK
aIP79>1/0Y1M9=1;9E=7F
R9;1/
79@=7F
,-./012
4567F
12R0?70
0R0=;
?0>E?29=@
1=2
/1:E?1;E?P
71N0;P;07;7
1?0
7;1=21?2
177077M0=;7
EN
71N0;P
1=2
;E/0?1:9/9;PK
TI0
?1=@0
EN
177077M0=;7
;E
:0
D0?NE?M02
97
200M02
1DD?ED?91;0
;E
20;0>;
1=P
71N0;P
79@=1/7K
'
h$! +

$!
"X"
"
"#X
$!
"+$ "X
'
$*i
"i
!(
L2R0?700R0=;
97
20N9=02
17
1=P
J=2079?1:/0
0YD0?90=>0
E>>J??9=@
;E
1
D1;90=;F
E?
8E?70=9=@
9=1D1;90=;F
2J?9=@
1
>/9=9>1/
7;J2PF
8I0;I0?
E?
=E;
>E=7920?02
?0/1;02
;E
;I0
7;J2P
;?01;M0=;K
L=12R0?70
0R0=;
M1P
:0
1=P
EN
;I0
NE//E89=@j
k
L=08
9//=077
k
L=0Y1>0?:1;9E=
EN
1
79@=
E?
7PMD;EM
EN
;I0
J=20?/P9=@
>E=29;9E=
J=20?
;?01;M0=;
E?
EN
1>E=>EM9;1=;9//=077
k
m=?0/1;02;ED1?;9>9D1;9E=9=;I0>/9=9>1/7;J2PE?1=0NN0>;EN;I07;J2P2?J@














 !"# $
%&'
(
*,-./01230-1
-4
-15
-6
.-65
-4
375
2/-85
42,3-69
:-,2;92<
65<230-1970=
>037
375
93;?@
36523.513
09
0.=<05?
/@
375
;95
-4
375
356.
A2?85695
58513BC*1
5D2,56/230-1
-4
2
=65E5D09301F
,-1?030-1
-6
0<<1599
09
?54015?
29
2
.-65
465G;513
-,,;6651,5
-6
29
21
01,65295
01
375
9585603@
-4
375
=65E5D09301F
,-1?030-1
-6
0<<1599
?;601F
375
93;?@BH<2115?
-6
5<5,3085
9;6F0,2<
-6
01829085
=6-,5?;659
4-6
=65E5D09301F
,-1?030-19
3723
72851-3>-69515?
265
1-3
2?85695
585139B
I->5856J
21@
,-.=<0,230-1
3723
-,,;69
?;601F
2
=<2115?-6
5<5,3085
9;6F56@
09
21
2?85695
58513
K04
375
58513
4039
375
9560-;9
,6035602J
9;,7
29
21
5D351?5?7-9=032<09230-1J
03
>0<<
/5
,-190?565?
3-
/5
9560-;9LB
M-1?030-19
<52?01F
3-
;1=<2115?
9;6F0,2<=6-,5?;659
.2@
/5
2?85695
585139B
*?85695652,30-1
09
?54015?
29
2<<
;13->26?
21?
;101351?5?
659=-1959
3-
93;?@
36523.513
65<235?3-21@
?-95
2?.01093565?B
N560-;92?85695
58513
KN*OL
09
21@
2?85695
5D=56051,5
3723P
(
Q59;<39
01
?5237
(
R9<045E3765235101F
(
Q5G;0659
01=230513
7-9=032<09230-1
-6
=6-<-1F230-1
-4
5D09301F
7-9=032<09230-1
(
Q59;<39
01
=569093513
-6
90F1040,213
?092/0<03@S01,2=2,03@J
TQ
(
R92,-1F51032<
21-.2<@S/0637
?545,3
(
T3756
.5?0,2<
585139U
UR.=-63213
.5?0,2<
585139
3723
.2@
1-3
/5
0..5?0235<@
<045E3765235101F
-6
659;<3
01
?5237
-6
7-9=032<09230-1
.2@
/5
,-190?565?
2
N*O
>751J
/295?
-1
2==6-=60235
.5?0,2<
V;?F5.513J
375@.2@V5-=26?095
375
=230513
-6
.2@
65G;065
.5?0,2<
-6
9;6F0,2<
0135685130-1
3-
=658513
-15
-4375-;3,-.59
<0935?
2/-85B
*1;15D=5,35?
2?85695
652,30-1
09
21
2?85695
652,30-1
01
>70,7
375
123;65
-6
9585603@
-4
>70,7091-3
,-19093513
>037
375
R185930F23-6
W6-,7;65B
N;9=5,35?
;15D=5,35?
9560-;9
2?85695
652,30-19
KNXN*QL
09
21@
9;9=5,35?
2?85695
652,30-1
65<235?3-375
93;?@
?6;F
3723
09
/-37
;15D=5,35?
21?
9560-;9B
Y
[%
[
$%
$[\
"\
*<<2?85695
585139J
>753756
65=-635?
9=-13215-;9<@
/@
375
=230513J
01
659=-195
3-
-=51
G;5930-101F
-1
36523.513
?2@9
-6
-/95685?
/@
375
R185930F23-6
-6
709S756
93244J
>0<<
/5
65,-6?5?46-.
014-6.5?
,-19513
;130<
375
51?
-4
93;?@
80903
K]0903
^LB

_759326321?
93-=
30.5
>0<<
/5
65,-6?5?
21?
2?85695
585139
>0<<
/5
2995995?
/@
375
R185930F23-6
4-6
375
4-<<->01FP
Y
`\a
b0<?P
Q59-<85?
>037-;3
36523.513
b-?56235P
Q59-<85?
-6
>29
3-<56235?
>037
9=5,040,
36523.513
>037-;3
2445,301F
93;?@
2,30803059
N58565P
c0?1-3659-<85-6>291-33-<56235?>03736523.513














 !"# $
%&
'
)
*+,-./12234+1,5
*+,-./
/6/,7
8+79
.+:+7/;
;<=37+1,
>,7/=:+77/,75

*/6/=3.
/?+41;/4
1@
3,
/6/,7A
/329
1@
.+:+7/;
;<=37+1,
B/=4+47/,75

C6/,7
89+29
=/:3+,/;
+,;/@+,+7/.D
'E
F)
G17H/.37/;
I9+4
237/-1=D
3??.+/4
71
7914/
3;6/=4/
/6/,74
89+29A
3@7/=
23=/@<.
21,4+;/=37+1,A
3=/
2./3=.D
;</
71
/J7=3,/1<4
23<4/4
K;+4/34/A
/,6+=1,:/,7A
/72LM

N,.+O/.D
>,
-/,/=3.A
79+4
237/-1=D
23,
P/
21,4+;/=/;
3??.+23P./
71
7914/
3;6/=4/
/6/,74
89+29A
3@7/=
23=/@<.
:/;+23.
21,4+;/=37+1,
37
79/
7+:/
79/D
3=/
<,=/.37/;
71
79/
7/47
;=<-L
Q,
3;6/=4/
/6/,7
:3D
P/
21,4+;/=/;
<,.+O/.D
71
P/
=/.37/;
+@
1=
89/,
K:<47
936/
781
1@
79/
@1..18+,-M5
RL
 >7
;1/4
,17
@1..18
3
=/341,3P./
7/:?1=3.
4/T</,2/
@=1:
3;:+,+47=37+1,
1@
79/
47<;D
7=/37:/,7L
UL
 >7
21<.;
=/3;+.D
936/
P//,
?=1;<2/;
PD
79/
?37+/,7V4
2.+,+23.
4737/A
/,6+=1,:/,73.
1=
71J+2
@3271=4A
1=
179/=
:1;/4
1@
79/=3?D
3;:+,+47/=/;
71
79/
?37+/,74L
WL
 >7
;1/4
,17
@1..18
3
O,18,
?377/=,
1@
=/4?1,4/
71
79/
47<;D
7=/37:/,7L
XL
 >7
;1/4
,17
=/3??/3=
1=
81=4/,
89/,
79/
47<;D
7=/37:/,7
+4
=/Y3;:+,+47/=/;L
B144+P.D
I9+4
237/-1=D
3??.+/4
71
7914/
3;6/=4/
/6/,74
@1=
89+29A
3@7/=
23=/@<.
:/;+23.
21,4+;/=37+1,
37
79/
7+:/
79/D
3=/
/63.<37/;A
3
21,,/27+1,
8+79
79/
47<;D
7=/37:/,7
3;:+,+47=37+1,
3??/3=4
<,.+O/.D
P<7
23,,17
P/
=<./;
1<7
8+79
2/=73+,7DL
Q,
3;6/=4/
/6/,7
:3D
P/
21,4+;/=/;
?144+P.D
=/.37/;
+@
1=
89/,
K:<47
936/
781
1@
79/
@1..18+,-M5
RL
 >7
@1..184
3
=/341,3P./
7/:?1=3.
4/T</,2/
@=1:
3;:+,+47=37+1,
1@
79/
47<;D
7=/37:/,7L
UL
 >7
21<.;
,17
=/3;+.D
936/
P//,
?=1;<2/;
PD
79/
?37+/,7V4
2.+,+23.
4737/A
/,6+=1,:/,73.
1=
71J+2
@3271=4A
1=
179/=
:1;/4
1@
79/=3?D
3;:+,+47/=/;
71
79/
?37+/,74L
WL
 >7
@1..184
3
O,18,
?377/=,
1@
=/4?1,4/
71
79/
47<;D
7=/37:/,7L
Z/@+,+7/.D
I9+4
237/-1=D
3??.+/4
71
7914/
3;6/=4/
/6/,74
89+29
79/
>,6/47+-371=
@//.4
3=/
+,21,7=16/=7+P.D
=/.37/;
71
47<;D
7=/37:/,7L
Q,
3;6/=4/
/6/,7
:3D
P/
344+-,/;
3,
377=+P<7+1,
1@
;/@+,+7/.D
=/.37/;
+@
1=
89/,
K:<47
936/
3..
1@
79/
@1..18+,-M5
RL
 >7
@1..184
3
=/341,3P./
7/:?1=3.
4/T</,2/
@=1:
3;:+,+47=37+1,
1@
79/
47<;D
7=/37:/,7L
UL
 >7
21<.;
,17
P/
=/341,3P.D
/J?.3+,/;
PD
79/
O,18,
293=327/=+47+24
1@
79/
?37+/,7V4
2.+,+23.
4737/A
/,6+=1,:/,73.A
1=
71J+2
@3271=4A
1=
179/=:1;/41@79/=3?D3;:+,+47/=/;7179/?37+/,74L
WL
>7;+43??/3=41=;/2=/34/41,2/4437+1,1==/;<27+1,+,;14/3,;
=/2<=48+79=/Y/J?14<=/71;=<-LKG17/579+4+4,1771P/21,47=</;














 !"# $
%&
'(
*+,-.*./0
*+1+234(-*+
45
67+
3'6.+/68
749+:+*;
'
<'6+04*=
45
>+5./.6+?=
*+?'6+>
<'/
4/?=
@+
-(+>
97+/
'
*+<-**+/<+
.(
4@(+*:+>AB
CA
 E6
54??49(
'
F/49/
3'66+*/
45
*+(34/(+
64
67+
(6->=
6*+'6G+/6A
H
$
J
K
L
M<6.4/
6'F+/
9.67
(6->=
6*+'6G+/6
N/4/+;
(6->=
6*+'6G+/6
(6433+>;
(6->=
6*+'6G+/6
6+G34*'*.?=
./6+**-36+>B
L
O67+*
'<6.4/(
N/4/+;
<4/<4G.6'/6
G+>.<'6.4/;
(6->=
>.(<4/6./-'6.4/;
74(3.6'?.('6.4/;
467+*B
L
P7+4-6<4G+
'/>
>'6+
45
4-6<4G+
'<<4*>./0
64
67+
54??49./0
>+5./.6.4/(Q
R
S+<4:+*+>
4*
*+(4?:+>
N'>:+*(+
+:+/6
>.('33+'*+>B
R
S+<4:+*./0
4*
*+(4?:./0
N3'6.+/6
.(
*+<4:+*./0B
R
T46
*+<4:+*+>
4*
/46
*+(4?:+>
N'>:+*(+
+:+/6
*+G'./(
9.674-6
(.0/(
45
.G3*4:+G+/6B
R
S+<4:+*+>
4*
*+(4?:+>
9.67
(+,-+?'+
N'>:+*(+
+:+/6
7'(
*+(-?6+>
./
3+*G'/+/6
>.('@.?.6=
4*
./<'3'<.6=B
R
U'6'?
R
V/F/49/
N4/?=
'33?.<'@?+
.5
3'6.+/6
7'(
@++/
?4(6
64
54??491-3B
L
W+*.4-(/+((
N=+(
4*
/4B
HX
%
JK
&
Y$"
P7+E/:+(6.0'64*
G-(6
*+34*6
'??
WMZ(
64
67+
W34/(4*
@=
6+?+374/+
'/>
./
9*.6./0
-(./0
67+
W34/(4*[(
*+34*6./0
54*G
'/>
+G'.?+>
N+G'.?
'>>*+((
./<?->+>
4/
\'0+
]B
64
'(
(44/
'(
3*'<6.<'?;@-6
'6
?+'(6
9.67./
]C
74-*(
45
'9'*+/+((A
M/=
5'6'?
WMZ(
/46.5.+>
./
67+
^_
>'=
3+*.4>'56+*
67+
?'(6
>4(+
45
(6->=
6*+'6G+/6
G-(6
'?(4
@+
*+34*6+>
WVWMS(9.??
@+
>+6+*G./+>
@=
67+
W34/(4*[(
`+>.<'?
`4/.64*A
WMZ(9.??
@+
*+34*6+>
64
67+
+67.<(
<4GG.66++
'/>
*+0-?'64*=
'-674*.6=
'<<4*>./0
64
?4<'?
*+,-.*+G+/6(A
M??'>:+*(+
+:+/6(
9.??
@+
54??49+>
-/6.?
67+=
7':+
'@'6+>;
4*
-/6.?
'
(6'@?+
(.6-'6.4/
7'(
@++/
*+'<7+>Aa+3+/>./0
4/
67+
+:+/6;
54??49
-3
G'=
*+,-.*+
'>>.6.4/'?
6+(6(
4*
G+>.<'?
3*4<+>-*+(
'(
./>.<'6+>;
'/>b4*
*+5+**'?
64
67+
3'6.+/6[(
0+/+*'?
37=(.<.'/
4*
'
G+>.<'?
(3+<.'?.(6A
E6.(67+*+(34/(.@.?.6=
45
67+
W34/(4*
'/>
45
67+
E/:+(6.0'64*
64
+/(-*+
67'6
'/=
/+<+(('*=
'>>.6.4/'?
67+*'3+-6.<
G+'(-*+(
'/>
54??491-3
3*4<+>-*+(
'*+
3+*54*G+>A
H
c%
&
%
W74-?>'5+G'?+
3'6.+/6
@+<4G+
3*+0/'/6
>-*./0
67+
(6->=
4*
./
67+
^_
>'=(
'56+*
67+
+/>
45
67+(6->=67+=G-(6./54*G 67+E/:+(6.0'64*.GG+>.'6+?=AP7+E/:+(6.0'64*9.??*+34*667.(
./54*G'6.4/6467+W34/(4*9.67./d>'=(45'9'*+/+((AP7+E/:+(6.0'64*9.??G'F+'??
*+'(4/'@?++554*6(64'(<+*6'./67+3*40*+(('/>4-6<4G+4567+3*+0/'/<=AE567+4-6<4G+
G++6(67+<*.6+*.'54*.GG+>.'6+<?'((.5.<'6.4/45'WMZN+A0A(34/6'/+4-(4*67+*'3+-6.<














 !"# $
%&
'()*+,)-.0+,11(,*+2.
-3)-'+'1
43'+2.
5)-63-,+'1
'-)7'18.
(,*+2
43935+:.
+23
;-<30+,6'+)*
7=0+
9)11)>+23
?*)534=*3
9)*
*3?)*+,-6
@AB0C

EF$ #G
$HHF$"
$!
EF$ #G
#
I230+=48
>,11
(3
5)-4=5+34
,-
'55)*4'-53
>,+2
+23
5=**3-+
'??*)<34
?*)+)5)1.
@JK0
'-4
'11
'??1,5'(13
6=,431,-30
'-4
*3L=,*373-+0C

$MN
N
 

I23@?)-0)*.
)*
,+0
430,6-33
7'8
5)-4=5+
'
L='1,+8
'00=*'-53
'=4,+C
A-
,-0?35+,)-
)9
+2,0
0+=487'8
'10)
(3
5'**,34
)=+
(8
*36=1'+)*8
'=+2)*,+,30
'+
+23,*
4,05*3+,)-C
@=52
'=4,+0
)*
,-0?35+,)-0
5'-
)55=*
'+
'-8
+,73
4=*,-6
)*
'9+3*
5)7?13+,)-
)9
+23
0+=48C
;9
'-
'=4,+
)*
,-0?35+,)-
)55=*0.
+23
;-<30+,6'+)*
'-4
,-0+,+=+,)-
'6*33
+)
'11)>
+23
'=4,+)*O,-0?35+)*
4,*35+
'55300+)'11
*313<'-+
4)5=73-+0
'-4
+)
'11)5'+3
2,0
+,73
'-4
+23
+,73
)9
2,0
0+'99
+)
+23
'=4,+)*)*,-0?35+)*
+)
4,05=00
9,-4,-60
'-4
'-8
*313<'-+
,00=30C

P%
N
HM
!M

&
I23@?)-0)*
>,11
'**'-63
9)*
+23
0+=48
+)
(3
7)-,+)*34
,-
'55)*4'-53
>,+2
+23
?*,-5,?130
)9
;QR SQKC
I23
9*3L=3-58
)9
7)-,+)*,-6
<,0,+0
>,11
(3
43+3*7,-34
(8
+23
*'+3
)9
?'+,3-+
*35*=,+73-+C
I239)11)>,-6
'*3
3T'7?130
)9
,+370
+2'+
>,11
(3
*3<,3>34
'+
+2303
<,0,+0U
V
Q)7?1,'-53
>,+2
+23
?*)+)5)1
V
Q)-03-+
?*)534=*3
V
@)=*53
4)5=73-+0
V
A4<3*03
3<3-+
?*)534=*30
V
@+)*'63
'-4
'55)=-+'(,1,+8
)9
7'+3*,'10
I237)-,+)*,-6
<,0,+0
'10)
?*)<,43
+23
@?)-0)*
>,+2
+23
)??)*+=-,+8
+)
3-0=*3
+2'+
+,7318
?'+,3-+'55*='1
'-4
+23
)+23*
;-<30+,6'+)*X0
)(1,6'+,)-0
'-4
'11
'??1,5'(13
*3L=,*373-+0
'*3
(3,-69=19,1134C
I23;-<30+,6'+)*
7=0+
?3*7,+
+23
0+=48
7)-,+)*.
+23
3+2,50
5)77,++33.
+23
@?)-0)*X0
'=4,+)*0
'-4*3?*303-+'+,<30
9*)7
*36=1'+)*8
'=+2)*,+,30
4,*35+
'55300
+)
'11
0)=*53
4)5=73-+0
9)*
5)-9,*7'+,)-
)9
+23
'55=*'58
'-4
*31,'(,1,+8
)9
4'+'
5)-+',-34
>,+2,-
+23
QYZ0
[0)=*53
4)5=73-+<3*,9,5'+,)-:C
K'+,3-+
5)-9,43-+,'1,+8
>,11
(3
?*)+35+34
'+
'11
+,730C
@)=*534)5=73-+0
'*3
439,-34
'0
+23
*30=1+0
)9
)*,6,-'1
)(03*<'+,)-0
'-4
'5+,<,+,30
)9
'
51,-,5'1,-<30+,6'+,)-.
,-51=4,-6
734,5'1
-)+30C
A11
0)=*53
4)5=73-+0
?*)4=534
,-
+2,0
0+=48
>,11(37',-+',-34
(8
+23
;-<30+,6'+)*
'-4
7'43
'<',1'(13
9)*
,-0?35+,)-C
I23
)*,6,-'1
0,6-34
,-9)*7345)-03-+
9)*7
9)*
3'52
?'+,3-+
>,11
(3
*3+',-34
(8
+23
;-<30+,6'+)*
'-4
+23
035)-4
0,6-34)*,6,-'1
6,<3-
+)
+23
?'+,3-+C
@)=*534'+'
,-51=43.
(=+
,0
-)+
1,7,+34
+).
+23
9)11)>,-6
'-4
>,11
(3
,43-+,9,34
,-
'
0)=*53
4'+'
1)5'+,)-1)6U
V
@5*33-,-6O3-*)173-+1)6
V
\34,5'1-)+30]>2,5202)=14(3=?4'+34'9+3*3'52<,0,++),-51=43<,0,+4'+30.734,5'1
2,0+)*8.4,'6-)0,0)9580+,59,(*)0,0.5)-5)7,+'-+734,5'+,)-.'-851,-,5'118*313<'-+














 !"# $
%&'
()*+)*,-
/(
01)*)021
3425)*26)/*-
/7
01)*)02118
731392*6
2+937-3
393*6-:53+)026)/*
0;2*,3-<
=>?-
2*+
)*(/7526)/*
/*
@26)3*6
A)6;+72A21
B
D*(/753+
0/*-3*6
(/75
B
EFG132+
?HI-
B
J2K/726/78
73@/76-
B
L)-)6
+263-

B
=6M+8
6732653*6
200/M*62K)1)68:)*93*6/78
(/75-
N;3-6M+8
5/*)6/7
A)11
02778
/M6
-/M703
+/0M53*6
937)()026)/*
26
73,M127
)*637921-O
N;)-
)-
2*
3--3*6)2131353*6
/(
PM21)68
0/*67/1<
2-
)6
211/A-
6;3
7306)()026)/*
/(
672*-07)@6)/*
377/7-
2*+
/5)--)/*-O
&
!
R%
S
S%
>*313067/*)0
HTU
A)11
K3
+3-),*3+
2*+
@7/+M03+
K8
6;3
=@/*-/7
V/7
+3-),*33W
2*+
-;/M1+
K3
0/5@1363+
)*
200/7+2*03
A)6;
)*-67M06)/*-O
N;3
D*93-6),26/7
)-
73-@/*-)K13
(/7
52)*62)*)*,
2+3PM2632*+
200M7263
53+)021
730/7+-
(7/5
A;)0;
200M7263
)*(/7526)/*
A)11
K3
672*-07)K3+
+)730618)*6/
6;3
HTU-
M-)*,
2
-30M73
)*637*36
0/**306)/*O
N;3
HTU-
-;/M1+
K3
()113+
/M6
0/5@136318
K8
6;3
D*93-6),26/7
V/7
+3-),*33WO
N;3
HTU
-8-635
A)11
K3
U//+
2*+
X7M,
>+5)*)-6726)/*
VUX>W
H/+3
/(
U3+3721
T3,M126)/*-
VHUTW
FE
Y276
EE
0/5@1)2*6O
X2623*6373+
)*6/
6;3
HTU
A)11
K3
921)+263+<
A;)0;
)*01M+3-<
KM6
)-
*/6
1)5)63+
6/<
921)+)68
0;30Z-V3O,O
72*,3
0;30Z-W<
0/*-)-63*08
0;30Z-
2*+
0M-6/5)-3+
0;30Z-
V1/,)021
0;30Z-
K36A33*927)2K13-
6/
3*-M73
6;26
-6M+8
+262
273
200M726318
73@/763+W
(/7
HTU
+262
2*+
34637*21
+262V3O,O12K/726/78
+262WO
>
52[/7)68
/(
3+)6
0;30Z-
A)11
K3
67),,373+
+M7)*,
+262
3*678
2*+
A)116;373(/73
(20)1)6263
3(()0)3*6
\@/)*6
/(
3*678]
+262
0132*)*,O

N;3=@/*-/7
V/7
+3-),*33W
A)11
@37(/75
K/6;
52*M21
HTU
739)3A
2*+
739)3A
/(
313067/*)0
3+)60;30Z-
6/
3*-M73
6;26
6;3
+262
273
0/5@1363<
0/*-)-63*6
2*+
732-/*2K13O
N;3
313067/*)0
3+)6
0;30Z-A)11
7M*
0/*6)*M2118
6;7/M,;/M6
6;3
0/M7-3
/(
6;3
-6M+8
2*+
6;3
)--M3-
A)11
K3
739)3A3+
52*M2118/*1)*3
6/
+36375)*3
A;26
206)/*
*33+-
6/
K3
62Z3*O
^2*M21PM37)3-
528
K3
2++3+
6/
6;3
-8-635
6;3
=@/*-/7
V/7
+3-),*33WO
T3@73-3*626)93-
/(
6;3
=@/*-/7273
2K13
6/
735/6318
2*+
@7/206)9318
5/*)6/7
6;3
HTU-
6/
)5@7/93
+262
PM21)68O
H3*672112K/726/78
@;27520/Z)*36)0
+262
A)11
K3
672*-(3773+
313067/*)02118
)*6/
6;3
-6M+8
+262K2-3OX)-073@2*0)3-
A)11
K3
PM37)3+
6/
6;3
-6M+8
03*673
2*+:/7
6;3
12K/726/78
M*6)1
6;3
313067/*)0+262
2*+
6;3
+262K2-3
273
730/*0)13+O

>11M@+263-
6/
PM37)3+
+262
A)11
K3
52+3
K8
2M6;/7)-3+
-6M+8
03*673
@37-/**31
/*18
2*+
211
5/+)()026)/*-
6/
6;3
+262K2-3
A)11
K3
730/7+3+
)*
2*
2M+)6
672)1O
_*03
211
6;3
PM37)3-
;293
K33*
73-/193+<HTU-
A)11
K3
1/0Z3+
K8
@2--A/7+
@7/6306)/*O
>*8
0;2*,3-
6/
1/0Z3+
HTU-
A)11
K3
2@@7/93+K8
6;3
D*93-6),26/7O
_*036;3(M11
-36
/(
HTU-
;293
K33*
0/5@1363+
2*+
1/0Z3+<
6;3
=@/*-/7
A)11
2M6;/7)-3
+262K2-31/0Z
2*+
211
313067/*)0
+262
A)11
K3
-3*6
6/
6;3
+3-),*263+
-626)-6)0)2*
(/7
2*218-)-O
=MK-3PM3*6
0;2*,3-
6/
6;3
+262K2-3
A)11
6;3*
/*18
K3
52+3
/*18
K8
A7)663*
2,73353*6
/(
6;3
=@/*-/7O
>+937-3393*6-2*+53+)021:02*037;)-6/786375-A)11K30/+3+(7/56;3937K26)5+3-07)@6)/*
VD*93-6),26/76375WM-)*,6;3^3+)021X)06)/*278(/7T3,M126/78>06)9)6)3-V^3+XT>WOY7)/7
2*+0/*0/5)62*653+)026)/*-2*+6;372@)3-A)11K30/+3+200/7+)*,6/6;3`a_ +7M,














 !"# $
%&
'()*(+,-./0
2+'(,3
.45(46
6(77
84
94.:+.;4'
8/
*<4
=9+,>+.
?+.
'4>(3,44@
9.(+.
*+
'-*-8->4
7+)A0
B<4)7(,()-7
'-*-
?(,
>*-*(>*()-7
-,-7/>(>
>+:*6-.4
C=D=E
:+.;-*@
6(77
84
*.-,>:4..4'
*+
*<4
=9+,>+.-*
*<4
4,'
+:
*<4
>*F'/0


H#$# H# $
I"#J!H

H
K
$L

B<(>>4)*(+,
9.4>4,*>
-
>F;;-./
+:
*<4
97-,,4'
>*-*(>*()-7
-,-7/>4>0
D
'4*-(74'
97-,
'4>).(8(,3
*<4
-,-7/>4>
*+
84
)+,'F)*4'
6(77
84
'4:(,4'
84:+.4
*<4
:(.>*
9-*(4,*
(>
4,.+774'0
D,/'45(-*(+,
:.+;
*<4
-,-7/>(>
>94)(:(4'
(,
*<4
9.+*+)+7
+.
*<4
>*-*(>*()-7
-,-7/>(>
97-,
6(77
84'4*-(74'
-,'
MF>*(:(4'
(,
*<4
)7(,()-7
>*F'/
.49+.*0

N


$LK
D77+)-*(+,
+:
9-*(4,*>
*+
*<4
-,-7/>(>
9+9F7-*(+,>
?-,'
6<4*<4.
-,/
9-*(4,*>
+.
>94)(:()
'-*-
:.+;-9-*(4,*
6(77
84
4O)7F'4'@
6(77
84
'4*4.;(,4'
-*
*<4
9.4P'-*-8->4
7+)A
;44*(,30
B<4:F77-,-7/>(>
>4*
6(77
)+,>(>*
+:
-77
.-,'+;(>4'
9-*(4,*>
6(*<
>F::()(4,*
'-*-
)+774)*4'
-:*4.
(,*-A4+:>*F'/
*.4-*;4,*
*+
)+;9F*4
*<4
9<-.;-)+'/,-;()
9-.-;4*4.>
+,
-*
74->*
*6+
>*F'/
5(>(*>0
B<4)+;974*4.
-,-7/>(>
>4*
6(77
)+,>(>*
+:
-77
.-,'+;(>4'
9-*(4,*>
6(*<
>F::()(4,*
'-*-
)+774)*4'-:*4.
(,*-A4
+:
>*F'/
*.4-*;4,*
*+
)+;9F*4
*<4
9<-.;-)+'/,-;()
9-.-;4*4.>
+,
-77
*<.44>*F'/
5(>(*>0
B<4>-:4*/
>4*
6(77
)+,>(>*
+:
-77
.-,'+;(>4'
9-*(4,*>
6(*<
>-:4*/
'-*-
)+774)*4'
-:*4.
(,*-A4
+:
>*F'/*.4-*;4,*
'F.(,3
-*
74->*
+,4
5(>(*0

B<49<-.;-)+A(,4*()
'-*-
>4*
6(77
)+,>(>*
+:
-77
.-,'+;(>4'
9-*(4,*>
6(*<
87++'
>-;97(,3
94.:+.;4'
-:*4.
-*
74->*
+,4
'+>4
+:
QRSTTU
-,'
6(*<
'-*-
>F::()(4,*
*+
)-7)F7-*4
9<-.;-)+A(,4*()
9-.-;4*4.>0
V
HNKL
"K
V
L
"K
QRSTTU9<-.;-)+A(,4*()
9-.-;4*4.>
?DW2X
2;-OX
*
;-OX
*
YZ[@0
V
HKL
"K
\
R4-A
-,'
DW2
^_`Y
+54.
UX
a
-,'
b
<+F.>
\
c4*4.;(,-*(+,
+:
+,>4*
+:
-)*(+,
\
c4*4.;(,-*(+,
+:
'F.-*(+,
+:
-)*(+,
\
=-:4*/
-,'
*+74.-8(7(*/d
e
2+,*(,F+F>
;+,(*+.(,3
+:
-'54.>4
454,*>
e
S-8+.-*+./
>-:4*/
*4>*>
C<-4;-*+7+3/X
8(+)<4;(>*./
-,'
F.(,-7/>(>E
e
Y[P74-'_2f?(,)7F'(,3gB)^-,'<4-.*.-*4@X>F9(,45(*-7>(3,>C87++'9.4>>F.4
-,'9F7>4.-*4E+54.b<+F.>














 !"# $
%&
''
")*
"+
,
./0/12
45
67518998:4;<
9/=68:4;2
67
2>?:?9
87=
2>?:?9
;@/414A<

B
C+

D7 A/7/;81E
?71/22
2:8:/=
4:@/;F62/E
G47:67?4?2
08;68H1/2
F611
H/
2?998;62/=
?267A
=/2G;6>:60/
2:8:62:6G2
I7?9H/;
45
>8:6/7:2E
8;6:@9/:6G
9/87E
2:87=8;=
=/068:647E
9/=687E
96769?9 87=
98J69?9
081?/2K
87=
54;
G8:/A4;6G81
I7496781K
08;68H1/2E
:@/
7?9H/;
87=
>/;G/7:8A/
45
>8:6/7:2
F611
H/
?2/=L


!
M@/7?9H/;
45
>8:6/7:2
/7;411/=E
;87=4962/=E
G49>1/:/=
4;
F6:@=;8F7
IF6:@
;/8247
54;
F6:@=;8F81K
F611
H/
2?998;62/=L


!N
O11>;4:4G41
=/068:6472
G411/G:/=
F611
H/
=606=/=
67:4
98P4;
4;
9674;
G8:/A4;6/2L
Q;64;
:4
=8:8H82/14GR
>;4:4G41
=/068:6472
F611
H/
;/06/F/=
87=
G472/S?/7G/2
54;
67G1?2647
45
>8:6/7:2
6708;64?28781<262
>4>?18:647
2/:2
=/:/;967/=
87=
=4G?9/7:/=L
'
!%
+

T

U/94A;8>@6G2
87=
H82/167/
G@8;8G:/;62:6G2
67G1?=67A
VWXY
ZH4:@
67
16:;/2
87=
67
>/;G/7:8A/
45
>;/=6G:/=74;981[E
VWXY
;/0/;26H616:<E
=62/82/
@62:4;<
87=
>;64;
87=
G47G496:87:
:@/;8>6/2
F611H/162:/=
87=
2?998;62/=
8>>;4>;68:/1<L

\:@/;9/=6G81
@62:4;<E
4:@/;
>;64;
87=
G47G496:87:
9/=6G8:6472E
06;81
2/;414A<
;/2?1:2
87=
>;/A787G<
:/2:
;/2?1:2
5;49
5/981/
>8:6/7:2
F611
H/
162:/=L

")
&
")]
+
#

O118=96762:;8:647
45
2:?=<
:;/8:9/7:
F611
H/
=47/
8:
:@/
G1676G
?7=/;
2?>/;062647
45
:@/
2:?=<
2:855^:@/;/54;/
74
54;981
8781<262
45
G49>1687G/
F611
H/
>/;54;9/=L
M@/
_Q.``a
/J>42?;/
F611H/G81G?18:/=
H82/=
47
;/26=?81
041?9/
67
:@/
7/H?162/;
G?>L

+*

V4;VWXY:@/
80/;8A/
/55/G:E
IW80KE
F611
H/
G81G?18:/=
82
:@/
Obc
=606=/=
H<
:@/
1/7A:@
45
:@/
:69/67:/;081
45
67:/;/2:L
D7
8==6:647
:@/
>/8R
/55/G:
47
VWXY
=?;67A
:@/2/
:69/
67:/;0812
F611
H/G49>?:/=
82
:@/
98J69?9
081?/
IW98JKL

c49>?:/=
>@8;98G4=<7896G
>8;89/:/;2
54;
VWXY
F611
H/
G49>8;/=
H/:F//7
>18G/H4
87=
:@/:F4=42/2
45
_Q.``a
?267A
8781<262
45
G408;687G/
IOdc\XOK
94=/12
F6:@
56J/=
58G:4;2
54;:;/8:9/7:E
>/;64=
87=
>8:6/7:E
87=
?267A
:@/
H82/167/
45
:@/
=8<

82
8
G408;68:/L
VWXY
F611
H/8781<2/=
?267A
9?1:6>16G8:60/
94=/12E
F@6G@
9/872
:@8:
=8:8
62
14AA/=
>;64;
:4
8781<262
87=:@/;/2?1:
:@/7
:;87254;9/=
H8GR
:4
:@/
167/8;
2G81/
A6067A
:;/8:9/7:
=655/;/7G/2
82
;8:642
45A/49/:;6G
9/872L

_/2?1:245:@/G49>8;62472F611H//J>;/22/=82:@/9/87A/49/:;6G;8:64F6:@e`f
G4756=/7G/67:/;081287=8224G68:/=Egh26=/=E>h081?/L














 !"# $
%&'
())+,-./+0121
/01/234
561
7.30
81234
/5.912707
6)/0:36/2;0
+,-./+0101<
=9;6)801
)011
/+63
>?52))@0
A.31270:07
1/6/21/2A6)),
12432B2A63/<
&
D
E)..716F-)234
B.:
-+6:F6A.G230/2A
611011F03/1
52))
@0
7.30
-:097.10
637
8-
/.
HI
+.8:1
-.1/97.10<
J:.F
/+0
-)61F6
A.3A03/:6/2.31
.B
K=L>>I
A.))0A/07M
/+0
B.)).5234
-+6:F6A.G230/2A
-6:6F0/0:1
52))
@0
A6)A8)6/07
81234
1/6376:7
3.39-6:6F0/:2A
F0/+.71<
N
(PQRST
21
/+0
6:06
8370:
/+0
-)61F6
A.3A03/:6/2.3
A8:;0
B:.F
/2F0
R
/.
23B232/,M
A.F-8/07
61
(PQRSUVQ/WXYM
5+0:0
Q/
703./01
/+0
)61/
-)61F6
A.3A03/:6/2.3
6@.;0
/+0
).50:
)2F2/
.B
Z863/2/6/2.3
[\]
XY
703./01
/+0
/0:F236)
0)2F236/2.3
:6/0<
(PQRSU
52))
@0
A.F-8/07
81234
/+0
)2306:
/:6-0Y.276)
F0/+.7
N
QF6_
703./01
/+0
+24+01/
-)61F6
A.3A03/:6/2.3
F0618:07
N
/
F6_703./01
/+0
/2F0
-.23/
A.::01-.37234
/.
QF6_
N
/
`aH703./01
/+0
01/2F6/07
+6)B9bcde
[\]
cf
ghijkUe]
[f
b\lmnWXY
=+6:F6A.G230/2A
-6:6F0/0:1
52))
@0
18FF6:2107
@,
7.10
)0;0)
81234
701A:2-/2;0
1/6/21/2A1
o38F@0:.B
-6/203/1M
40.F0/:2A
F063M
A.0BB2A203/
.B
;6:26/2.3M
F232F8FM
F6_2F8F
637
F07263B.:
(PQ
-6:6F0/0:1M
QF6_M
/
`aHp
637
38F@0:
.B
-6/203/1M
6:2/+F0/2A
F063M
1/6376:7
70;26/2.3MF232F8FM
F6_2F8F
637
F07263
B.:
/
F6_q<


r's

t6B0/,76/6
23A)87234
16B0/,
)6@.:6/.:,
/01/1M
`H9)067
uQv
-6:6F0/0:1M
;2/6)
12431
637
-+,12A6)0_6F236/2.31M
52))
@0
18FF6:2107
@,
/:06/F03/
4:.8-
637
/2F0
-.23/M
5+03
6--:.-:26/0<
J.:
A.3/238.81
;6:26@)01M
/+0
A+6340
B:.F
@610)230
o-:097.10
6/
06A+
/:06/F03/
;212/q/.06A+
-.1/97.10
/2F0
-.23/
52))
6)1.
@0
A6)A8)6/07
637
18FF6:2107<
w6/6
52))
B8:/+0:
@02))81/:6/07
@,
1+2B/
/6@)01
o1+.5234
A+63401
B:.F
).5a3.:F6)a+24+q
637
1+2B/
-)./1
B.:
10)0A/07/2F0
-.23/1<

Q.70767;0:10
0;03/
/0:F1
52))
@0
-:0103/07
@,
1,1/0F
.:463
A)611
otxQq
637
-:0B0::07
/0:F
63718FF6:2107
@,
/:06/F03/
4:.8-<
(
18FF6:,
/6@)0
@,
/:06/F03/
4:.8-
52/+
/./6)
38F@0:
63738F@0:
.B
-6/203/1
52/+
67;0:10
0;03/1M
t(u1M
67;0:10
0;03/1
)067234
/.
721A.3/2386/2.3
.B1/87,/:06/F03/M
A6816)),
:0)6/07
67;0:10
0;03/1
637
10;0:0
67;0:10
0;03/1
52))
@0
-:.78A07<J8:/+0:
t(u1M
A6816)),
:0)6/07
67;0:10
0;03/1
637
67;0:10
0;03/1
.B
06A+
23/0312/,
52))@018FF6:2107
@,
txQ
637
-:0B0::07
/0:F<


y
z{%
'
|{}

~%
!
=6/203/1 52/+7:653
6B/0:
.3),
.30
/:06/F03/
-0:2.7
52))
3./
@0
23A)8707
23
/+0
-+6:F6A.7,36F2A
636),101<
F-8/6/2.3
.B
76/6
B.:
A6)A8)6/2.3
.B
6;0:640
o(PQq
0BB0A/1
B.:
Ju`52))
@0
701A:2@07
23
/+0
1/6/21/2A6)
636),121
-)63<
.
./+0:
2F-8/6/2.3
.B
F211234
76/6
52))@0-0:B.:F07<
())6;62)6@)0
76/6
B:.F
6))
-6/203/1
5+.
+6;0
:0A02;07
1/87,
/:06/F03/
52))
@0
)21/07
637
18FF6:2107<
(3,
831A+078)07
.:
83-)63307
:0672341
52))
@0
-:0103/07
52/+23
/+0
-6/203/
)21/2341M@8/
.3),
/+0
1A+078)07
:0672341
52))
@0
8107
23
63,
18FF6:201<
B
6
;212/
21
:01A+078)07780/.;6:26@2)2/,23Ju`.:./+0::061.3M/+0:01A+078)07;212/52))@0)21/07637
18FF6:210761/+0;6)27;212/<














 !"# $
%&

 
$(
)*,*-./0
1234-1.
/2/05616
16
70/2248
,*-
394
63:85;

!
&
<
<=
>91616/6/.704
61?4
*,
@*2A42142@4;
)*
@/0@:0/31*2
*,
7*B4-
B/6
74-,*-.48;

"#C $
< !"$# <

DEF
>9463:85
B100
G4
74-,*-.48
12
/@@*-8/2@4
B139
394
HIJ
KIL
M:18401246N
394
7-12@17046
*:30124812
394
O4@0/-/31*2
*,
J40612P1
QRSSTUN
394
7-*3*@*0
/28
/7701@/G04
-4M:0/3*-5
-4V:1-4.4236;

"
F
%E(
$W
>94X7*26*-
B100
6:7705
/00
G/@PM-*:28
8/3/
24@466/-5
3*
42/G04
6:G.1661*2
3*
394
/77-*7-1/34
4391@6
@*..13344
/28
-4M:0/3*-5
/:39*-135;
>94
63:85
B100
2*3
@*..42@4
G4,*-4
,*-./04391@/0
/28
-4M:0/3*-5
/77-*A/06
9/A4
G442
M-/2348;
Y00@9/2M46
*-
-4A161*26
*,
3916
7-*3*@*0
B100
G4
8*@:.42348;
>94
-4/6*2
,*-
394
/.428.423
B100G463/348;
>94
X7*26*-
B100
426:-4
4391@/0
/28
-4M:0/3*-5
/77-*A/0
16
*G3/1248
,*-
/00
6:G63/231/0
/.428.4236
3*
394
*-1M12/0
/77-*A48
8*@:.4236;
Z
 &F


H316394-467*261G10135
*,
394
H2A4631M/3*-
3*
*G3/12
B-13342
12,*-.48
@*26423
,-*.
7/314236;
Y00@*26423
8*@:.423/31*2
.:63
G4
12
/@@*-8/2@4
B139
/7701@/G04
-4M:0/31*26
/28
KIL;
[/@9
7/3142316-4V:46348
3*
61M2
/28
8/34
394
12,*-.48
@*26423
,*-.
/,34-
Q6U94
9/6
-4@41A48
/28
-4/83947/31423
12,*-./31*2
69443
/28
-4@41A48
/2
4\70/2/31*2
*,
B9/3
394
63:85
12A*0A46N
12@0:812MG:3
2*3
01.1348
3*]
394
*G^4@31A46N
7*34231/0
G424,136
/28
-16PN
12@*2A42142@46
/28
3947/31423_6
-1M936
/28
-467*261G1013146;
L/314236
B100
G4
M1A42
/84V:/34
31.4
3*
4A/0:/34
394
12,*-./31*2
M1A42
3*
394.
G4,*-4
61M212M
394
12,*-.48
@*26423
,*-.;
`24*-1M12/0
*,
394
61M248
12,*-.48
@*26423
,*-.
.:63
-4./12
*2
,104
/28
.:63
G4
/A/10/G04
,*-A4-1,1@/31*2
G5
394
63:85
.*213*-
/3
/25
31.4;
Y
64@*28
*-1M12/0
*,
394
12,*-.48
@*26423
,*-.70:6394
7/31423
12,*-./31*2
69443
.:63
G4
M1A42
3*
394
7/31423
*-
394
7/31423_6
04M/005
/:39*-1648
-47-46423/31A4;


&F(
O/3/@*004@348
8:-12M
3916
63:85
./5
G4
:648
3*
6:77*-3
394
84A40*7.423N
-4M163-/31*2
*-
./-P4312M
*,
394
63:85
3-4/3.423;
>94
X7*26*-
B100
@*23-*0
/00
8/3/
@*004@348
8:-12M
394
63:85N
/28B100/G184
G5
394
[:-*74/2
a21*2
O1-4@31A4
*2
O/3/
L-1A/@5
@*2@4-212M
394
7-*@46612M
/28:64*,
7/31423_6
74-6*2/0
8/3/;
b*-
394
7:-7*64
*,
8/3/
7-1A/@5
04M160/31*2N
394
X7*26*-
B100G4394
8/3/
@*23-*004-;
Y,34-7/314236
9/A4
@*2642348
3*
3/P4
7/-3
12
394
63:85
3941-
.481@/0
-4@*-86
/28
394
8/3/
@*004@3488:-12M39463:85B100G4-4A14B48G5394X7*26*-/28c*-136-47-46423/31A46;>9464
-4@*-86/288/3/./5N12/88131*2NG4-4A14B48G5394,*00*B12M]12847428423/:813*-6B9*














 !"# $
%&'
()*+,)-.-0.
,)-)
12
3.0)*4
14
-0.
56127189
8.:;*)-18<
);-018+-+.7
)2,
-0.
.-0+=7
=1>>+--..
?0+=0:)(.
+-7
)6681()*
418
-0+7
7-;,<
-1
681=..,@
A*-01;:06)-+.2-7
?+**
3.
B21?2
3<
)
;2+C;.
2;>3.8D
-0.+8
+2+-+)*7
?+**
)*71
3.
=1**.=-.,
)2,
;7.,-1)77+7-
-0.
E2(.7-+:)-18
-1
8.=12=+*.
,)-)
=*)8+4+=)-+12
418>7D
418
.F)>6*.D
-0)-
-0.
8.7;*-7147-;,<
)77.77>.2-7
)8.
)77+:2.,
-1
-0.
=188.=-
6)-+.2-@
G0.
8.7;*-7
14
-0+7
7-;,<
=12-)+2+2:
-0.
;2+C;.
2;>3.8D
3;-
21-
-0.
6)-+.2-H7
+2+-+)*7
)2,
8.*.()2-
>.,+=)*
+2418>)-+12
>)<3.8.=18,.,
)2,
-8)274.88.,
-1
)2,
;7.,
+2
1-0.8
=1;2-8+.7
-081;:01;-
-0.
?18*,D
?0+=0
>)<21-)4418,
-0.
7)>.
*.(.*
14
681-.=-+12
-0)-
)66*+.7
?+-0+2
-0.
I;816.)2
J2+12@
G0.
6;8617.14
)2<
7;=0
-8)274.8
?1;*,
3.
-1
7;6618-
8.:;*)-18<
7;3>+77+127
>),.
3<
-0.
5612718+2
7;=0
=1;2-8+.7@

L
MN
G0.E2(.7-+:)-18
?+**
8.-)+2
-0.
18+:+2)*7
14
)**
71;8=.
,1=;>.2-7
:.2.8)-.,
)-
0+7
0176+-)*
;2+-144+=.
418
)
6.8+1,
14
O
<.)87
)4-.8
-0.
8.618-
14
-0.
7-;,<
0)7
3..2
4+2)*+7.,D
)4-.8
?0+=0
)**7-;,<P8.*)-.,
,1=;>.2-7
?+**
3.
)8=0+(.,
)==18,+2:
-1
QRS
8.:;*)-+127@

 $"
$!
 TU$"
V+2)2=+)*)88)2:.>.2-7
)8.
,.-)+*.,
+2
-0.
E2(.7-+:)-18
A:8..>.2-
3.-?..2
-0.
5612718
)2,
E2(.7-+:)-18@
G0.5612718
?+**
)88)2:.
=*+2+=)*
7-;,<
+27;8)2=.
-1
=1>6.27)-.
6)-+.2-7
418
)2<
61-.2-+)*
+2W;8<18,.)-0
=);7.,
3<
-0.
7-;,<@

X
UY $# 
 Z
G0.6;3*+=)-+12
61*+=<
+7
,.-)+*.,
+2
-0.
E2(.7-+:)-18
A:8..>.2-
3.-?..2
-0.
5612718
)2,
E2(.7-+:)-18@















 !"# $
%&

""""(
)**+,,-./0012
456
7/81
97:
;</=
7;>?@A
/0B
7;>A
C0DC*C,+2EF
0+G1=
,21/,H10,E
I+2
9J7;
/0B +,D12
C0I=/HH/,+2K
/C2L/K
BCE1/E1E:
./ECM
9=C0
7D/2H/M+=
N+OCM+=:
PQRA
S/KTRRAUVWF?XV-YX:
;+CF
RQ:RRRR@*MZ,:RPPQ[:
>Z<*
PQRA
S/2
X:
.\12H12]6
^,1L/2,
_6
)**+,,-./0012
46
`1LH/0
4:
a7]VVA6
/
IC2E,-C0-M=/EE
B</=
7;>?@A
C0DC*C,+2CE
1b<C1II1M,CG1
/E
/
*2+0MD+BC=/,+2
,+
H/OCH/=
B+E1E
+I
E/=*<,/H+=
C0
/E,DH/,CME
*<,LC,DI1L12
/BG12E1
1G10,E:
)H
_
a1EZC2
92C,
9/21
S1B
PQRX6
)YYYQ
9/=G12=1K7S6
^/0MD1c-N+2C=
d6
SMeG+2
)
1,
/=:
>II1M,
+I
R-K1/2
,21/,H10,
LC,D
2+I=<HC=/E,
C0
E1G121 MD2+0CM
+*E,2<M,CG1
Z<=H+0/2K
BCE1/E1:
)H
_
a1EZC2
92C,
9/21
S1B
PQQYT
RYXUPWFRVA-RXR:
9/=c1,,/]6
7/81
976
^ZC0/
;6
1,
/=
ND1
1II1M,
+I
,D1
HCO1B
ZD+EZD+BC1E,12/E1
?@A
C0DC*C,+2
a7]VVA+0
D<H/0
CE+=/,1B
*2+0MDC/=
EH++,D
H<EM=1
,+01:
_
7D/2H/M+=
>OZ
ND12
PQR?T
^1ZT?AXU?WFARA-AP?
9/=c1,,/]6
9/cc+=/
S6
7/81
97
1,
/=:
7D/2H/M+=+8CM/=
MD/2/M,12Cc/,C+0
+I
,D1
C0,12/M,C+0
*1,L110,D1
B</=
ZD+EZD+BC1E,12/E1
U7;>W
?@A
C0DC*C,+2
a7]VVA
/0B
8=KM+ZK22+0C<H
+0
D<H/0CE+=/,1B
*2+0MDC
/0B
EH/==
/C2L/KE:
7<=H
7D/2H/M+=
ND12
PQRV
)Z2
Rf:
ZCCF
^RQ[A-
VV?[URVWQQQAP-V:

91==C.a6S/M`11
g6
)N^@>a^
N/Eh
d+2M1:
^,/0B/2BE
I+2
,D1
BC/80+ECE
/0B
,21/,H10,
+I
Z/,C10,ELC,D
9J7;F
/
E<HH/2K
+I
,D1
)N^@>a^
Z+EC,C+0
Z/Z12:
><2
a1EZC2
_6
PQQAT
i+=
PF[?Pj[AX:
9+HZ,+0956
k<**
_6
`C1H/0
a
1,
/=:
9C=+HC=/E,6
/
E1=1M,CG1
ZD+EZD+BC1E,12/E1-A
C0DC*C,+2
I+2,21/,H10,
+I
Z/,C10,E
LC,D
MD2+0CM
+*E,2<M,CG1
Z<=H+0/2K
BCE1/E1F
/
2/0B+HCE1B6
B+E1-
2/08C08E,<BK:
]/0M1,
PQQRT
?VfU[PYfWFPXV-PYQ:
;+L01K;k6
S/2,C0
^]6
;1HZE,12
S6
1,
/=:
ND1
21=/,C+0EDCZ
+I
M=C0CM/=
/0B
C0I=/HH/,+2K
H/2h12E,+
+<,M+H1
C0
E,/*=1
Z/,C10,E
LC,D
MKE,CM
IC*2+ECE:
71BC/,2
7<=H+0+=:
PQQY
S/2TAPU?WFPRX-PPQ:
>l;C21M,CG1
[V@AX@>9F
ND1
;/,/
72+,1M,C+0
;C21M,CG1:
d2/0MC+EC]k6
;C/H/0,
m6
./0012
456
1,
/=:
>IICM/MK
/0B
E/I1,K
+I
a7]VVA6
/
B</=
7;>?
/0B
7;>AC0DC*C,+26
C0
D1/=,DK
G+=<0,112E
/0B
C0
Z/,C10,E
LC,D
/E,DH/
+2
MD2+0CM
+*E,2<M,CG1
Z<=H+0/2K
BCE1/E1F
IC0BC08E
I2+H
I+<2
M=C0CM/=
,2C/=E:
]/0M1,
a1EZC2/,+2K
S1BCMC01
PQR?T
RU[WFYRA-YPY:
k/H*=1>6
k2++,10B+2E,
;96
.2C8D,=C08
9>
1,
/=:
)0,C-C0I=/HH/,+2K
1II1M,E
+I
,D1
ZD+EZD+BC1E,12/E1-A
C0DC*C,+2
MC=+HC=/E,
U)2CI=+W
C0
MD2+0CM
+*E,2<M,CG1
Z<=H+0/2K
BCE1/E1:
)H_a1EZC2
92C,
9/21
S1B
PQQ?T
RXfUfWF[YX-[fP:
k2++,10B+2E,
;6
k/<L
^)6
i12D++E1=
aS6
1,
/=:
a1B<M,C+0
C0
EZ<,<H
01<,2+ZDC=
/0B
1+EC0+ZDC=
0<H*12E
*K
,D1
7;>A
C0DC*C,+2
2+I=<HC=/E,
C0
Z/,C10,E
LC,D
9J7;:
ND+2/O
PQQYT
XPURPWTRQfR-RQfY:
5/2*C0E+0
7]6
S/M]1+B
;6
5/LhEL+2,D
a
1,
/=:
ND1
1II1M,
+I
/
0+G1=
+2/==K
/M,CG1
E1=1M,CG1
7;>ACE+10cKH1
C0DC*C,+2
U9;7fAQW
+0
/==12810-C0B<M1B
21EZ+0E1E
C0
/E,DH/,CM
E<*\1M,E:
><2a1EZC2
_
R[[YT
RQUVWFRQQf-RQRA:
5+2E=1K)6a+<EE1/<46aCB=1K961,/=:a1/EE1EEH10,+I,D1CHZ+2,/0M1+IH<MC0EC0
B1,12HC0C08EZ<,<HZ2+Z12,C1EC0MKE,CMIC*2+ECE:_9KE,dC*2+E:PQRAS/KTR?U?WFPXQ-X:B+CF
RQ:RQRX@\:\MI:PQR?:RR:QQP:>Z<*PQR?;1MRP:














 !"# $
%&
'()*+(,)-.(,/
1.(2*+*(3*
.(
4,+5.(-6,)-.(
7.8-3
9:;
'14
4,+5.(-6*<
7+-8,+)-)*
=>-<*/-(*;
=..<1/-(-3,/
?+,3)-3*;
@*-+A ,(<
?,B*
1;
C?DEEFG
,
<>,/
8H.68H.<-*6)*+,6*
I?J9K
LMF
-(H-N-).+
,3)6
6O(*+B-6)-3,//O
P-)H
5>63,+-(-3
+*3*8).+
,(),B.(-6)6
,(<
N*),Q,<+*(.3*8).+
,B.(-6)6
).
8+.<>3*N+.(3H.<-/,).+
-(
R-R.;
S5
T
C*68-+
1+-)
1,+*
U*<
VWXY
Z[VF
SFZVW
U,3\**]G
C*((,+<
A'G
4>()
T^G
*)
,/;
9R,/>,)-.(
.2
*_H,/*<
N+*,)H
3.(<*(6,)*
84
,6
,
N-.5,+`*+
2.+
1a?J;

C*68-+,).+O
U*<-3-(*
Z[VVc
V[EYV[Ld*V[FE
U-//*+UCG
4,(`-(6.(
TG
e+>6,63.
fG
*)
,/;
A),(<,+<-6,)-.(
.2
68-+.5*)+O;
9>+
C*68-+
T
Z[[EcZ:IZKYLVXQLLW;
g>,(h*+?4G
A),(.h*R-3
AG
1./*
7T
*)
,/;
U>/)-Q*)H(-3
+*2*+*(3*
R,/>*6
2.+
68-+.5*)+O
2.+
)H*
LQXEO*,+,B*
+,(B*Y
)H*
B/.N,/
/>(B
2>(3)-.(
Z[VZ
*i>,)-.(6;
C*8.+)
.2
)H*
=/.N,/
D>(B
^>(3)-.('(-)-,)-R*
I=D'KG
9CA
7,6`
^.+3*
).
*6),N/-6H
-58+.R*<
D>(B
^>(3)-.(
C*2*+*(3*
f,/>*6;9>+
C*68-+
T
Z[VZ
J*3c
F[
I:KYVLZFQVLFL;
C,N*@^Ge,)*5,(
9JG
aj
J.((*//
JG
*)
,/;
C.2/>5-/,6)QQ,(
.+,/
,()-Q-(2/,55,).+O
)+*,)5*()
2.+3H+.(-3
.N6)+>3)-R*
8>/5.(,+O
<-6*,6*Y
,
+,(<.5-6*<
3.()+.//*<
)+-,/;
D,(3*)
Z[[Ec
L::IXFWEKYE:LQEdV;
C*((,+<A'G
A3H,3H)*+
\G
A)+*`
UG
*)
,/;
1-/.5-/,6)
2.+
1a?JY
+*6>/)6
.2
,
:Q5.()H
8/,3*N.
3.()+.//*<
6)><O
.2
,
8.)*()G
6*/*3)-R*
-(H-N-).+
.2
8H.68H.<-*6)*+,6*
F;
1H*6)
Z[[:c
VZXIVKYE:
::;
A-(BHGJG
SNN.))Qe,((*+
@G
\*P5,(
@;
S
?H,6*
'G
+,(<.5-6*<G
<.>N/*
N/-(<G
8/,3*N.
3.()+.//*<G
6)><O
).
,66*66
)H*
6,2*)OG
)./*+,N-/-)O
,(<
8H,+5,3.`-(*)-36
.2
6-(B/*
-(H,/*<
<.6*6.2)H*
<>,/
8H.68H.<-*6)*+,6*
LMF
I?J9LMFK
-(H-N-).+
C?DEEF
,<5-(-6)*+*<
NO
(*N>/-6*+).
H*,/)HO
5,/*
6>Nh*3)6;
S5
T
C*68-+
1+-)
1,+*
U*<
Z[V:G
S:WLX
A-(BHGJG
SNN.))Qe,((*+
@G
\*P5,(
@;
S
?H,6*
'G
+,(<.5-6*<G
<.>N/*
N/-(<G
8/,3*N.
3.()+.//*<G
6)><O
).
,66*66
)H*
6,2*)OG
)./*+,N-/-)O
,(<
8H,+5,3.`-(*)-36
.2
5>/)-8/*
-(H,/*<
<.6*6.2C?DEEF
,<5-(-6)*+*<
NO
(*N>/-6*+
).
H*,/)HO
5,/*
6>Nh*3)6
,(<
6),N/*
1a?J
8,)-*()6;S5
T
C*68-+
1+-)
1,+*
U*<
Z[V:G
S:WLW
7>+(*+UTG
U,))H*6
9G
e-//*)
SG
*)
,/;
7H*
<>,/
8H.68H.<-*6)*+,6*
L
,(<
F
-(H-N-).+
C?DEEF
6)-5>/,)*6
1^7C
,(<
3-/-,+O
N*,)-(B
-(
8+-5,+O
3>/)>+*6
.2
N+.(3H-,/
*8-)H*/-,;
S5
T
?HO6-./
D>(B1*//
U./
?HO6-./;
Z[V:
T,(
VcLV[IVKYDEXQd[;
<.-Y
V[;VVEZM,h8/>(B;[[LZF;Z[VE;
98>N
Z[VE\.R:;
k`*(,JGC*()l
@G
C*-N*+
1G
*)
,/;
922*3)6
.2
)H*
5-_*<
8H.8H.<-*6)*+,6*
'''M'f
-(H-N-).+G
l,+<,R*+-(*G
.(
,-+P,O
2>(3)-.(
-(
8,)-*()6
P-)H
3H+.(-3
,-+2/.P
.N6)+>3)-.(;
C*68-+
U*<
VXXEcWXI:KY
FFVQFFF;
R,( A3H,/`PO`
9G
A)+O<.5
@G
]-//-,56
m
*)
,/;
C.2/>5-/,6)G
,(
.+,/G
.(3*Q<,-/O
8H.68H.<-*6)*+,6*
F
-(H-N-).+G
,))*(>,)*6
,//*+B*(Q-(<>3*<
,6)H5,)-3
+*,3)-.(6;
T
S//*+BO
1/-(
'55>(./Z[[Ec
VV:
IZKYZXZ
ZXW;

f*+.(,?H,+5,
8/3
;
C?DEEF
'(R*6)-B,).+
e+.3H>+*
I3>++*()
R*+6-.(K;

f*+.(,?H,+5,
8/3
;
C?DEEF
'(R*6)-B,)-.(,/
U*<-3-(,/
?+.<>3)
J.66-*+
I3>++*()
R*+6-.(K;
].+/<U*<-3,/
S66.3-,)-.(G
J*3/,+,)-.(
.2
4*/6-(`-;
9)H-3,/
?+-(3-8/*6
2.+
U*<-3,/
C*6*,+3H
'(R./R-(B4>5,(
A>Nh*3)6;
D,6)
,5*(<*<
NO
)H*
FW)H
].+/<
U*<-3,/
S66.3-,)-.(
=*(*+,/
S66*5N/OGA.5*+6*)]*6)GVXX:;














 !"# $
%&

$"! "(
$)*

$
+)
&

,-./0-134
567089-/:7;<
=3>-;>7/0
.?1>
6/@-
9--;
?17;<
/
53;171>-;>
/;8
:-07/90-
43:.
34
53;>:/5-=>73;
/553:87;<
>3
>6-
43003A7;<
071>
4:3.
>6-
0/1>
.-;1-1
9-43:-
>6-
47:1>
1>?8B
>:-/>.-;>/8.7;71>:/>73;C
/;8
.?1>
53..7>
>3
53;>7;?-
>3
83
13
8?:7;<
>6-
1>?8B
/;8
43:
D.3;>61/4>-:
>6-
0/1>
831-
34
1>?8B
>:-/>.-;>E
F
H/0-
=/:>;-:
A63
71
1>-:70-
/;8
71
>6-
130-
1-I?/0
=/:>;-:
43:
>6/>
4-./0-
1?9J-5>
F
K91>7;-;5-
4:3.
1-I?/0
7;>-:53?:1-L
F
M.=0/;>1
34
0-@3;3:<-1>:-0
3:
->3;3<-1>:-0
F
M;J-5>/90-
=:3<-1>3<-;
F
N:/0
53;>:/5-=>7@-
F
N-1>:3<-;75
@/<7;/0
:7;<
F
O-:5?>/;-3?1
53;>:/5-=>7@-
=/>56-1
F
K;B
7;>:/?>-:7;-
8-@75-

A7>6
/
835?.-;>-8
4/70?:-
:/>-
34
0-11
>6/;
PQ
=-:
B-/:
F
H/0-
53;83.
53.97;-8
A7>6
/
@/<7;/0
1=-:.7578-
F
H/0-
53;83.
53.97;-8
A7>6
/
4-./0-
87/=6:/<.L

SAP_000.pdf: 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 2 of 22 
Version: Final 2.0 
 
 
Contents 
 
ABBREVIATIONS ................................................................................................................................... 3 
1 
INTRODUCTION ............................................................................................................................. 5 
2 
STUDY OBJECTIVES ..................................................................................................................... 5 
2.1 
Primary Objective........................................................................................................................ 5 
2.2 
Secondary Objectives ................................................................................................................. 5 
2.3 
Exploratory Objectives ................................................................................................................ 5 
3 
OVERALL STUDY DESIGN ............................................................................................................ 5 
3.1 
Overview of Study Design .......................................................................................................... 5 
3.2 
Withdrawals ................................................................................................................................ 6 
3.3 
Replacements ............................................................................................................................. 7 
4 
STUDY MEASUREMENTS AND VARIABLES ............................................................................... 7 
4.1 
Endpoints .................................................................................................................................... 7 
4.1.1 
Primary Endpoint ..................................................................................................................... 7 
4.1.2 
Secondary Endpoints ............................................................................................................... 7 
4.1.3 
Exploratory Endpoints .............................................................................................................. 7 
4.2 
Screening and Demographic Measurements ............................................................................. 7 
4.3 
Pharmacokinetic Measurements and Variables ......................................................................... 8 
4.4 
Pharmacodynamic Measurements and Variables ...................................................................... 8 
4.4.1 
Spirometry ............................................................................................................................... 8 
4.4.2 
Sputum Inflammatory Mediators .............................................................................................. 8 
4.4.3 
Exhaled Breath pH ................................................................................................................... 9 
4.5 
Safety Measurements and Variables .......................................................................................... 9 
4.5.1 
Adverse Events ........................................................................................................................ 9 
4.5.2 
Laboratory Safety Measurements and Variables .................................................................. 10 
4.5.3 
Vital Signs .............................................................................................................................. 11 
4.5.4 
Physical Examination ............................................................................................................. 11 
4.5.5 
12-Lead ECG ......................................................................................................................... 11 
5 
DATA MANAGEMENT .................................................................................................................. 11 
6 
STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE ...................................... 11 
6.1 
Statistical Evaluation ................................................................................................................. 11 
6.2 
Description of Analysis Sets ..................................................................................................... 11 
6.3 
Summary Statistics ................................................................................................................... 12 
6.4 
Methods of Statistical Analysis ................................................................................................. 12 
6.4.1 
Disposition ............................................................................................................................. 12 
6.4.2 
Demographic and Other Baseline Characteristics ................................................................ 12 
6.4.3 
Extent of Exposure and Treatment Compliance .................................................................... 12 
6.4.4 
Protocol Deviations ................................................................................................................ 13 
6.4.5 
Pharmacokinetic Analysis ...................................................................................................... 13 
6.4.6 
Pharmacodynamic Analysis................................................................................................... 13 
6.4.7 
Safety Analysis ...................................................................................................................... 14 
6.5 
Determination of Sample Size .................................................................................................. 16 
6.6 
Statistical Issues ....................................................................................................................... 16 
6.7 
Interim Analyses ....................................................................................................................... 16 
6.8 
Changes in the Conduct of the Study or Planned Analyses ..................................................... 16 
7 
REFERENCES .............................................................................................................................. 16 
8 
DATA PRESENTATION PLAN ..................................................................................................... 17 
8.1 
Tables for Section 14.1-3 .......................................................................................................... 17 
8.2 
Graphs for Section 14.2-3 ......................................................................................................... 18 
8.3 
Listings for Section 16.2 ........................................................................................................... 19 
APPENDICES ....................................................................................................................................... 20 
Appendix 1 Inclusion and Exclusion Criteria ......................................................................................... 20 
Appendix 2 Allowed and Disallowed Concomitant Medication ............................................................. 22 
 
 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 3 of 22 
Version: Final 2.0 
 
ABBREVIATIONS 
Abbreviation Term 
AE 
Adverse Event 
ANCOVA 
ATC 
Analysis of Covariance 
Anatomic Therapeutic Chemical 
ATS 
AUC 
American Thoracic Society 
Area Under the Curve 
BMI 
CAS 
Body Mass Index 
Completer Analysis Set 
CF 
Cystic Fibrosis 
CRF 
Case Report Form 
CS 
CV 
Clinically Significant 
Coefficient of Variation 
EBC 
Exhaled Breath Content 
ECG 
EDTA 
Electrocardiogram 
Ethylenediaminetetraacetic Acid 
eCRF 
Electronic Case Report Form 
FAS 
Full Analysis Set 
FEV1 
Forced Expiratory Volume in 1 Second 
FSH 
Follicle Stimulating Hormone 
FVC 
Forced Vital Capacity 
HIV 
Human Immunodeficiency Virus 
ICH 
International Conference on Harmonisation (of Technical 
Requirements for Registration of Pharmaceuticals for Human Use) 
ICS 
Inhaled Corticosteroid 
IL-8 
Interleukin 8 
LABA 
Long-Acting β2-Agonist 
LAMA 
Long-Acting Muscarinic Antagonist 
MedDRA 
MPO 
Medical Dictionary for Regulatory Activities 
Myeloperoxidase 
NCS 
PKS 
Not Clinically Significant 
PharmacoKinetic data Set 
PT 
Preferred Term 
QTcF 
SAE 
Heart-rate corrected QT interval (Fridericia’s method) 
Serious Adverse Event 
SAP 
SAS 
Statistical Analysis Plan 
Statistical Analysis Software 
SD 
Standard Deviation 
SOC 
System Organ Class 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 4 of 22 
Version: Final 2.0 
 
SOP 
SUSAR 
Standard Operating Procedure 
Suspected Unexpected Serious Adverse Reaction 
TEAE 
Treatment-Emergent Adverse Event 
TFL 
Tables, Figures and Listings 
TNF-α 
Tumour Necrosis Factor Alpha 
 
 
 
 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 5 of 22 
Version: Final 2.0 
 
1 INTRODUCTION 
This is the Statistical Analysis Plan (SAP) for study RPL554-010-2015.  It is based 
on the Clinical Study Protocol version 4.0 dated 23 August 2017.  
2 STUDY OBJECTIVES 
2.1 Primary Objective 
To investigate pharmacokinetics of single nebulised doses of RPL554 in patients 
with cystic fibrosis (CF). 
2.2 Secondary Objectives 
Secondary objectives are: 
 
• To investigate the bronchodilator effect on peak Forced Expiratory Volume in one 
second (FEV1) after single nebulised doses of RPL554 as compared to placebo 
 
• To investigate the bronchodilator effect on AUC FEV1 over 4, 6 and 8 hours of 
single nebulised doses of RPL554, as compared to placebo 
 
• To assess the tolerability and safety of single nebulised doses of RPL554  in 
patients with CF. 
2.3 Exploratory Objectives 
To examine the anti-inflammatory effects of RPL554 after a single dose in patients 
with CF. 
3 OVERALL STUDY DESIGN 
3.1 Overview of Study Design 
This is a Phase IIa, randomised, double blind, placebo controlled, complete block 
three way crossover study to investigate the pharmacokinetics of nebulised RPL554 
(1.5 mg and 6 mg) in adult patients with CF. It is planned to enrol sufficient patients 
to assure that 10 patients complete all three treatment periods at one centre in the 
UK. The study comprises five visits: screening (Visit 1), three treatment visits (Visit 2 
to Visit 4) and an end of study visit (Visit 5). Patients will be screened for eligibility 
(Visit 1), including a reversibility test with salbutamol, between 3 and 14 days prior to 
the first dose of study treatment. 
Eligible patients will then attend for three separate 1 day treatment visits (Visits 2 to 
Visit 4) each separated by a at least a 3-day washout period. Patients will be 
randomised pre-dose at Visit 2. Patients will receive a single nebulised dose of 1.5 
mg RPL554 or 6 mg RPL554 or placebo at each visit.  The pre-dose FEV1 at Visit 3 
and Visit 4 must be within ±20% of the pre-dose FEV1 at Visit 2 in order to ensure 
consistent baseline FEV1 for each study treatment. At each visit, patients will be 
resident at the study centre from the morning until at least 8 hours after dosing. 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 6 of 22 
Version: Final 2.0 
 
Patients will be discharged after 8 hours, but return the following morning for final 
assessments 24 hours after dosing. 
The following will be performed at each treatment visit: 
• Measurements of lung function (FEV1 and forced vital capacity [FVC]) pre-dose 
and up to 24 hours post-dose 
• Blood sampling pre-dose and up to 24 hours post-dose for pharmacokinetic 
analysis 
• Sputum sampling pre-dose and at 8 and 24 hours post-dose for rheology and 
measurement of  inflammatory mediators (interleukin 8 [IL-8], tumour necrosis 
factor alpha [TNF-α], myeloperoxidase [MPO]) 
• Exhaled breath pH measurement pre-dose and at 8 and 24 hours post-dose  
• Urine pregnancy test pre-dose (female patients only) 
• Vital signs and 12-lead electrocardiogram (ECG)s pre-dose and up to 8 hours 
post-dose 
An end of study visit (Visit 5) will be performed 3 to 10 days after the last dose of 
study treatment. Adverse events will be recorded throughout the study and 
laboratory safety tests, a physical examination and urine pregnancy tests (female 
patients only) will be performed at screening (Visit 1) and at the end of study visit 
(Visit 5). 
Inclusion/exclusion criteria are given in Appendix 1. Allowed/disallowed medications 
are given in Appendix 2.  
3.2 Withdrawals 
Investigators have the authority to ask for the withdrawal of a patient at any time for 
medical or non-compliance reasons. Should the Investigator decide it is necessary to 
withdraw any patient for specific reasons, this should be recorded in writing and 
discussed with the patient in question. Such reasons for withdrawal are expected to 
be medical or related to lack of co-operation by the patient. 
If a patient withdraws following randomisation, every attempt should be made to 
contact the patient to determine the reason for withdrawal and to complete the 
recording of any available pharmacodynamic data and all adverse event data. If a 
patient agreed to enter the study and signed a consent form but withdrew from the 
study, or was withdrawn from the study, without receiving any study treatment, no 
further follow-up is necessary. 
End of study visits will occur 3 to 10 days after the last dose of study treatment. All 
withdrawn patients will follow this routine unless it is considered by the Investigator 
that they require greater medical supervision and/or investigations and in which case 
an unscheduled visit prior to and in addition to the scheduled follow up visit may be 
performed. 
If a patient decides to withdraw voluntarily, or is withdrawn by the Investigator 
responsible at any time, the reasons for withdrawal and results of all relevant tests 
will be recorded in the case report form (CRF). Patients who withdraw may be 
replaced. 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 7 of 22 
Version: Final 2.0 
 
3.3 Replacements 
A total of 10 patients must complete all three treatment visits (Visit 2 to Visit 4) up to 
the 24 hour assessments in the study. Any patients who do not complete will be 
replaced. This should be discussed with the Sponsor on a case by case basis. 
Replacement patients will be allocated the next randomisation number in the 
randomisation list. 
4 STUDY MEASUREMENTS AND VARIABLES 
4.1 Endpoints 
4.1.1 
Primary Endpoint 
Plasma RPL554 pharmacokinetic parameters (AUC0−24, Cmax, tmax). 
4.1.2 
Secondary Endpoints 
Secondary endpoints are: 
• Peak and AUC FEV1 over 4, 6 and 8 hours 
• Determination of onset of action 
• Determination of duration of action 
• Safety and tolerability 
o Continuous monitoring of adverse events 
o Laboratory safety tests (haematology, biochemistry and urinalysis) 
o 12-lead ECG (including QTcF and heart rate), supine vital signs (blood 
pressure and pulse) over 8 hours 
4.1.3 
 Exploratory Endpoints 
Levels of inflammatory mediators in sputum and sputum rheology.  
4.2 Screening and Demographic Measurements 
Written informed consent will be obtained by the Investigator prior to any study 
related procedures being performed.  
Demographic variables, including date of birth, sex (plus details confirming 
non-childbearing status for females), height, weight, BMI (weight [kg]/height [m]2), 
race, ethnic origin and smoking status will be collected at screening (Visit 1). The 
date of diagnosis of CF and the specific CF mutations will also be recorded. 
Active medical conditions and all surgeries will be recorded at screening (Visit 1), 
including disease history which includes date of diagnosis.  
A reversibility test in response to salbutamol will be performed at screening (Visit 1). 
Spirometry (FEV1 and FVC) will be performed before and after (at 30 minutes and 1 
hour) two puffs of salbutamol administered using a pressurised metered dose 
inhaler. The pre-bronchodilator FEV1 must be ≥40% and ≤80% of predicted normal 
for inclusion. The reversibility response is not an eligibility measure. 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 8 of 22 
Version: Final 2.0 
 
At all three time points, three technically acceptable measurements should be made 
and recorded in the CRF. Spirometry assessments may be repeated up to eight 
times to obtain three acceptable readings according to American Thoracic Society 
[ATS] guidelines (Miller, 2005). The highest reading from each assessment will be 
used for calculation of predicted values and increase from baseline. European 
Community of Coal and Steel reference equations (Quanjer, 1993) will be used as a 
reference for predicted normal values.  
Laboratory safety assessments will be performed to check eligibility.  Unscheduled 
and/or repeat testing may be performed at the discretion of the Investigator. 
Prior respiratory therapies and medications will be recorded at screening (Visit 1) as 
well as concomitant use during the study. Other medications used prior or as 
concomitant use during the study will be recorded separately.  
Patients will be confirmed as eligible according to the inclusion and exclusion criteria 
from assessments made at screening (Visit 1) with a final check of all results 
pre-dose at Visit 2.  
4.3 Pharmacokinetic Measurements and Variables 
Pharmacokinetic analysis will be performed on samples taken from all patients. 
Blood samples (4 mL) will be collected at the following time points at Visit 2 to Visit 4: 
pre-dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post-dose. Samples will 
be collected by venepuncture or via indwelling cannula in the forearm into lithium 
heparin tubes and will be immediately chilled (ice bath). The blood will be centrifuged 
within 15 minutes of collection. The plasma will be separated in a refrigerated 
centrifuge (about 4°C) at 1100 g for 15 minutes and transferred into polypropylene 
tubes. After each blood collection, the plasma will be dispensed into two aliquots. 
After appropriate labelling, the plasma samples will be stored at, or below -20°C. The 
plasma samples will then be transported in dry ice to the central laboratory where 
they will be stored at or below -20°C until they are analysed using a validated 
method. 
4.4 Pharmacodynamic Measurements and Variables 
4.4.1 
Spirometry 
Spirometry assessments (FEV1 and FVC) will be made at the following time points at 
Visit 2 to Visit 4: pre-dose (at -15 minutes) and 5, 15 and 30 minutes and 1, 2, 4, 6, 8 
and 24 hours post-dose in accordance with ATS guidelines (Miller, 2005). At all time 
points, three technically acceptable measurements should be made and recorded in 
the CRF. Spirometry assessments may be repeated up to eight times to obtain three 
acceptable readings. The highest FEV1 and FVC readings from each assessment 
will be used for analysis even if the FEV1 and FVC values come from two different 
forced exhalations. 
4.4.2 
Sputum Inflammatory Mediators 
Sputum samples will be taken pre-dose and at 8 and 24 hours post-dose at Visit 2 to 
Visit 4 by spontaneous expectoration over no more than 5 minutes and transported 
on ice for rapid processing (collection to storage within 30 minutes). Whole sputum 
will be immediately frozen at -20°C and then transferred to −80°C for storage prior to 
analysis (Horsley et al, 2014). 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 9 of 22 
Version: Final 2.0 
 
Rheological analysis will be performed before and after incubation at 37°C for 
60 minutes (Horsley et al, 2014). Inflammatory mediators (IL-8, TNF-α and MPO) will 
be measured according to the published methodology (Downey et al, 2007).  
4.4.3 
Exhaled Breath pH 
Exhaled breath pH will be measured pre-dose and at 8 and 24 hours post dose at 
Visit 2 to Visit 4. Exhaled breath pH measurement will be performed in accordance 
with the method described by MacNee et al, 2011. In brief, exhaled breath 
condensate (EBC) samples will be collected during tidal breathing for 10 minutes, 
without nose clips, using the RTubeTM (Respiratory Research Inc., Charlottesville, 
Virginia). A 200 µL aliquot of EBC will be used for the pH assay. Measurement of pH 
will be performed after deaeration by bubbling argon through the sample at 2 L/min 
while monitoring pH until the reading stabilised, usually after 8 minutes of deaeration 
with argon.  
4.5 Safety Measurements and Variables 
4.5.1 
Adverse Events 
Adverse event is defined as any undesirable experience occurring to a patient, or 
worsening in a patient, during a clinical study, whether or not considered related to 
the study treatment. An adverse event may be any of the following: 
• A new illness 
• An exacerbation of a sign or symptom of the underlying condition under treatment 
or of a concomitant illness 
• Unrelated to participation in the clinical study or an effect of the study drug 
• A combination of one or more of the above factors 
No causal relationship with the study treatment is implied by the use of the term 
“adverse event.” An exacerbation of a pre-existing condition or illness is defined as a 
more frequent occurrence or as an increase in the severity of the pre-existing 
condition or illness during the study. Planned or elective surgical or invasive 
procedures for pre-existing conditions that have not worsened are not adverse 
events. However, any complication that occurs during a planned or elective surgery 
is an adverse event (if the event fits the serious criteria, such as an extended 
hospitalisation, it will be considered to be serious). Conditions leading to unplanned 
surgical procedures may be adverse events. 
Adverse reaction is defined as all untoward and unintended responses to study 
treatment related to any dose administered. 
Serious adverse event (SAE) is any adverse experience that: 
• Results in death 
• Is life-threatening 
• Requires inpatient hospitalisation or prolongation of existing hospitalisation 
• Results in persistent or significant disability/incapacity, OR 
• Is a congenital anomaly/birth defect 
• Other medical events* 
*Important medical events that may not be immediately life-threatening or result in 
death or hospitalisation may be considered a SAE when, based on appropriate 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 10 of 22 
Version: Final 2.0 
 
medical judgement, they may jeopardise the patient or may require medical or 
surgical intervention to prevent one of the outcomes listed above. 
An unexpected adverse reaction is an adverse reaction in which the nature or 
severity of which is not consistent with the Investigator Brochure. 
Suspected unexpected serious adverse reactions (SUSAR) is any suspected 
adverse reaction related to the study drug that is both unexpected and serious. 
All adverse events, whether reported spontaneously by the patient, in response to 
open questioning on treatment days or observed by the investigator or his/her staff, 
will be recorded from informed consent until the end of study visit (Visit 5). The start 
and stop time will be recorded and adverse events will be assessed by the 
investigator for the following: 
• severity (mild, moderate, severe) 
• chronicity (single occasion, intermittent, persistent) 
• causality (not related, unlikely, possibly, definitely) 
• action taken with study treatment (none, study treatment stopped, study 
treatment temporarily interrupted) 
• other 
actions 
(none, 
concomitant 
medication, 
study 
discontinuation, 
hospitalisation, other) 
• outcome and date of outcome (recovered or resolved, recovering or resolving, 
not recovered or not resolved, recovered or resolved with sequelae, fatal, 
unknown) 
• seriousness (yes, no) 
4.5.2 
Laboratory Safety Measurements and Variables 
All female patients will have a urine pregnancy test at screening (Visit 1), pre-dose at 
Visit 2 to Visit 4 and at the end of study visit (Visit 5) according to the study centre’s 
standard operating procedures (SOPs). 
All other laboratory safety assessments will be performed at the study centre’s local 
laboratory. Two samples will be collected at each time point, one sample for 
haematology using a ethylenediaminetetraacetic acid (EDTA) whole blood collection 
tube and one sample for biochemistry using a serum tube. A midstream urine 
sample will also collected in a sterile container. Samples will be taken at screening 
(Visit 1) and end of study visit (Visit 5) and analysed for: 
Haematology: haemoglobin, haematocrit, total white cell count, leukocyte differential 
count and platelet count 
Biochemistry: 
creatinine, 
total 
bilirubin, 
alkaline 
phosphatase, 
aspartate 
aminotransferase, 
alanine 
transaminase, 
gamma-GT, 
lactate 
dehydrogenase, 
creatine 
kinase, 
thyroid 
stimulating 
hormone, 
triiodothyronine and thyroxine, glucose, potassium, sodium and calcium 
Urinalysis:  leukocytes, blood, ketones, bilirubin, urobilinogen, protein and glucose 
using a dipstick. In the event of an abnormal dipstick urinalysis result, 
microscopic urinalysis may be conducted. The referral criteria will be 
specified in the laboratory manual 
In addition, unscheduled and/or repeat testing may be performed at the discretion of 
the Investigator. Laboratory results will be provided to the Investigator for each 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 11 of 22 
Version: Final 2.0 
 
patient and each visit. The Investigator should assign whether each abnormal result 
is not clinically significant or clinically significant. 
4.5.3 
Vital Signs 
Blood pressure and pulse rate will be measured at screening (Visit 1) and pre-dose, 
30 minutes and 1, 2, 4, 6 and 8 hours post-dose at Visit 2 to Visit 4  
At each time point, supine vital signs will be assessed while the patient has been at 
rest for at least 5 minutes. 
4.5.4 
Physical Examination 
A full physical examination, covering major body systems (assessments of the nose, 
throat, skin, thyroid gland, neurological system, respiratory system, cardiovascular 
system, abdomen [liver and spleen], lymph nodes and extremities) will be performed 
at screening (Visit 1). Results will be recorded in the CRF as normal, abnormal not 
clinically significant or abnormal clinically significant. The physical examination will 
be repeated at the end of study visit (Visit 5), and any changes only recorded. 
4.5.5 
12-Lead ECG 
12-lead ECGs will be taken at screening (Visit 1) and pre-dose and 1, 2, 4 and 8 
hours post-dose at Visit 2 to Visit 4.  
At each time point, 12-lead ECGs should be taken after at least 5 minutes in the 
supine position. An ECG printout must be taken at each time point and signed and 
dated by the Investigator. An overall assessment (normal, abnormal not clinically 
significant or abnormal clinically significant) and continuous variables, including QT 
interval, QTcF and heart rate, will be recorded in the CRF. 
5 DATA MANAGEMENT 
Data management will be performed by Syne-qua-non. Data handling will be 
described in a Data Management Plan and a Data Validation Plan. 
6 STATISTICAL METHODS AND DETERMINATION OF SAMPLE 
SIZE 
6.1 Statistical Evaluation 
The statistical analysis will be conducted by StatMind AB using SAS version 9.3 or 
higher. Validation will be performed using Gauss 6.25. 
The statistical analyses and reporting of results (tables, figures and listings [TFL]) for 
this study follows the International Conference on Harmonisation (ICH) guidelines. 
6.2 Description of Analysis Sets 
Allocation of patients to the analysis populations (and whether any patients or 
specific data from a patient will be excluded) will be determined at the pre-database 
lock meeting. 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 12 of 22 
Version: Final 2.0 
 
The full analysis set [FAS] will consist of all randomised patients with sufficient data 
collected after intake of study treatment to compute the pharmacodynamic 
parameters on at least two study visits. 
The completer analysis set [CAS] will consist of all randomised patients with 
sufficient data collected after intake of study treatment to compute the 
pharmacodynamic parameters on all three study visits. 
The safety set will consist of all randomised patients with safety data collected after 
intake of study treatment during at least one visit.  
The pharmacokinetic data set [PKS] will consist of all randomised patients with blood 
sampling performed after at least one dose of RPL554 and with data sufficient to 
calculate pharmacokinetic parameters. 
6.3 Summary Statistics 
Continuous variables will be summarised using descriptive statistics (number of 
patients [N], arithmetic mean, standard deviation [SD], median, minimum and 
maximum values) and for categorical (nominal) variables, the number and 
percentage of patients will be used. For continuous variables with an expected skew 
distribution (plasma RPL554 concentrations, some pharmacokinetic parameters 
[AUC0−24, Cmax], inflammatory cell mediators [IL-8, TNF-α, MPO]), geometric mean 
and coefficient of variation (CV) will be given instead of arithmetic mean and SD.  
6.4 Methods of Statistical Analysis 
6.4.1 
Disposition 
A summary of the patient flow (number and percentage) will be made of all patients 
enrolled in the study, randomized in the study, belonging to each of the analysis 
sets, completed the study or prematurely discontinued the investigational product. 
The primary reason for withdrawal from the study will be summarized into the 
following categories: consent withdrawn, adverse event, protocol violation, 
investigator’s decision, sponsor decision or other reason. Patient disposition data 
including individual reasons for withdrawal will be listed. 
6.4.2 
Demographic and Other Baseline Characteristics 
Demographics and baseline characteristics including age, sex, race, ethnic origin, 
height, weight, BMI, smoking status, pack years, time since CF diagnosis, CF 
mutations, FEV1 [both in litres and in percentage of predicted normal], FVC and 
FEV1 reversibility will be listed and summarised by descriptive statistics. 
Prior and concomitant CF therapies will be listed and summarised by ATC class for 
all enrolled patients (long-acting and short-acting LABAs and LAMAs will be 
separated).  
Other medical history and other prior and concomitant medications will be listed. 
Medical history events will be coded using the MedDRA Dictionary in addition to the 
verbatim. 
6.4.3 
Extent of Exposure and Treatment Compliance 
All administration of study treatment will be done at the clinic under supervision of 
the study staff; therefore no formal analysis of compliance will be performed. The 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 13 of 22 
Version: Final 2.0 
 
RPL554 exposure will be calculated based on residual volume in the nebuliser cup 
and summarised by treatment group. The exposure would equal (nominal volume – 
residual volume) times the drug concentration. 
6.4.4 
Protocol Deviations 
Protocol deviations will be categorized as eligibility deviation, sample handling error, 
missed assessment, late or early assessment, outside visit window or other 
category. All protocol deviations collected will be divided into major or minor 
categories. Prior to database lock protocol deviations will be reviewed and 
consequences for inclusion of patients in various analysis population sets 
determined and documented. All details of protocol deviations in the study will be 
listed. Further protocol deviation will be summarised by category and minor/major 
assessment. 
6.4.5 
Pharmacokinetic Analysis 
Blood sampling for pharmacokinetic assessments will be done pre-dose and up to 24 
hours post-dose. From the plasma concentrations of RPL554 collected, the following 
pharmacokinetic parameters will be calculated using standard non-parametric 
methods. 
• AUC0−24 is the area under the plasma concentration curve from time 0 to 24 
hours post-dose, computed using the linear trapezoidal method 
• Cmax denotes the highest plasma concentration measured 
• tmax denotes the time point corresponding to Cmax 
Pharmacokinetic parameters will be summarised by dose level using descriptive 
statistics. Graphics will include individual and mean plasma concentration – time 
curves (both on linear and semi-log scale) and scatter plots of computed 
pharmacokinetic parameters with mean levels indicated. 
6.4.6 
Pharmacodynamic Analysis 
6.4.6.1 Spirometry 
For FEV1 the average effect, (Eav), will be calculated as the Area Under the Curve 
(AUC) divided by the length of the time interval of interest. The AUC will be 
computed using the linear trapezoidal rule. Linear interpolation/extrapolation will be 
used to fill in a missing value (at most one missing value allowed) at end of the 
computational interval prior to calculation. In addition, the peak effect on FEV1 will be 
computed as the maximum value (Emax) within 4 hours post-dosing. In analysis, Eav 
and Emax will be normalized using the baseline value.  
Computed pharmacodynamic parameters for FEV1 will be compared between 
placebo and the two doses of RPL554 using analysis of covariance (ANCOVA) 
models with fixed factors for treatment, period and patient, and using the baseline of 
the day as a covariate. FEV1 will be analysed using multiplicative models, which 
means that data is logged prior to analysis and the result then transformed back to 
the linear scale giving treatment differences as ratios of geometric means. All three 
pairwise comparisons will be stated and expressed as the geometric mean ratio with 
95% confidence interval and associated, 2-sided, p-value. 
All spirometry data will be listed and summarized by treatment and assessment point 
as well as the change from baseline. Pharmacodynamic parameters will be 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 14 of 22 
Version: Final 2.0 
 
summarized by treatment. Graphics will include individual and mean FEV1 and FVC 
curves over time (expressed as change from baseline on absolute scale) and scatter 
plots of computed pharmacodynamic parameters with the mean levels indicated. 
Onset of effect will be defined as time to reach a 10% increase in FEV1 counted from 
start/end of nebulization. Patients not reaching a response after 2 hours will be 
censored. Outcome will be illustrated using a Kaplan-Meier plot and, if appropriate, 
the median time to onset by (active) treatment group determined. 
Duration of effect will be assessed by consecutively testing effect of active treatment 
versus placebo for increasing time points using similar models as the analysis of the 
pharmacodynamics parameters. If missing values exist, these will be filled in using 
linear interpolation/extrapolation prior to analysis. 
6.4.6.2 Sputum inflammatory mediators, rheology and exhaled breath pH 
Il-8, TNF-α, MPO, exhaled breath pH and sputum viscoelasticity (log G) collected 6 
and 24 h after dose administration will be compared between treatments using 
similar ANCOVA models as for the FEV1 parameters. Multiplicative models will be 
used for the sputum inflammatory mediators, additive (linear) models for exhaled 
breath pH and sputum viscoelasticity (log G) that already are expressed on log 
scales.  
All data will be listed and summarized by treatment and assessment point as well as 
the change from baseline. Graphics will include individual and mean value curves 
over time for each variable. 
6.4.7 
Safety Analysis 
6.4.7.1 Adverse Events 
Adverse events (AEs) will be collected throughout the study and will be coded 
according to the current version of the MedDRA dictionary. A treatment-emergent 
adverse event (TEAE) is defined as an AE that started or worsened after intake of 
study treatment in each treatment period. If the start date is unknown then the AE 
will be assumed to be treatment emergent unless the partial start date, or other data 
(i.e. stop date) indicates differently. The TEAEs will be assigned to the treatment 
given prior to onset of the event. In summaries, causally related AEs will consist of 
AEs classified as Unlikely, Probably or Definitely related to study treatment. 
Coded adverse event terms will be presented by system organ class (SOC) and 
preferred term and summarised by treatment group. A summary table by treatment 
group with total number and number of patients with adverse events, SAEs, adverse 
events leading to discontinuation of study treatment, causally related adverse events 
and severe adverse events will be produced. Further SAEs, causally related adverse 
events and adverse events of each intensity will be summarised by SOC and 
preferred term. 
AEs will be presented in decreasing frequency of the total number of patients with 
TEAEs. All AEs, including those which are not treatment emergent, will be listed. If 
appropriate, SAEs and AEs leading to discontinuation of study treatment will also be 
separately listed. 
6.4.7.2 Laboratory tests 
Safety laboratory test data will be summarised by treatment group and time point. 
For continuous variables, the change from baseline (pre-dose at each treatment 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 15 of 22 
Version: Final 2.0 
 
visit) to each post-dose time point will also be calculated and summarised. Data will 
further be illustrated by shift tables (showing changes from low/normal/high) and shift 
plots for change over the study. 
The baseline value will be defined as the last scheduled, unscheduled or repeat 
value collected prior to first dosing. The tabulation will only include scheduled visits; 
all unscheduled assessments will be displayed in the listing as appropriate.  
All laboratory values will be listed showing reference ranges and flagging all 
abnormal findings and their clinical significance (CS or NCS). Out of reference range 
values will be flagged as high (H) or low (L). A similar listing including all post-dose 
laboratory values found abnormal, including the baseline result and clinical 
significance, will also be produced.  
6.4.7.3 Vital Signs 
Vital signs data will be summarised by treatment group and time point. The change 
from baseline (pre-dose at each treatment visit) to each post-dose time point will also 
be calculated and summarised. Data will further be illustrated by shift tables 
(showing changes from low/normal/high) and shift plots for the change from baseline 
to worst case during the treatment period.  
The baseline value will be defined as the last scheduled, unscheduled or repeat 
value collected prior to dosing in a period. The tabulation will only include scheduled 
visits; all unscheduled assessments will be displayed in the listing as appropriate.  
Vital signs will be listed showing reference ranges and flagging all abnormal findings 
and their clinical significance (CS or NCS). Out of reference range values will be 
flagged as high (H) or low (L). A similar listing including all post-dose vital signs 
values found abnormal, including the baseline result and clinical significance, will 
also be produced.  
Further, for data collected during treatment days, graphics will include individual and 
mean value curves over time for each variable expressed as change from baseline. 
6.4.7.4 12-Lead ECG 
12-lead ECG data will be summarised and illustrated in the same way as vital signs 
data. In addition, for QTcF, a plot showing the baseline value of the treatment day on 
the x-axis versus the post-dose value indicating the largest absolute change on the 
y-axis will be constructed. QTcF data will also be summarised according to 
frequencies of values >450 ms, >480 ms and >500 ms and according to frequencies 
of shifts from baseline of the treatment day to post-dose of >30 ms and >60 ms. 
6.4.7.5 Physical Examination 
Physical examination data (changes in status between Visit 1 and Visit 5) will be 
listed.  
6.4.7.6 Rescue Medication 
Rescue medication used during the treatment visits will be summarised by treatment 
group and all individual use listed. 
6.4.7.7 Concomitant Medications 
Prior medications are defined as those with a stop date prior to the date of the first 
dose of study treatment. Concomitant medications are defined as those medications 
with either a start date or a stop date that is after the date of first dose of study 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 16 of 22 
Version: Final 2.0 
 
treatment. If the start date is unknown then it will be assumed to be concomitant 
unless the partial start date, or other data (i.e. stop date) indicates differently. 
All prior and concomitant medications will be listed by reported name, medication 
class, standardised medication name, indication. dose, dose unit, route of 
administration, dosing frequency, start and end dates.  
6.4.7.8 Pregnancy tests 
Pregnancy test results, or reasons for not performing the test(s), from females at 
screening, pre-dose at each treatment visit and at end-of-study will be listed. 
6.5 Determination of Sample Size 
This is a sample size of convenience. No calculation of power was performed. 
6.6 Statistical Issues 
All hypothesis testing will be done using two-sided alternative hypotheses. P-values 
less than 5% will be considered statistically significant. 
No adjustment for multiple testing will be done. A closed testing procedure will be 
applied: first the higher dose of RPL544 will be tested versus placebo and then, if 
statistically significant, the lower dose of RPL554 versus placebo. Finally the two 
doses of RPL554 will be compared. 
Patients withdrawn after only one treatment period will not be included in the efficacy 
analyses. No imputation of missing data other than described under Section 6.4 will 
be performed. 
Sensitivity analyses of pharmacodynamic data will be done to explore the impact of 
outliers or, for FEV1 parameters, the use of rescue medication during the clinic visits. 
All available data from all patients who have received study treatment will be listed 
and summarised. Any unscheduled or unplanned readings will be presented within 
the patient listings, but only the scheduled readings will be used in any summaries. If 
a visit is rescheduled due to variability in FEV1 or other reason, the rescheduled visit 
will be listed and summarised as the valid visit. 
6.7 Interim Analyses 
No formal interim analysis is planned for the study. 
6.8 Changes in the Conduct of the Study or Planned Analyses 
Clinical Study Protocol version 2.2 stated that the pharmacokinetic parameters 
should include AUC0-∞, Cmax, Tmax and the terminal half-life, t1/2. Due to the sampling 
scheme was considered insufficient to capture an appropriate t1/2 estimate, this 
parameter was omitted and AUC0-∞ was replaced with an AUC0-24 (area under the 
scheduled sampling period). 
7 REFERENCES 
Miller MR, Hankinson J, Brusasco V et al. Standardisation of spirometry. Eur Respir 
J 2005;26(2):319-338 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 17 of 22 
Version: Final 2.0 
 
Quanjer PH, Tammeling GJ, Cotes JE et al. Lung volumes and forced ventilatory 
flows. Report Working Party Standardization of Lung Function Tests, European 
Community for Steel and Coal. Official Statement of the European Respiratory 
Society. Eur Respir J Suppl. 1993 Mar; 16:5-40 
8 DATA PRESENTATION PLAN 
8.1 Tables for Section 14.1-3 
Safety set used for tables if not otherwise indicated  
o 14.1.1.1 Patient disposition 
o 14.1.1.2 Patient flow 
o 14.1.2.1 Summary of protocol deviations  
o 14.1.3.1 Summary of demographic data and baseline characteristics 
o 14.1.3.2 Summary of prior cystic fibrosis medications  
o 14.1.3.3 Summary of life-style restrictions and nebuliser training  
o 14.1.3.4 Summary of drug exposure data from nebulisations   
o 14.2.1.1 Summary of plasma RPL554 concentrations [PKS] 
o 14.2.1.2 Summary of pharmacokinetic parameters based on plasma RPL554 
concentrations [PKS] 
o 14.2.2.1 Summary of spirometry (FEV1 and FVC) at clinic visits [FAS and 
CAS] 
o 14.2.2.2 Summary of pharmacodynamic parameters based on FEV1 [FAS and 
CAS] 
o 14.2.2.3 Statistical analysis of pharmacodynamic parameters based on FEV1 
(multiplicative models) [FAS and CAS] 
o 14.2.2.4 Statistical analysis of FEV1 by assessment point (duration of action, 
multiplicative models) [FAS] 
o 14.2.3.1 Summary of inflammatory mediators, sputum rheology and exhaled 
breath pH at clinic visits [FAS] 
o 14.2.3.2 Statistical analysis of inflammatory mediators (multiplicative models) 
[FAS] 
o 14.2.3.3 Statistical analysis of sputum rheology and exhaled breath pH 
(additive models) [FAS] 
o 14.3.1.1 Summary of treatment emergent adverse events  
o 14.3.1.2 Summary of adverse events by system organ class and preferred 
term  
o 14.3.1.3 Summary of adverse events causally related to treatment by system 
organ class and preferred term  
o 14.3.1.4 Summary of adverse events of moderate or severe intensity by 
system organ class and preferred term  


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 18 of 22 
Version: Final 2.0 
 
o 14.3.1.5 Summary of adverse events with chronicity intermittent or persistent 
by system organ class and preferred term  
o 14.3.2.1 Summary of serious adverse events by system organ class and 
preferred term  
o 14.3.4.1 Summary of  laboratory tests (continuous variables) at clinic visits  
o 14.3.4.2 Summary of laboratory tests (categorical variables) at clinic visits  
o 14.3.4.3 Summary of abnormal findings on laboratory data  
o 14.3.5.1 Summary of vital signs at clinic visits  
o 14.3.5.2 Summary of abnormal findings on vital signs  
o 14.3.5.3 Summary of 12-lead ECG data at clinic visits  
o 14.3.5.4 Summary of abnormal findings on 12-lead ECG  
o 14.3.5.5 Summary of abnormal findings on physical examination  
o 14.3.5.6 Summary rescue medication use during clinic visits  
o 14.3.5.7 Summary of pregnancy tests  
8.2 Graphs for Section 14.2-3 
Safety set used for graphics if not otherwise indicated 
o 14.2.1.1 Individual plasma concentration-time curves for RPL554 [PKS] 
o 14.2.1.2 Mean plasma concentration-time curves for RPL554 [PKS] 
o 14.2.1.3 Scatter plots of computed pharmacokinetic parameters [PKS] 
o 14.2.2.1 Individual curves for FEV1 on absolute scale [FAS] 
o 14.2.2.2 Individual curves for FEV1 as change from baseline [FAS] 
o 14.2.2.3 Mean value curves for FEV1 on absolute scale [FAS and CAS] 
o 14.2.2.4 Mean value curves for FEV1 as change from baseline [FAS and CAS] 
o 14.2.2.5 Scatter plots of pharmacodynamic parameters based on FEV1 [FAS] 
o 14.2.2.6 Individual curves for FVC, absolute and as change from baseline 
[FAS] 
o 14.2.2.7 Mean value curves for FVC, absolute and as change from baseline 
[FAS]  
o 14.2.3.1 Individual curves for inflammatory mediators, exhaled breath pH and 
sputum rheology by treatment [FAS] 
o 14.2.3.2 Mean value curves for inflammatory mediators, exhaled breath pH 
and sputum rheology, absolute and change from baseline [FAS] 
o 14.3.4.1 Shift plots for laboratory data 
o 14.3.5.1 Individual curves for vital signs, absolute and change from baseline 
o 14.3.5.2 Mean value curves for vital signs, absolute and change from baseline 
o 14.3.5.3 Individual curves for 12-lead ECG, absolute and change from 
baseline 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 19 of 22 
Version: Final 2.0 
 
o 14.3.5.4 Mean value curves for 12-lead ECG, absolute and change from 
baseline 
o 14.3.5.5 Scatter plot of baseline QTcF versus post-dose assessment 
indicating largest absolute change from baseline 
8.3 Listings for Section 16.2 
Safety set used for listings if not otherwise indicated 
o 16.2.1.1 Randomised patients that completed the study 
o 16.2.1.2 Randomised patients that were withdrawn the study 
o 16.2.1.3 Visit dates by patient 
o 16.2.1.4 Eligibility by patient 
o 16.2.2.1 Listing of protocol deviations 
o 16.2.3.1 Analysis dataset allocation by patient 
o 16.2.4.1 Demographic data and baseline characteristics 
o 16.2.4.2 Lung function at baseline and diagnosis of cystic fibrosis 
o 16.2.4.3 Listing of medical history 
o 16.2.5.1 Listing of drug exposure 
o 16.2.5.2 Life-style restrictions to adhere to prior to visits and nebuliser training 
o 16.2.5.3 Plasma concentrations of RPL554 [PKS] 
o 16.2.5.4 Pharmacokinetic parameters [PKS] 
o 16.2.6.1 Listing of spirometry data [FAS] 
o 16.2.6.2 Derived pharmacodynamic parameters based on FEV1 [FAS] 
o 16.2.6.3 Listing of inflammatory mediators, sputum rheology and exhaled 
breath pH [FAS] 
o 16.2.7.1 Listing of adverse events 
o 16.2.7.2 Listing of serious adverse events 
o 16.2.7.3 Listing of adverse events leading to discontinuation of study 
treatment 
o 16.2.8.1 Listing of laboratory data 
o 16.2.9.1 Listing of vital signs 
o 16.2.9.2 Listing of 12-lead ECG 
o 16.2.9.3 Listing of physical examination 
o 16.2.9.4 Concomitant medications at entry and during the study 
o 16.2.9.5 Rescue medication used during clinic visits 
o 16.2.9.6 Listing of pregnancy tests (female patients) 
 
 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 20 of 22 
Version: Final 2.0 
 
 
APPENDICES 
Appendix 1 Inclusion and Exclusion Criteria 
Inclusion Criteria: 
 
1. 
Sign an informed consent document indicating they understand the purpose of 
and procedures required for the study and are willing to participate in the study. 
2. 
Male or female aged ≥18 years at the time of informed consent. Females of 
childbearing potential must have been using a consistent and reliable form of 
contraception from the last menses before the first study treatment 
administration, and must commit to continue to do so during the study and for 3 
months after the last dose of study treatment. 
3. 
Have a 12-lead electrocardiogram (ECG) recording at screening (Visit 1) and 
Visit 2 pre-dose showing the following: 
• 
Heart rate between 45 and 90 beats per minute 
• 
QT interval corrected for heart rate using Fridericia’s formula (QTcF) 
interval ≤450 msec  
• 
QRS interval ≤120 msec 
• 
PR interval ≤220 msec 
• 
No clinically significant abnormality including morphology (e.g. left bundle 
branch 
block, 
atrioventricular 
nodal 
dysfunction, 
ST 
segment 
abnormalities) 
4. 
Capable of complying with all study restrictions and procedures including ability 
to use the study nebuliser correctly. 
5. 
Body mass index (BMI) between 18 and 30 kg/m2 (inclusive) with a minimum 
weight of 40 kg. 
6. 
Patients with a genetic diagnosis of CF  
7. 
Spirometry at screening demonstrating an FEV1 ≥40% and ≤80% of predicted 
normal. 
8. 
Capable of withdrawing from long acting bronchodilators for 48 hours prior to 
study visits, and short acting bronchodilators for 8 hours prior to study visits. 
9. 
Clinically stable CF in the 2 weeks prior to randomisation (Visit 2). 
Exclusion Criteria: 
 
1. 
History of cirrhotic liver disease or portal hypertension. 
2. 
CF exacerbation requiring hospitalization in the month prior to screening 
(Visit 1) or prior to randomisation (Visit 2). 
3. 
Use of oral or intravenous antibiotics (in additional to usual maintenance 
therapy) in the 2 weeks prior to screening (Visit 1) or randomisation (Visit 2). 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 21 of 22 
Version: Final 2.0 
 
4. 
Other non-CF related respiratory disorders: Patients with a current diagnosis of 
asthma, active tuberculosis, lung cancer, sarcoidosis, sleep apnoea, known 
alpha-1 antitrypsin deficiency or other active pulmonary diseases. 
5. 
Previous lung resection or lung transplant. 
6. 
History of, or reason to believe a patient has, drug or alcohol abuse within the 
past 3 years. 
7. 
Received an experimental drug within 3 months or five half-lives, whichever is 
longer.  
8. 
Patients with a history of chronic uncontrolled disease including, but not limited 
to, cardiovascular (including arrhythmias), endocrine, active hyperthyroidism, 
neurological, hepatic, gastrointestinal, renal, haematological, urological, 
immunological, or ophthalmic diseases that the Investigator believes are 
clinically significant. 
9. 
Documented cardiovascular disease: angina, recent or suspected myocardial 
infarction, congestive heart failure, a history of unstable, or uncontrolled 
hypertension, or has been diagnosed with hypertension in last 3 months. 
10. 
Has had major surgery, (requiring general anaesthesia) in the 6 weeks prior to 
screening (Visit 1), or will not have fully recovered from surgery, or planned 
surgery through the end of the study. 
11. 
Infection 
with 
nontuberculous 
mycobacteria, 
methicillin-resistant 
Staphylococcus aureus (MRSA), B. Cepecia, or B. cenocepecia. 
12. 
Use of immune-suppression; long term use of prednisolone >10 mg/day 
13. 
History of malignancy of any organ system within 5 years with the exception of 
localised skin cancers (basal or squamous cell) 
14. 
Clinically significant abnormal values for safety laboratory tests (haematology, 
biochemistry or urinalysis) at screening, as determined by the Investigator. 
15. 
A disclosed history or one known to the Investigator, of significant 
non-compliance in previous investigational studies or with prescribed 
medications. 
16. 
Requires oxygen therapy on a regular basis. 
17. 
Pregnancy or lactation (female patients only) 
18. 
Any other reason that the Investigator considers makes the patient unsuitable 
to participate. 
 


Verona Pharma plc  
 
 
SAP: RPL554-010-2015 
 
Date: 03Jan2018   
Page 22 of 22 
Version: Final 2.0 
 
Appendix 2 Allowed and Disallowed Concomitant Medication 
Patients taking inhaled steroids may continue their medication only if the dose is 
stable from at least four weeks prior to screening and is expected to remain stable. 
All long acting (once or twice daily) bronchodilators will be stopped at the screening 
visit and are not allowed during the study. Patients should not use a long acting 
bronchodilator 
(long 
acting 
muscarinic 
antagonists 
[LAMA], 
long 
acting 
beta2-agonists [LABA], or combination LABA/inhaled steroid) on the day of 
screening.  
• Patients taking LAMAs and LABAs should be placed on short acting 
bronchodilators (e.g. salbutamol, ipratropium or Combivent) as per the discretion 
of the Investigator. These can be dosed on a regular scheduled basis and/or as 
needed use 
• Patients taking combination products should be prescribed the inhaled steroid at 
the same or equivalent dose contained in the combination product to allow 
continuation of steroid use regularly throughout the study while stopping the 
LABA component  
Patients currently taking terbutaline will be switched to other short acting 
bronchodilators (e.g. salbutamol). 
Short acting bronchodilators must be withheld for at least 8 hours prior to spirometry 
at each study visit (Visit 1 to Visit 4). If this withhold is not met, the patent should be 
rescheduled for a repeat visit within 7 days.  
Patients may continue other prescribed non-respiratory therapies during the study 
that the Investigator considers to neither compromise patient safety nor affect study 
data. Pulmonary rehabilitation programs should not be started or completed during 
this period. Oxygen therapy is an exclusion criterion for this study.